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Abstract 
Annexin 1 is an important mediator in the active process of inflammation resolution. 
The protein controls leukocyte trafficking to inflammatory sites, promotes their 
nonphlogistic removal from the tissue and polarises infiltrating macrophages 
towards a pro-resolving phenotype. ANCA-associated vasculitis (AAV) is 
characterised by a necrotising glomerulonephritis that develops following neutrophil 
infiltration, accumulation of macrophages and T lymphocytes, and formation of 
cellular glomerular crescents. The aim of this thesis is to address whether Annexin 1 
might play a beneficial role in the resolution of glomerular inflammation in AAV. 
In the following experiments I examined the effect of the genetic absence of Annexin 
1 in two murine models of crescentic glomerulonephritis; nephrotoxic nephritis 
(NTN) and anti-myeloperoxidase associated glomerulonephritis (murine 
experimental vasculitis/MEV). In addition, the relationship between Annexin 1 
cleavage and proteinase 3 expression was investigated in neutrophils and the ability 
of a PR3-cleavage resistant Annexin 1 peptide (SuperAnnexinA1) to inhibit 
neutrophil activation was examined to understand the potential role of Annexin 1 in 
AAV. Annexin 1 deficiency resulted in a significant exacerbation of disease severity 
in the NTN model, and administration of SuperAnnexinA1 polarised infiltrating 
macrophages towards a less inflammatory phenotype. The disease penetrance 
across experimental groups in the MEV model was not substantial enough to 
conclude whether the absence of Annexin 1 had an effect on disease. In vitro, there 
was a significant correlation observed between an increased proportion of PR3high 
neutrophils and abundance of Annexin 1 cleavage products in neutrophils from 
healthy controls and PR3-ANCA positive AAV patients. The activation of human 
neutrophils was inhibited in a dose-dependent manner by increasing concentrations 
of SuperAnnexinA1. 
These data indicate that Annexin 1 plays an important protective role in 
experimental glomerular injury. There is a rationale established to hypothesise an 
increased degree of Annexin 1 cleavage within an inflamed glomerulus where 
neutrophils are abundant. This supports the potential for Annexin 1 peptidomimetics 
to be used in the treatment of glomerular injury.  
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Chapter 1 Introduction 
This thesis investigates the role of Annexin 1 in glomerular inflammation. Chapter 1 
investigates the genetic absence of Annexin 1 in a murine model of nephrotic 
nephritis and examines the effect of a PR3 proteolysis-resistant Annexin 1 peptide 
on disease. Chapter 2 describes the establishment of the murine model of anti-
myeloperoxidase associated glomerulonephritis and explores the effect of the 
genetic absence of Annexin 1 on disease. Chapter 3 investigates human neutrophil 
surface expression of PR3 and abundance of Annexin 1 cleavage products in vitro 
and considers whether the activation of primed neutrophils by ANCA might be 
modulated by Annexin 1 peptidomimetics. 
1.1 Annexin 1 
1.1.1 Introduction 
Annexin 1, also known as lipocortin 1, is one member of a family of calcium- and 
phospholipid-binding proteins termed the Annexins. Each of the Annexin proteins 
encompasses a core domain, comprised of a varying number of conserved 70 
amino acid repeats, and an N-terminal region, which is unique to each Annexin and 
understood to account for the varying functions of the protein family members. It is 
only through binding of calcium that the functional N-terminal becomes exposed 
(Rosengarth and Luecke, 2003). 
The initial discovery that Annexin 1 blocks phospholipase A2 enzyme activity in the 
presence of calcium, highlighted the proteins’ potential role in regulating 
inflammation. Phospholispase A2 hydrolyses phospholipids; leading to the release of 
arachidonic acid; which is a vital component of prostaglandins and leukotrienes, 
both inflammatory mediators (Gryglewski et al., 1975). Indeed, the generation of an 
Annexin 1 deficient mouse strain revealed that these mice have increased levels of 
cytosolic phospholipase A2 and a propensity for greater inflammatory responses 
(Hannon et al., 2003). Wallner et al. (1986) were the first to identify Annexin 1 as an 
anti-inflammatory substance mediating the actions of glucocorticoids (GCs) (Wallner 
et al., 1986) and these anti-inflammatory actions were reproduced in in vivo models 
of acute inflammation soon after (Errasfa and Russo-Marie, 1989, Cirino et al., 
1989). The Annexin 1 knockout mouse generated by Hannon has partial resistance 
to GC treatment in a number of models of acute and chronic inflammation (Hannon 
et al., 2003, Yang et al., 2004). 
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1.1.1.1 Expression of Annexin 1 
Annexin 1 is predominantly expressed in the cells of the innate immune system; the 
highest levels of Annexin 1 expression are found within monocytes/macrophages, 
neutrophils and natural killer (NK) cells, compared to B and T lymphocytes which 
express much lower levels of Annexin 1 (Morand et al., 1995, Spurr et al., 2011). 
Annexin 1 is expressed in a range of human tissues, the highest levels being found 
in tissues involved in the immune response or tolerance functions e.g. spleen and 
placenta. The protein is also expressed within the kidney by podocytes, collecting 
ducts and within epithelial cells of the Bowman’s capsule (Dreier et al., 1998) (see 
Table 1). The expression of the Annexin 1 receptor; formyl peptide receptor type 2 
or lipoxin A4 receptor, (hereafter termed FPR2/ALXR) in human cells and tissues 
has not been explored to the same extent as its ligand, but anecdotal reports 
suggest that the receptor exhibits a similar expression pattern to that of Annexin 1. 
FPR2/ALXR is highly expressed in monocytes, but on differentiation to 
macrophages the protein expression is nullified (Waechter et al., 2012). 
Table 1 Expression of Annexin 1 in human cells and tissues 
Cell type: Expression of Annexin 1 
 extracellular 
Monocytes/macrophages +++ 
Neutrophils ++ 
NK cells ++ 
B lymphocytes + 
T lymphocytes + 
 total 
Tissue type:  
Respiratory tract +++ 
Lymphatic tissue ++ 
Digestive tract + 
Hepato-pancreatic system - 
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Female reproductive tract ++ 
Male reproductive tract ++ 
Urinary system +++ 
Endocrine organs + 
Skin + 
Nerve tissue +++ 
Tissue expression of Annexin 1 is adapted from (Dreier et al., 1998). 
Annexin 1 comprises 2-4% of total neutrophil cytosolic protein (Francis et al., 1992, 
Rosales and Ernst, 1997) and is found predominantly within the gelatinase granules 
of resting neutrophils (Perretti et al., 2000). As Annexin 1 has no known signal 
peptide, it is believed that neutrophil-derived Annexin 1 is exported to the cell 
surface through the exocytosis of these granules on adhesion to the endothelium 
(Oliani et al., 2001) and indeed Annexin 1 itself may play a direct role in promoting 
exocytotic membrane fusion (Francis et al., 1992). Annexin 1 expression is partially 
controlled by endogenous and exogenous glucocorticoid hormones and addition of 
GC can result in the increased total expression of Annexin 1 in neutrophils and 
monocytes in vitro and in vivo (Goulding et al., 1990, Perretti and Flower, 1996). 
Annexin 1 has a number of residues within the N-terminus and C-terminal core 
which can undergo phosphorylation to influence the protein’s binding capacity and 
function; for example, phosphorylation of tyrosine decreases the calcium 
requirement for binding to phosphatidylserine (PS) (Schlaepfer and Haigler, 1987). 
Phosphorylation of Annexin 1 can also determine its subcellular localisation (Kim et 
al., 2003) and GCs have been shown to induce phosphorylation of Annexin 1 at 
particular sites; in some cases causing the protein’s subsequent translocation to the 
cytoplasmic membrane (John et al., 2003, Solito et al., 2003b).  
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1.1.2 Anti-inflammatory and pro-resolving actions of Annexin 1 
 
Figure 1-1 Key pro-resolving actions of Annexin 1 
Annexin 1 has been implicated in a number of processes within the innate immune system 
that contribute to the resolution of an inflammatory reaction. I. Annexin 1 exposed on the 
neutrophil surface plays an inhibitory role in their extravasation into the tissue. II. 
Upregulation of Annexin 1 expression in neutrophils leads to an increase in pro-apoptotic 
pathways. III. Annexin 1 deficient macrophages are impaired in their phagocytic capacity. 
IV. Annexin 1 expression by BM macrophages is required for efficient phagocytosis of 
apoptotic neutrophils. V. Engulfment of secondary necrotic cells expressing Annexin 1 
reduces macrophage pro-inflammatory cytokine production and exogenous Annexin 1 
administration polarises M1 macrophages towards a more resolution-type phenotype. 
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1.1.2.1 Leukocyte trafficking 
Annexin 1 was first shown to have an inhibitory effect on neutrophil trafficking to 
inflammatory sites in 1989, as exogenous administration of the protein reduced 
neutrophil accumulation in an in vivo model of inflammation (Errasfa and Russo-
Marie, 1989). Following work demonstrated that recombinant human Annexin 1 
could reduce the IL-1 and IL-8 dependent accumulation of neutrophils in an 
inflammatory air-pouch murine model (Perretti and Flower, 1993, Perretti et al., 
1993) and revealed that endogenous Annexin 1 modulates monocyte and neutrophil 
accumulation during acute inflammation in vivo (Getting et al., 1997, Lim et al., 
1998). Experiments in the Annexin 1 deficient mouse have also shown a markedly 
enhanced infiltration of neutrophils to inflammatory sites in models of acute 
inflammation stimulated by zymosan (Chatterjee et al., 2005) and carrageenan 
(Gastardelo et al., 2009). 
The means by which Annexin 1 regulates neutrophil accumulation has been 
attributed to its inhibition on leukocyte extravasation, rather than any effect on rolling 
or adhesion (Mancuso et al., 1995, Chatterjee et al., 2005, Damazo et al., 2006). 
Under normal conditions, circulating neutrophils are thought to externalise Annexin 1 
on adhesion with the endothelium, allowing Annexin 1 to act as an autocrine 
inhibitor, preventing neutrophil emigration through the vessel wall (Perretti et al., 
1996, Perretti, 1997). However, under inflammatory conditions Annexin 1 is cleaved 
at the cell surface, allowing neutrophil extravasation into the tissue (Perretti and 
Flower, 1996, Goulding et al., 1998).  
L-selectin plays an important role in mediating neutrophil-endothelial interactions 
and the adhesion of neutrophils to the inflamed microvasculature (Hafezi-
Moghadam and Ley, 1999, Hickey et al., 2000). It has been reported that exogenous 
Annexin 1 promotes L-selectin shedding from neutrophils and monocytes and 
Annexin 1 antibodies can inhibit L-selectin shedding induced by dexamethasone 
treatment, providing some insight into how Annexin 1 may mediate its inhibitory 
effect on neutrophil extravasation into the tissue (Strausbaugh and Rosen, 2001, de 
Coupade et al., 2003). 
Experiments investigating detachment of polymorphonuclear leukocytes (PMN) from 
the vascular bed have demonstrated the efficacy of administering a truncated 
Annexin 1 peptide; Ac2-12 in preventing diapedesis (Lim et al., 1998). Interestingly, 
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it is this fraction of Annexin 1 that mediates interactions with the S100 proteins; both 
Annexin 1 and S100A8/A9 are expressed at the neutrophil surface on activation and 
have been demonstrated to bind carboxylated glycans found on endothelial cells 
(Srikrishna et al., 2001a). These glycan interactions have been shown to be involved 
in the extravasation of neutrophils and monocytes into inflamed tissue (Srikrishna et 
al., 2001b), providing an additional putative link behind how Annexin 1 inhibits 
diapedesis. 
Monocytes externalise Annexin 1 on adhesion to the endothelium, but not to the 
same extent as neutrophils (Perretti et al., 1999). Annexin 1 expressed on the 
surface of the monocyte is believed to interact with the α4β1 integrin on the 
endothelial cell surface to exert inhibitory effects on monocyte adhesion (Solito et 
al., 2000). However, the expression of Annexin 1 may also play an important role in 
the accumulation of macrophages required to resolve an inflammatory reaction as in 
several experimental models of peritonitis Annexin 1 deficient mice have a reduction 
in the number of infiltrating macrophages (Damazo et al., 2006, Chatterjee et al., 
2005). Further work needs to be done to uncover the role that Annexin 1 performs in 
the accumulation of monocytes and macrophages within inflamed tissue. 
Recent research has suggested an alternate pro-inflammatory role for a ~33kDa C-
terminal Annexin 1 fragment within neutrophil transendothelial migration. This 
fragment generated by calpain 1 cleavage can activate the endothelial ERK1/2 
signalling pathway and is believed to promote the transmigration of neutrophils 
through the clustering of ICAM-1, a process which is essential for the formation of 
transmigratory cups required for neutrophil transendothelial migration (TEM) 
(Williams et al., 2010, Shaw et al., 2004). 
1.1.2.2 Promotion of apoptosis 
Programmed cell death is a vital step in the resolution of an inflammatory reaction. 
Apoptosis is preferable to necrosis as it avoids the release of proinflammatory 
mediators, contributing to any already established inflammatory reaction and this 
process can also avert autoimmune reactions to self-antigens. 
Interaction of PMN with extracellular matrix during extravasation leads to Annexin 1 
gene activation, which appears to be counter-intuitive if the only role for surface 
expression of Annexin 1 would be to limit diapedesis (Oliani et al., 2001). This 
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increased expression of Annexin 1 by extravasated neutrophils is GC-independent 
(Vergnolle et al., 1997). 
Sakamoto et al. first linked Annexin 1 to influencing apoptosis in 1996, when they 
demonstrated that exogenous administration of Annexin 1 promotes the apoptosis of 
rat thymocytes and prevents cell necrosis under H202 treatment (Sakamoto et al., 
1996). Subsequent work by Solito et al. has revealed that apoptosis can be 
augmented in either monocytic cells transfected with Annexin 1 or neutrophils when 
treated with human recombinant Annexin 1 and is associated with changes in 
calcium and increased caspase 3 activity (Solito et al., 2001, Solito et al., 2003a). 
Recent work by Vago et al. has supported a pro-apoptotic role for endogenous 
Annexin 1 in vivo using LPS-induced pleurisy. The pro-resolution effect of Annexin 1 
in their study was associated with an increase in pro-apoptotic pathways (Bax levels 
and caspase-3 cleavage) and an inhibition of pro-survival pathways (Mcl-1, ERK1/2 
and NF-κB). The pro-apoptotic effect could be abolished by a pan-caspase inhibitor 
(Vago et al., 2012).  
1.1.2.3 Efferocytosis by macrophages  
There is a growing body of understanding that endogenous signalling molecules act 
to regulate the phagocytosis of apoptotic cells (Fadok et al., 1992, Moffatt et al., 
1999, Hanayama et al., 2002, Anderson et al., 2003). The efferocytosis of apoptotic 
neutrophils can in fact lead to proresolution effects through the suppression of pro-
inflammatory mediators and release of anti-inflammatory cytokines from the 
phagocytic macrophage (Voll et al., 1997, Fadok et al., 1998). 
Experiments using macrophages from Annexin 1 null mice have revealed that 
Annexin 1 deficient macrophages are impaired in their ability to phagocytose non-
opsonised zymosan particles in vitro and in vivo and produce more pro-inflammatory 
cytokines (TNF-α and IL-6). Additionally, studies using monoclonal antibodies to 
neutralise Annexin 1 show a requirement for Annexin 1 in the phagocytosis of 
apoptotic Jurkat cells, but not primary thymocytes, by macrophages in vitro (Yona et 
al., 2006, Yona et al., 2004). Interestingly Maderna et al. have demonstrated that 
Annexin 1 released by dexamethasone-treated macrophages or Annexin 1 N-
terminal peptide Ac2-26 can stimulate the phagocytosis of apoptotic neutrophils by 
human monocyte-derived macrophages in vitro (Maderna et al., 2005). In addition, 
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Maderna et al. found a reduced phagocytic capacity of bone marrow-derived 
macrophages from Annexin 1 deficient mice. Subsequent experiments have 
revealed that in vitro full length Annexin 1 and Annexin 1 cleaved peptides are 
released from apoptotic PMN, Jurkat T lymphocytes and human mesangial cells that 
promote their nonphlogistic phagocytosis by human monocyte-derived macrophages 
via actin filament reorganization. This mechanism of engulfment is totally dependent 
on caspase activity (Scannell et al., 2007). 
Although exogenously administered Annexin 1 peptide mimetics have the ability to 
enhance macrophage efferocytosis in vitro (Dalli et al., 2013), there is no in vivo 
evidence to suggest that endogenous Annexin 1 promotes the phagocytosis of 
apoptotic neutrophils within the inflammatory milieu and Annexin 1 deficient mice do 
not exhibit a deficiency in the clearance of apoptotic neutrophils by inflammatory 
macrophages (Chatterjee et al., 2005). However, there is an increased accumulation 
of senescent neutrophils in the bone marrow of Annexin 1 deficient mice, when 
compared to wild-type animals which results from the fact that Annexin 1 deficient 
mice have a reduced capacity for the phagocytosis of apoptotic neutrophils by 
resident bone marrow macrophages in vivo. This deficiency is conferred by the 
absent macrophage expression of Annexin 1 (Dalli et al., 2012). 
The ability to bind phospholipids externalised to the cell surface on apoptosis is 
common to all Annexins and research suggests that the core region of Annexin 1 
can act as a bridging molecule between phosphatidylserine (PS) on the apoptotic 
cell and macrophage surface, permitting tethering and engulfment (Fan et al., 2004, 
Morand et al., 1995, Dreier et al., 1998) (Blume et al., 2009). In addition, the non-
PS-binding N terminal region (aa 1-46) can promote phagocytosis through 
FPR2/ALXR receptor binding (Maderna et al., 2005). 
In vitro evidence suggests that Annexin 1 is released from apoptotic cells as a 
mechanism to stimulate phagocytosis by macrophages (Arur et al., 2003, Debret et 
al., 2003, Scannell et al., 2007). Secondary necrotic cells also externalise Annexin 
1, although the protein acts to reduce the production of proinflammatory cytokines 
(most notably IL-6) by macrophages on engulfment, rather than promote their 
efferocytosis (Blume et al., 2009). In addition, cleavage of Annexin 1 externalised by 
secondary necrotic cells by membrane-bound (metallo-)proteinase ADAM10 
releases a 7aa N-terminal peptide which acts to promote monocyte chemotaxis in 
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vitro, contributing to the nonphlogistic phagocytosis of apoptotic cells (Blume et al., 
2012).  
1.1.2.4 Macrophage polarization 
Re-defining the rigid distinctions of macrophages from M1 (pro-inflammatory) and 
M2 (anti-inflammatory) phenotypes, pro-resolution macrophages have been 
identified as expressing a mixture of M1 and M2 cytokines (COX2, iNOS, IL-10, and 
arginase 1) and may play a role in antigen presentation, phagocytosis, lymphocyte 
repopulation and inhibition of leukocyte trafficking (Bystrom et al., 2008, Rajakariar 
et al., 2008, Stables et al., 2011). Annexin 1 peptides have been shown to augment 
IL-10 production in vitro and in vivo and IL-10 responses are diminished in Annexin 
1 deficient mice (Damazo et al., 2005, Guido et al., 2013, Cooray et al., 2013). 
Recombinant Annexin 1 can also induce phosphorylated AMP-activated protein 
kinase (pAMPkα1) in M1 macrophages and stimulate IL-10 gene expression 
(Perretti et al. unpublished data). Current data suggest an ability of Annexin 1 to act 
as a phenotypic switch for the polarisation of macrophages to a resolution 
phenotype, but further work needs to be done to establish whether Annexin 1 can 
lead to the accumulation of pro-resolution macrophages in an in vivo setting. 
1.1.2.5 Influence on the adaptive immune response 
Although Annexin 1 expression is primarily found in cells of the innate immune 
system, all extravasated lymphocytes are positive for Annexin 1 (Perretti et al., 
1999). Whereas dexamethasone upregulates Annexin 1 expression in innate 
immune cells, the glucocorticoid downregulates Annexin 1 expression in T cells in 
vitro and in vivo (Damazo et al., 2005, Damazo et al., 2006, D'Acquisto et al., 2008). 
Early research attributing a role for Annexin 1 in T cell responses suggested a 
mirroring of its anti-inflammatory actions within the innate arm of the immune 
response as in vitro studies utilising recombinant Annexin 1 and Annexin 1 peptide-
derivatives attributed a role for the protein in inhibiting antigen-driven T cell 
proliferation and reducing pro-inflammatory cytokine production (Gold et al., 1996, 
Kamal et al., 2001). This hypothesis was supported by in vivo studies in a Th1-
driven mouse model of antigen-induced arthritis (AIA); demonstrating a role for 
endogenous Annexin 1 in limiting chronic inflammation (Yang et al., 2004), 
accompanied by the inhibition of pro-inflammatory cytokine expression (IL-1β, 
TNFα, IL-6, and MIF). In addition, a recent paper from Weyd et al. describes how 
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externalized Annexin 1 on early apoptotic cells can suppress DC-mediated immune 
responses through Toll-like receptor (TLR) signalling (Weyd et al., 2013). 
Conflicting evidence for the role of Annexin 1 in the adaptive immune response has 
pointed towards a function in positively modulating T-cell proliferation and activation 
and skewing the immune response to a Th1 phenotype, through TCR signalling 
(D'Acquisto et al., 2007a, D'Acquisto et al., 2007b). D’Acquisto’s group have 
described how Annexin 1 affects the strength of TCR signalling and could be 
responsible for manipulating T cell development through the regulation of positive 
and negative selection (Paschalidis et al., 2010). In vivo evidence to support this 
hypothesis for Annexin 1 playing a pro-inflammatory role in the adaptive immune 
response comes from a murine model of multiple sclerosis. In experimental 
autoimmune encephalomyelitis (EAE) Annexin 1 deficient mice exhibit impaired 
ability to develop the disease, accompanied by a markedly reduced infiltration of 
macrophages and T lymphocytes and decreased T cell proliferation responses in 
vitro. Compared to the wild-type animals, the ability of Annexin 1 null cells from the 
draining lymph nodes to produce Th1 and Th17 cytokines was significantly reduced 
(Paschalidis et al., 2009).  
Th2 responses play an important role in allergic reactions and autoimmune diseases 
such as asthma and Annexin 1 deficient mice are more susceptible to spontaneous 
airway hyperresponsiveness and exhibit higher antibody responses in a murine 
model of asthma (Ng et al., 2011). Recent research supports the idea that Annexin 1 
can play a protective role in Th2-driven inflammation and inhibits the proliferation of 
both CD4+ and CD8+ T cell subsets (Yang et al., 2013). However, Yang et al.s work 
also confounds the evidence for Annexin 1 exacerbating Th1-driven inflammation; 
describing that in a Th1/Th17-driven model of collagen-induced arthritis, Annexin 1 
is protective and inhibits T cell proliferation. The researchers attribute the effects of 
Annexin 1 to intrinsically expressed protein derived from CD4+ cells. Yang et al. 
also describe Annexin 1 as preventing Th17 activation, contrary to what was 
observed in the murine model of multiple sclerosis. This is supported by the recent 
observation that Annexin 1 deficient mice are more susceptible to an autoimmune 
Th17-mediated retinal inflammatory disease (Yazid et al., 2015). Interestingly, Yang 
et al. describe how Annexin 1 can prevent neutrophil, CD4+ and CD8+ cell adhesion 
in a T cell-dependent model of inflammation. Annexin 1 has previously been 
demonstrated to influence PMN extravasation, rather than rolling or adhesion and 
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this observation may reflect how the effects of Annexin 1 can vary as a result of the 
arm of the immune response involved in each disease model. 
To account for the alternate roles of Annexin 1 mentioned in the above studies, it is 
important to recognise that the in vitro experiments by Gold et al. and Kamal et al., 
perpetrating an anti-inflammatory role, were performed with mixed populations of 
PBMCs. In these studies, Annexin 1 may be having an effect on other cells, which in 
turn influence the behaviour of the T cells in culture. The conflicting evidence for the 
in vivo role of Annexin 1 in the adaptive immune response is perplexing but is most 
likely explained by the differing etiology of the experimental models used; the 
inflammatory stimuli employed, subtle differences in T cell subset involvement and 
signalling pathways involved. 
1.1.2.6 Mechanism of action: signalling through FPR2/ALXR 
Annexin 1 binds the G-protein-coupled receptor (GPCR) formyl peptide receptor 
(FPR) type 2 also known as the lipoxin A4 receptor, FPR2/ALXR (Perretti et al., 
2002). There are 3 members of the FPR family in humans and 8 members identified 
in the mouse, termed FPR 1-8. Receptors FPR1 and FPR2/ALXR are orthologous in 
mouse and human. The murine equivalent of FPR3 is highly homologous to FPR2 
and their differential expression, roles and ligands are yet to be dissected. Mouse 
and human neutrophils and monocytes/macrophages express FPR1 and 
FPR2/ALXR, whereas FPR3 is found predominantly in human 
monocytes/macrophages and mature DCs (Yang et al., 2002, Migeotte et al., 2005). 
The fomyl-peptide receptors are also found in various tissues and non- 
hematopoietic cell types including fibroblasts and endothelial cells (summarised in 
(Migeotte et al., 2006)). 
The FPRs are involved in recognising peptides and lipids generated from 
exogenous pathogens and endogenous sources. Activation of FPRs can modulate 
intracellular kinase activities e.g. protein kinase C (PKC) and mitogen-activated 
protein kinases (MAPKs) and NADPH oxidase activation, leading to processes 
including the mobilization of calcium, chemotaxis and cell activation (Le et al., 1999) 
(reviewed in (Ye et al., 2009)).  
As well as binding Annexin 1, FPR2/ALXR is also the receptor for lipoxin A4 (LXA4) 
and serum amyloid protein A (SAA) (see Figure 1-2). Unusually, FPR2/ALXR can 
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transduce pro- or anti-inflammatory responses, depending on the agonist engaged. 
For instance, like most other FPR2/ALXR ligands, LXA4 mediates anti-inflammatory 
effects, specifically through the inhibition of NF-κB, a transcription factor responsible 
for the production of many pro-inflammatory cytokines and chemokines. LXA4 can 
prevent the adhesion and transmigration of neutrophils as well as promoting the 
apoptosis of neutrophils and their phagocytosis by macrophages, and the 
eicosanoid is understood to be a key player in the resolution of inflammation 
(Serhan, 2005). Conversely, SAA acts as a pro-inflammatory agonist for 
FPR2/ALXR; it has been shown to be responsible for the secretion of IL-8 by 
neutrophils through NF-κB activation and the secretion of TNF-α by monocytes, as 
well as promoting the chemotaxis of both neutrophils and monocytes. Different 
ligands for FPR2/ALXR may also exhibit different potencies in terms of activating 
and sustaining signalling pathways (Pederzoli-Ribeil et al., 2010) and FPRs can 
exhibit alternate affinities for ligands, allowing the activation of distinct pathways at 
different agonist concentrations (Hartt et al., 1999) reviewed in (Ye et al., 2009).  
 
Figure 1-2 Dual nature of FPR2/ALXR 
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The FPR2/ALX receptor can mediate distinctive anti- or pro-inflammatory effects depending 
on the agonist that binds. Binding of Annexin 1 and lipoxin A4 to FPR2/ALXR can reduce 
the production of pro-inflammatory cytokines through the inhibition of NF-κB, prevent 
neutrophil adhesion and transmigration and promote neutrophil apoptosis and their 
efferocytosis by macrophages. Conversely, binding of serum amyloid A to FPR2/ALXR acts 
as a pro-inflammatory agonist, through the activation of NF-κB, promotion of neutrophil and 
monocyte chemotaxis and by enhancing pro-inflammatory cytokine production from these 
cells. 
Recent research has shed light on the mechanism by which FPR2/ALXR may exert 
opposing effects on inflammation depending on the agonist involved. Experiments 
have suggested that binding of alternate ligands to the receptor initiates 
conformational changes that determine downstream signalling pathways. Binding of 
Annexin 1, its N-terminal peptide Ac2-26 and LXA4 leads to homodimerization of 
FPR2/ALXR, whereas SAA binding decreases this phenomenon. Binding of Annexin 
1, Ac2-26 and LXA4 also promotes heterodimerization of FPR1 and FPR2/ALXR. 
Functional studies have revealed that Ac2-26 and LXA4 can inhibit neutrophil 
survival promoted by SAA through the heterodimerization of FPR1 and FPR2/ALXR, 
activating the JNK pathway, leading to caspase-3 activation (El Kebir et al., 2007, 
Cooray et al., 2013).  
It is thought that, under non-inflammatory conditions, the Annexin 1 receptors are 
expressed on the neutrophil surface, acting in a paracrine manner to endogenously 
limit neutrophil infiltration into the tissues. Following initial cell activation stimulated 
by an inflammatory insult, there is a loss of Annexin 1 binding capacity, 
accompanied by the proteolytic cleavage of Annexin 1 (which has been translocated 
to the cell surface) and it’s receptor; allowing neutrophil transmigration and full 
activation of the cells (Goulding et al., 1998). However, on adhesion to the 
endothelium, it is understood that FPR2/ALXR is translocated to the neutrophil 
surface as Annexin 1 binding capacity is augmented (Euzger et al., 1999). This 
allows renewed signalling through the receptor, with Annexin 1 binding and 
modulating further PMN accumulation. Patients with rheumatoid arthritis (RA), 
untreated or treated with non-steroidal anti-inflammatories (NSAIDs) only have 
significantly less binding sites for Annexin 1 on monocytes and neutrophils than 
healthy controls and patients with other chronic inflammatory diseases and this 
could explain the chronic inflammatory processes apparent in the disease as 
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Annexin 1 is unable to perform its endogenous anti-inflammatory role (Goulding et 
al., 1992). 
Experiments utilizing mice deficient in FPR1 or both FPR2/ALXR and FPR3 have 
highlighted the receptors’ roles in mediating the inhibitory effects of Annexin 1 and 
its N-terminal peptide Ac2-26 on PMN accumulation and limiting PMN infiltration 
after an inflammatory insult, in the context of acute and chronic pathologies (Perretti 
et al., 2001, Dufton et al., 2010, Gavins et al., 2005, Patel et al., 2012, Kao et al., 
2014). 
1.1.3 Cleavage of Annexin 1 by proteinase 3 
Both proteinase 3 (PR3) and Annexin 1 are externalised to the plasma membrane 
on neutrophil activation where they co-localize allowing the cleavage of Annexin 1 
by PR3 (Muller Kobold et al., 1998, Vong et al., 2007). PR3 cleaves Annexin 1 at 
three sites: Ala11, Val22, and Val36 (Vong et al., 2007). The shorter two peptides 
generated by this cleavage; 12 and 23 amino acids long, respectively, are thought to 
be unstable and unlikely to play a physiological role. The 33kDa peptide generated 
corresponds to a fragment found in bronchoalveolar lavage fluid (BALF) of patients 
with cystic fibrosis and can also be generated through proteolytic cleavage by 
human neutrophil elastase (HLE) (Smith et al., 1990, Tsao et al., 1998, Rescher et 
al., 2006). It is unclear whether generation of the 33kDa peptide is merely a result of 
proteolysis limiting the biological actions of Annexin 1 or whether the peptide has a 
physiological role itself. This shortened peptide has been reported to bind to 
monocytes with similar efficacy as the full length protein and one study suggested 
that it retains its ability to inhibit phospholipase A2 activity in vitro (Huang et al., 
1987). However, it is largely believed that the 33kDa peptide is an inactive form of 
Annexin 1 as the cleaved N-terminus holds much of the biological activity of Annexin 
1 and the capacity for binding to FPR2/ALXR. Unlike the full length protein, in vitro 
the 33kDa peptide fails to exert anti-inflammatory effects on peritoneal macrophages 
and does not inhibit superoxide production in monocytes (Euzger et al., 1999, Smith 
et al., 1990).  
Excessive Annexin 1 cleavage has been shown to be associated with PMN 
infiltration in an experimental model of colitis and also when comparing BALF 
between normal subjects and those with various lung diseases. Neutrophils are an 
important reservoir of PR3 and these observations suggest that neutrophil 
accumulation could contribute to Annexin 1 cleavage, limiting the protein’s anti-
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inflammatory/pro-resolution actions in these disease settings (Vergnolle et al., 1995, 
Smith et al., 1990). 
1.1.3.1 Serine protease-cleavage-resistant forms of Annexin 1 
A serine protease-cleavage-resistant form of Annexin 1 (SuperAnxA1 or SAnxA1) 
has been generated by Pederzoli-Ribeil et al. which is resistant to PR3 proteolysis 
across the three cleavage sites (Pederzoli-Ribeil et al., 2010). Their experiments 
using SAnxA1 demonstrate that the molecule can significantly inhibit PMN adhesion 
to endothelial monolayers in vitro. In vivo, SAnxA1 promotes increased and 
continued inhibition of cell adhesion to the postcapillary venule when compared to 
exogenous administration of the recombinant native protein in a model of IL-1β 
induced inflammation of the microcirculation. SAnxA1 also inhibits PMN 
accumulation when fMLP is used as an inflammatory stimulus (Pederzoli-Ribeil et 
al., 2010). This observation has been supported in a more prolonged model of 
inflammation induced by λ-carrageenan injection into mouse paw, which highlights 
the ability of SAnxA1 to sustain its anti-inflammatory actions, including through 
reduced infiltration of PMN, over longer periods than the native protein. Patel et al. 
reasoned to test the effects of SAnxA1 in a neutrophil- and macrophage-dependent 
mouse model of serum-induced inflammatory arthritis, due to the discovery of 
increased PR3 mRNA levels in the arthritic joint. Excitingly, when dosed at 1µg 
daily, SAnxA1 can accelerate the resolution phase of disease (Patel et al., 2012). 
Anti-inflammatory actions of cleavage-resistant Annexin 1 have been reproduced 
more recently with a recombinant N-terminal Annexin 1 in which Val25 is replaced 
with a leucine residue, preventing proteolytic cleavage, termed CR-AnxA12–50 (Dalli 
et al., 2013). Experiments using this novel peptide have shown the potential for anti-
inflammatory effects in murine IL-1β induced inflammation and the acceleration of 
the inflammation resolution phase in a model of zymosan peritonitis, mediated by 
the reduction of PMN migration into inflammatory sites and an increase in clearance 
of apoptotic cells by macrophages, respectively. Effects in a translational setting 
also suggest that CR-AnxA12–50 can enhance the inhibition of human leukocyte 
recruitment to endothelial monolayers at low concentrations, compared to 
exogenous administration of the native protein and can prevent serum amyloid A 
(SAA) induced-neutrophil survival. CR-AnxA12–50 also increases the phagocytosis of 
apoptotic neutrophils by human primary macrophages in vitro. Additionally, in vivo 
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experiments have demonstrated tissue-protective actions of CR-AnxA12–50 in a 
murine model of cardiac ischemia/reperfusion injury (Dalli et al., 2013).  
These cleavage-resistant forms of the full-length Annexin 1 protein have higher 
affinity for FPR2/ALXR than shorter N-terminal based peptides, hence their more 
potent and sustained anti-inflammatory effects across in vitro and in vivo studies. 
Taken together, these experiments using SAnxA1 and CR-AnxA12–50 suggest a 
potential function as pro-resolution therapeutics in acute and chronic inflammatory 
disease settings. 
1.2 Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis 
ANCA-associated vasculitis (AAV) is a chronic necrotising inflammation, 
predominantly affecting small blood vessel walls. Disease commonly manifests as 
glomerulonephritis and is typically associated with the presence of auto antibodies 
to proteins found in the granules of neutrophils and lysosomal compartments of 
monocytes; most notably myeloperoxidase (MPO) and proteinase 3 (PR3), although 
disease can also occur in the absence of an auto-antibody. According to the Chapel 
Hill Consensus (2012), the ANCA-associated vasculitides comprise three disease 
entities; granulomatosis with polyangiitis (GPA, formerly known as Wegener’s 
granulomatosis), microscopic polyangiitis (MPA) and eosinophilic granulomatosis 
with polyangiitis (eGPA, formerly known as Churg-Strauss syndrome). These three 
conditions are defined by their clinical features; GPA is distinguished by the 
presence of extravascular granulomatous inflammation in the respiratory tract, MPA 
usually manifests as glomerulonephritis in the absence of upper airway involvement 
and eGPA is associated with eosinophilic inflammation, asthma and nasal polyps. 
Unlike other vasculitides, AAV is characterised by the presence of few or no immune 
deposits. GPA is predominantly associated with the presence of a PR3-ANCA and 
MPA with an MPO-ANCA. Less than half of eGPA patients have a detectable ANCA 
and ANCA-negative eGPA patients are least likely to have renal involvement 
(Jennette et al., 2013).  
The annual incidence of AAV is in the range of ~13 to 20 per million (Watts et al., 
2015) and the disease is predominantly found in Caucasian populations.  In terms of 
the disease subtypes, GPA is more commonly found in northern Europe and MPA in 
southern Europe (Mahr et al., 2004). Global variation in disease incidence is likely 
partly explained by genetic factors (Lyons et al., 2012) although similar penetrance 
across the sexes and an increase in disease occurrence in older age suggest strong 
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environmental factors also contributing to disease. Environmental risk factors that 
have been attributed to the incidence of AAV have included UV radiation exposure 
(Gatenby et al., 2009), silica inhalation (Yashiro et al., 2000) and levamisole-
contaminated cocaine use (Pendergraft et al., 2014). A seasonal occurrence of GPA 
points towards a link with infection and it has been suggested that there is molecular 
mimicry between human LAMP-2, a recently identified ANCA, and the bacterial 
protein FimH (Kain et al., 2008). 
AAV is associated with considerable morbidity and mortality, with end stage renal 
failure developing in more than 30% of patients at 5 years (Little et al., 2004).  
Current treatment encompasses a general immune-suppressive approach, which is 
often associated with other adverse events; treatment-induced complications 
including severe infection now outweigh disease complication in terms of cause of 
death (Little et al., 2010, Calich et al., 2014). Of those patients who go into 
remission, there is a relapse rate of 50% over 5 years (Booth et al., 2003). This is of 
particular concern in GPA patients with a PR3-ANCA who are prone to relapse. 
There is a need to define the pathogenic mechanisms of disease more clearly and 
find alternative therapies not associated with current toxicities. 
1.2.1 Pathogenesis of AAV 
Glomerular injury in AAV is characterised by an initial influx of neutrophils followed 
by the crescentic accumulation of macrophages and T cells, leading to fibrosis and 
subsequent deterioration in renal function. Research over the last 25 years has led 
to the general acceptance of the following mechanism leading to disease: 
When neutrophils are primed by proinflammatory cytokines such as tumour necrosis 
factor alpha (TNF-α) or lipopolysaccharide (LPS) there is a rapid translocation of 
MPO and PR3 to the cell surface where the antigens become exposed for ANCA 
binding (Schreiber et al., 2004, Falk et al., 1990, Charles et al., 1991, Hoshino et al., 
2007). Activation of primed neutrophils by ANCA occurs through the crosslinking of 
ANCA antigens on the cell surface through F(ab)2 engagement and is modulated 
through Fcγ receptor binding (Porges et al., 1994, Mulder et al., 1994, Kettritz et al., 
1997). Binding of ANCA to primed neutrophils causes their activation, adherence to 
endothelial cells and increased transmigration into the tissue (Falk et al., 1990, 
Nolan et al., 2008). On activation neutrophils also degranulate, releasing lytic 
enzymes and reactive oxygen species (ROS) as well as proinflammatory cytokines 
e.g. IL-8, causing damage to the surrounding tissue, promoting further inflammation 
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and injury (Falk et al., 1990, Cockwell et al., 1999) (see Figure 1-3). ANCA inhibit 
the normal efferocytosis of apoptotic macrophages and this in turn leads to a build-
up of necrotic neutrophils (Harper et al., 2000). As ANCA-binding increases the 
surface expression of MPO and PR3, the response is perpetuated, leading to a 
continual antigen-driven response. 
 
Figure 1-3 Involvement of the innate and adaptive arms of the immune response 
in the pathology of AAV 
1. Exposure to infectious stimuli skews the adaptive immune response to a Th17 cell 
phenotype. 2. IL-17 produced from Th17 cells stimulates the release of TNF-α and IL-1β 
from macrophages. 3. Neutrophils are primed by these cytokines, leading to the exposure of 
ANCA antigens on the neutrophil surface. 4. ANCA binding to primed neutrophils causes 
full activation, degranulation and release of free radicals. 5. Adherent neutrophils activated 
by ANCA release proteolytic enzymes and reactive oxygen species leading to endothelial 
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detachment, lysis and apoptosis. 6. MPO and PR3 released by activated neutrophils is 
presented to Th cells by APCs, resulting in the production of ANCA from B cells. 
1.2.1.1 Pathogenicity of ANCA 
Circulating ANCA titres have been shown to correlate to a degree with disease 
activity (van der Woude et al., 1985) and the persistence of ANCA in GPA patients 
in remission is a strong predictor of relapse (Stegeman et al., 1994, Sanders et al., 
2006). Recent observations of patients treated with rituximab, a B-cell depletion 
agent, have supported the pathogenic role of ANCA; Cartin-Ceba et al. (Cartin-Ceba 
et al., 2012) observed that all relapses following treatment with rituximab and 
corticosteroids were preceded by the reconstitution of the B-cell population and a 
rise in ANCA-titre. Although a rising ANCA titre has been used successfully as a 
predictor of relapse in AAV, the relationship is not robust and a relapse can occur 
more than 6 months subsequent to a rising ANCA titre (Boomsma et al., 2000, 
Finkielman et al., 2007). Recently Roth and colleagues (Roth et al., 2013) have 
described how only epitope-specific MPO-ANCA are pathogenic and these epitopes 
only exist in active disease. Their studies explain why MPO-ANCA can be found in 
healthy individuals as they lack the pathogenic epitopes. More importantly, this 
explains the phenomenon of MPO-ANCA negative AAV; in which detection of the 
circulating pathogenic auto-antibody is masked by a protein fragment. This 
addresses the quandary of describing ANCA as pathogenic when AAV can be 
diagnosed in the absence of an ANCA. A single case report of a neonate born from 
a mother with active MPO-associated AAV developing glomerulonephritis and 
pulmonary haemorrhage is direct evidence for MPO-ANCA pathogenicity, thought to 
have occurred through placental transfer of the antibody (Bansal and Tobin, 2004). 
1.2.1.2 Genetics 
Familial clustering of AAV suggests genetic risk factors for disease and Knight et al. 
have determined a 1.56 relative risk factor for first degree relatives of patients with 
GPA (Knight et al., 2008, Tanna et al., 2012). However, multiple cases of AAV in a 
family are rare due to disease incidence, so there are limited genetic associations 
that can be drawn from familial studies. A number of autoimmune diseases such as 
RA, systemic lupus erythematosus (SLE) and type 1 diabetes are strongly 
associated with particular human major histocompatibility complex variants. Two 
recent genome-wide association studies (GWAS), from the European Vasculitis 
Genetic Consortium (EVGC) and the US Vasculitis Clinical Research Consortium 
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(VCRC), as well as a number of smaller studies have revealed significant 
associations between several HLA SNPs and AAV, supporting a strong role of 
autoimmunity in disease. Interestingly, these HLA associations appear to correlate 
strongly with ANCA specificity, rather than clinical classifications, suggesting that the 
diseases have a distinct genetic background. Notable associations have been 
observed between PR3-ANCA and variations in HLA-DP and MPO-ANCA and 
particular HLA-DQ alleles (Lyons et al., 2012, Xie et al., 2013). The EVCG GWAS 
also revealed significant associations between PR3-positive AAV and an SNP of the 
promoter region of the gene encoding PR3 in addition to an SNP in a gene encoding 
a low-activity allele for alpha-1 antitrypsin, a major inhibitor of PR3 activity. Both of 
these associations support a pathogenic role for PR3 in PR3-associated AAV. Other 
notable genetic associations that have been identified as risk factors for AAV include 
a PTPN22 variant encoding lymphoid tyrosine phosphatase, involved in abnormal 
regulatory T cell and enhanced neutrophil function (Jagiello et al., 2005, Maine et 
al., 2012, Bayley et al., 2015) and an SNP in CTLA4, a glycoprotein involved in T-
cell stimulation, a target for a recently trialled monoclonal antibody abatacept, which 
showed some efficacy in controlling disease in GPA patients (Kamesh et al., 2009, 
Langford et al., 2014). 
1.2.1.3 Complement 
Although immune deposits are not a defining clinical observation in AAV, 
components of the alternative complement pathway (factor B, C5a and properdin) 
have been detected at elevated levels in AAV patients with acute disease (Xing et 
al., 2010, Gou et al., 2013). In vivo studies investigating mice deficient in alternative 
complement pathway factors have revealed that factor B and C5a are essential for 
the development of MPO-associated glomerulonephritis in the murine model (Xiao 
et al., 2007, Schreiber et al., 2009). Work by Schreiber et al. (2009) has been crucial 
in hypothesising the potential pathogenic role for the alternative complement 
pathway in terms of AAV. Their in vitro experiments demonstrated that neutrophils 
activated by ANCA release C5a, which itself becomes a self-perpetuating 
inflammatory stimulus, through the further priming of neutrophils for ANCA-induced 
activation via the C5a receptor (C5aR). C5a has also been described as a strong 
neutrophil chemoattractant and C5aR stimulation upregulates PR3 on the neutrophil 
surface (Schreiber et al., 2009, Chen et al., 2010). There is currently a phase 2 trial 
recruiting to examine the efficacy of a C5aR inhibitor (CCX168) in AAV 
(http://www.clinicaltrials.gov, NCT01363388). 
 36 
 
1.2.1.4 Neutrophils 
Neutrophils and monocytes are traditionally seen as the main effector cells in AAV. 
Seminal work by Falk et al. (1990) suggested the mechanism by which neutrophils 
are not only activated by ANCA, but subsequently degranulate and release free 
radicals, damaging the endothelium and leading to necrotic tissue injury (Falk et al., 
1990). This view is still held as one of the most central processes contributing to 
disease in AAV. Xiao et al. were the first to demonstrate the essential role for 
neutrophils in pauci-immune necrotising and crescentic glomerulonephritis (NCGN); 
as in their mouse model of anti-MPO associated glomerulonephritis, animals 
depleted of neutrophils are completely protected from disease (Xiao et al., 2005).  
The activation of primed neutrophils and monocytes by ANCA leads to the release 
of cytoplasmic granule and lysosome components, encompassing proteolytic 
proteins; neutrophil serine proteases (NPSs) including PR3 and neutrophil elastase 
(NE), as well as MPO and matrix metallopeptidase 9 (MMP9). NSPs are released in 
inactive forms which are processed into active forms by the lysosomal cysteine 
protease dipeptidyl peptidase I (DPPI). DPPI-deficient and PR3/NE-double-deficient 
mice are protected from the development of anti-MPO induced NCGN, through the 
reduced production of IL-1β; highlighting the crucial role of these proteases released 
by neutrophils in disease (Schreiber et al., 2012). Extracellular MPO, primarily 
released by infiltrating neutrophils is found deposited in the glomeruli of AAV 
patients (O'Sullivan et al., 2015). In addition to acting as a planted auto-antigen, 
MPO released from neutrophils and monocytes can bind to endothelium causing 
oxidative damage and MPO deficient mice are partially protected from glomerular 
injury in a model of MPO-associated glomerulonephritis (Vargunam et al., 1992, 
Grattendick et al., 2002, Ruth et al., 2006).  
In addition to degranulation, primed neutrophils respond to ANCA through a process 
termed NETosis. Neutrophils were first identified as producing extracellular traps 
(NETs) in a response to bacterial assault (Brinkmann et al., 2004). Lately these 
networks of chromatin fibres, histones and granule proteins have been identified in a 
number of chronic inflammatory diseases including RA, SLE and atherosclerosis 
(Lande et al., 2011, Khandpur et al., 2013, Knight et al., 2014). Kessenbrock et al. 
were the first to report detection of NETs in patients with AAV. They demonstrated 
that isolated IgG from AAV patients induced the formation of NETs from primed 
neutrophils in vitro and these NETs express MPO and PR3 that are accessible to 
 37 
 
ANCA (Kessenbrock et al., 2009). Increased detection of NETs in AAV may result 
from their reduced clearance due to low levels of DNase I activity, as seen in SLE 
(Sallai et al., 2005, Hakkim et al., 2010, Nakazawa et al., 2014). This accumulation 
of NETs may cause direct damage to the endothelium, due to the excess of 
proteases, and could also act as a platform for ANCA antigen exposure, leading to 
breaking of tolerance; it has been demonstrated that NETs themselves and NET-
treated DCs can induce the formation of ANCA and vasculitis in rodents (Nakazawa 
et al., 2012, Sangaletti et al., 2012). Recently it has been demonstrated that 
neutrophils from AAV patients produce more intracellular ROS and NETs when 
stimulated by ANCA, compared to healthy controls (Ohlsson et al., 2014). 
1.2.1.4.1 Neutrophil surface PR3 expression 
PR3 is an ANCA antigen closely associated with a diagnosis of GPA, which exhibits 
a granular cytoplasmic staining in fixed neutrophils. PR3 is released by primed 
neutrophils on activation by ANCA through degranulation and formation of NETs. In 
addition acting as an antigen for PR3-ANCA, the protease itself can cause 
endothelial cell detachment, lysis and apoptosis and has been demonstrated to 
impair the efferocytosis of apoptotic PMN and prevent phagocytic macrophages 
from polarizing towards a resolutive phenotype (Ballieux et al., 1994, Yang et al., 
1996, Kantari et al., 2007, Gabillet et al., 2012, Millet et al., 2015) (see Figure 1-4). 
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Figure 1-4 Pathogenic role of PR3 in AAV 
1. PR3 acts as an ANCA autoantigen, leading to the activation of primed neutrophils and 
monocytes. 2. Adherent neutrophils expressing PR3 are activated by ANCA, releasing 
proteolytic enzymes and ROS leading to endothelial detachment, lysis and apoptosis. 3. PR3 
expression on the surface of apoptotic PMN impairs macrophage phagocytosis and 
stimulates pro-inflammatory cytokine release, leading to further PMN and monocyte 
recruitment and the production of Th17 cells. 4. PR3 can process pro-IL-1β into bioactive 
IL-1β in monocytes/macrophages. 
Csernok et al. (Csernok et al., 1994) originally reported PR3 expression on the 
neutrophil surface and it has since been established that expression is bimodal; 
consisting of a negative or weakly positive population of cells and a PR3 positive 
population. It is generally understood that PR3 expression on the neutrophil surface 
is genetically determined and the percentages of PR3low and PR3high cells are stable 
under resting and inflammatory conditions, although the expression of PR3 in both 
populations increases on activation (Schreiber et al., 2003, Halbwachs-Mecarelli et 
al., 1995). It has been suggested that a high percentage of membrane-expressing 
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PR3-positive neutrophils is a risk factor for AAV and RA (Witko-Sarsat et al., 1999) 
and a higher surface expression of PR3 on resting neutrophils in GPA patients 
correlates with risk of relapse (Rarok et al., 2002), indicating a pathogenic role for 
PR3. Gene expression of AAV patients has also revealed that PR3 expression 
correlates with disease activity and patients with a high PR3 expression are less 
likely to achieve remission within 6 months (Cheadle et al., 2010, Grayson et al., 
2015). 
1.2.1.5 Microparticles 
Microparticles (MPs) are produced by activated and apoptotic cells as a result of 
disruption to the asymmetrical phospholipid cell membrane; as PS accumulates on 
the outer leaflet of the lipid bi-layer, there is blebbing and shedding of PS 
microvesicles (hereafter termed microparticles) (Zwaal and Schroit, 1997, Comfurius 
et al., 1990). MPs from different cellular sources can range from 0.1-1 micrometer in 
size and vary in their physiological function; they have been suggested to play a role 
in coagulation, homeostasis, cellular signalling, apoptosis, inflammation and 
immunity (Chou et al., 2004, Morel et al., 2006, Abid Hussein et al., 2007, 
Freyssinett, 2005). The production of MPs has to date been documented in 
platelets, erythrocytes, monocytes, granulocytes, epithelial and endothelial cells and 
a number of cancer cells and their cellular origin is reflected in their antigenic 
properties.  
The first indication that leukocyte MPs could be involved in vascular injury came 
from in vitro experiments by Mesri and Altieri in 1999 in which they described 
activation of endothelial cells by leukocyte MPs (Mesri and Altieri, 1999). 
Subsequently, several studies of vasculitis patients have demonstrated significantly 
elevated numbers of circulating neutrophil MPs (NMPs) and platelet MPs (PMPs) in 
active disease (Daniel et al., 2006). Brogan et al. (2004) reported that in a cohort of 
children with systemic vasculitis, the proportion of endothelial MPs (EMPs) and 
PMPs were elevated in active disease; EMP numbers correlated with the 
Birmingham Vasculitis Activity Score (BVAS) and acute-phase reactant levels, 
supporting a role for EMP counts in disease monitoring and their possible 
involvement in perpetuating vascular injury (Brogan et al., 2004a). Interestingly, 
EMPs can be produced by endothelial cells acting to present superantigen to T 
cells, providing a potential link to vascular injury in antibody-mediated vascular 
disease (Brogan et al., 2004b), and PMPs can bind to and activate neutrophils in 
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vitro; relevant to neutrophil activation in AAV pathogenesis (Jy et al., 1995). Most 
recently, it has been demonstrated that ANCA can stimulate the release of MPs 
from primed neutrophils (Hong et al., 2012). These NMPs, which bind to endothelial 
cells via CD18 and intercellular adhesion molecule-1 (ICAM-1) interactions, have 
been shown to activate endothelial cells, assessed by their increase in IL-6, IL-8 and 
ROS production (Stassen et al., 2008). In addition, NMPs express the proteolytic 
enzymes MPO and PR3, allowing the capacity for direct endothelial injury 
(Taekema-Roelvink et al., 2000). NMPs can also exert thrombotic effects through 
CD11b/CD18 interactions with platelets; thromboses has been associated with 
disease activity in AAV, supporting a role for NMPs in mediating vascular injury in 
AAV (Pluskota et al., 2008). 
There is a general consensus that the circulating pool of MPs consists of pro- and 
anti-inflammatory elements. As well as pro-inflammatory properties, NMPs have 
been shown to exert anti-inflammatory effects on monocyte-derived macrophages 
and endothelial cells in vitro and in vivo inhibit neutrophil recruitment to an 
inflammatory site (Gasser and Schifferli, 2004, Dalli et al., 2008, Jansen et al., 
2012). The role that these anti-inflammatory microparticles might play in AAV is yet 
to be established. 
1.2.1.6 Monocytes and macrophages 
Monocytes contain reservoirs of MPO and PR3 in their lysosomal compartments 
and produce IL-8 and free radicals in response to ANCA (Charles et al., 1992, 
Ralston et al., 1997, Weidner et al., 2001). Human monocytes are conventionally 
divided into three subsets determined by their CD16 and CD14 expression; classical 
(CD14highCD16neg/low), intermediate (CD14highCD16high) and non-classical 
(CD14lowCD16high). Recently a pathogenic role for intermediate monocytes has been 
proposed in AAV as this population is expanded in AAV patients compared to 
healthy controls. These intermediate monocytes have been shown to express the 
highest levels of MPO and PR3, compared to their classical and non-classical 
counterparts, and also produce the greatest amounts of IL-1β in response to 
monoclonal anti-MPO and MPO-ANCA purified from patients. This cytokine 
response is not seen with monoclonal anti-PR3 or PR3-ANCA purified from patients 
and is independent of Fcγ receptor binding (O'Brien et al., 2015).  
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Unlike neutrophils which are transient and are typically removed from an 
inflammatory site, infiltrating monocytes can differentiate into macrophages and 
persist in a chronic inflammatory setting. It has been reported that macrophages can 
produce NET-like structures containing proteases and MPO, so may act directly in 
tissue damage and auto-antigen presentation in AAV (O'Sullivan et al., 2015). Acute 
vascular lesions in AAV can progress from areas of necrotising neutrophils to an 
aggregation of monocytes, macrophages and T lymphocytes, leading to fibrosis and 
sclerosis, as well as leading to granulomatous inflammation, found in GPA and 
eGPA, which is characterised by an extravascular accumulation of monocytes, 
macrophages, multinucleated giant cells and T lymphocytes (Weidner et al., 2004). 
Monocytes differentiate into broadly defined M1 (classical) or M2 (alternative) 
macrophages, depending on the surrounding stimuli. M1 macrophages are 
associated with the adaptive immune response, responding to cytokine stimuli such 
as IFN-γ, TNF-α and LPS and driving a Th1 response; activating more M1 
macrophages and producing Th1 cytokines. M2 macrophages play a role in the 
innate immune response through IL-4, IL-10, IL-13 and TGF-β signalling and induce 
a Th2 response, including matrix deposition and fibrosis and the production of Th2 
cytokines (IL-4, TGF-β). Serum from AAV patients has been described as polarising 
macrophages in vitro towards an M2 phenotype and M2 macrophages may 
predominant in focal pauci-immune necrotising GN as well as within areas of tubular 
injury (Ohlsson et al., 2014, Palmer et al., 2014, Zhao et al., 2015). There has been 
no intrinsic phagocytosis defect defined in macrophages from AAV patients although 
it has been suggested that ANCA may decrease the phagocytic ability of 
macrophages (Ohlsson et al., 2012). 
1.2.1.7 T cells 
T lymphocytes have been implicated in the pathogenesis of AAV as CD4+ T cells 
are a main component of renal and granulomatous lesions and CD4+ T cells can be 
detected in the urine of AAV patients, where their levels correlate with disease 
activity (Ronco et al., 1983, Abdulahad et al., 2009). Persistent CD4+ T cell 
activation is characteristic in patients, even in disease remission (Marinaki et al., 
2006). In vitro studies have revealed that T lymphocytes from MPO- and PR3-AAV 
patients respond to their respective antigens in vitro and produce MPO-ANCA when 
stimulated (Griffith et al., 1996, Brouwer et al., 1994, Yoshida et al., 2005). In vivo 
models of GN demonstrate that autoreactive MPO-specific T cells are required for 
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the development of glomerular injury (Xiao et al., 2002, Ruth et al., 2006). The 
current hypothesis is that MPO-specific autoreactive effector T cells recognise 
deposited antigen in the glomeruli and produce a delayed type hypersensitivity 
response. This theory is supported by the recent discovery of an immunodominant 
MPO T-cell epitope that when planted in the glomeruli, induces FCGN (Ooi et al., 
2012). 
There is evidence for both Th1 and Th17 involvement in the pathogenesis of AAV. T 
cells isolated from patients with GPA produce increased levels of IFN-γ and TNF-α 
compared to healthy controls in vitro (Ludviksson et al., 1998). These Th1 cytokines 
have an important role in cell recruitment and activation and can upregulate 
neutrophil and endothelial cell surface expression of PR3 (Baudeau et al., 1994, 
Csernok et al., 1994). Neutrophils and monocytes are a potential source of IL-12, 
with increased cytokine levels identified in monocytes from GPA patients with active 
disease as well as in remission, which could potentiate a Th1 immune response 
(Romani et al., 1997, Ludviksson et al., 1998). Serum levels of IL-17A and IL-23 are 
elevated in AAV patients with acute disease, compared to healthy controls, and IL-
23 levels correlate with disease activity. Elevated numbers of circulating PR3-
specific IL-17 producing T cells are found in PR3-positive GPA patients supporting a 
role for the Th17 axis in disease (Abdulahad et al., 2008, Nogueira et al., 2010). IL-
17A is a strong neutrophil and monocyte/macrophage chemoattractant and 
activator, connecting both the innate and adaptive arms of the immune response 
(Jovanovic et al., 1998, Laan et al., 1999, Shahrara et al., 2009). Notably, IL-17A 
deficient mice are protected from developing a delayed-type hypersensitivity 
response to deposited MPO in a mouse model of anti-MPO focal necrotising 
glomerulonephritis, accompanied by the absence of neutrophil and macrophage 
infiltration and a reduction in CCL5 levels (Gan et al., 2010). When mouse 
neutrophils are stimulated with MPO-ANCA in vitro they produce IL-23, favouring a 
Th17 response (Hoshino et al., 2008). 
T regulatory cells (Tregs) are responsible for maintaining immune tolerance to self-
antigens (Sakaguchi, 2004). A number of studies have shown that there is a 
functional defect in Tregs in AAV patients and patients with higher proportions of 
Tregs are most likely to respond to treatment (Abdulahad et al., 2007, Morgan et al., 
2010, Free et al., 2013). The depletion of Tregs in a mouse model of MPO-
associated glomerulonephritis exacerbates the severity of disease and shows 
enhanced autoantibody responses to MPO (Tan et al., 2013). Tregs can inhibit T 
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cell expansion and prevent their migration into inflamed tissue and have also been 
reported to suppress Th17 cells (Enarsson et al., 2007, Fletcher et al., 2009, 
Tanriver et al., 2009). Current consensus is that a defect in Tregs in AAV may 
predispose towards a Th17 response, leading to the recruitment of macrophages to 
the inflammatory site, perpetuating a delayed-type hypersensitivity reaction. 
1.2.1.8 B cells 
Most of the research on the pathogenic mechanisms in AAV has focused on 
neutrophils, T cells and ANCA. Since the identification of the anti-CD20 monoclonal 
antibody rituximab as an effective agent in the induction of remission in AAV 
patients, studies have begun to address the contribution of B cells to disease (Jones 
et al., 2010, Specks et al., 2013, Stone et al., 2010). There is B cell infiltration 
apparent in granulomatous lesions in GPA, of which the persistence may be 
associated with relapse (Ferraro et al., 2008, Voswinkel et al., 2008). 
Regulatory B cells (Bregs) are able to suppress CD4+ T cell functions through IL-10 
signalling and may inhibit Th1/Th17 responses (Bouaziz et al., 2010, Carter et al., 
2011). Bregs can also inhibit TNF-α production by activated monocytes in vitro 
(Iwata et al., 2011). Decreased serum levels of IL-10 have been found in AAV 
patients, correlating with an increased risk of relapse (Hruskova et al., 2009, 
Sanders et al., 2006) and a numerical deficiency in Bregs has been reported in 
active and quiescent AAV which may be associated with increased Th1 activation 
through reduced IL-10 production (Todd et al., 2014, Wilde et al., 2013). 
1.3 Animal models of AAV 
Key in the elucidation of pathological mechanisms involved in AAV has been the 
development of rodent models of disease. Two murine models have been used in 
the following experimental work; a mouse model of nephrotoxic nephritis (NTN) and 
a model of murine experimental vasculitis (MEV). NTN is a model of immune-
complex mediated crescentic glomerulonephritis that shares many features with the 
crescentic GN often seen in antibody-mediated vasculitis. The disease model is 
characterised by glomerular thrombosis and crescent formation, associated with 
macrophage and T cell infiltration. Two alternative models of MEV are used in the 
following work; both are mouse models of myeloperoxidase anti-neutrophil 
cytoplasm antibody disease. The first MEV model is induced by the passive transfer 
of anti-MPO antibodies into recipient mice and results in a pauci-immune vasculitis, 
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mimicking human MPA. The second is generated through the immunisation of 
human MPO into recipient mice, followed by administration of sub-nephritogenic 
anti-glomerular basement membrane antibody, directing the immune response to 
the kidney. These two alternative models of MEV provide the opportunity to 
investigate both the cellular and the humoral arms of the immune response in AAV. 
All models were set up de novo in our laboratory.  
1.3.1 Nephrotoxic Nephritis 
NTN is a model of immune-complex mediated glomerulonephritis. The disease 
induced shares a common pathology with human glomerulonephritis and has been 
widely used to model glomerular thrombosis and crescent formation. Antibodies to 
mouse glomerular basement membrane are typically raised in sheep or rabbit by the 
injection of isolated glomeruli in adjuvant. Injection of this resulting nephrotoxic 
serum (NTS) into the mouse causes acute heterologous injury followed by an 
adaptive immune response to the deposited antigen, termed the autologous phase. 
The adaptive immune response to the deposited antigen varies between mouse 
strains; C57BL/6 mice exhibit delayed-type hypersensitivity to the NTS, with 
crescentic accumulation of macrophages and T cells and deposition of fibrin, 
characteristic of the Th1 type response seen in AAV, whereas BALB/c mice develop 
a Th2 polarised response, with a glomerular accumulation of complement, with less 
T cell and macrophage infiltration (Huang et al., 1997). Pre-immunisation of animals 
with serum from the host species in which the nephrotoxic serum is generated elicits 
a more rapid response to the NTS. This model is termed accelerated NTN (see 
Figure 1-5). 
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Figure 1-5 Cellular immune response in accelerated nephrotoxic nephritis in 
C57BL/6 mice 
Accelerated NTN is a murine model of immune-complex mediated glomerulonephritis. Pre-
sensitised mice elicit a rapid cellular response to injected nephrotoxic serum, followed by an 
adaptive immune response to the deposited antigen, leading to a crescentic accumulation of 
macrophages and T lymphocytes and deposition of fibrin. DCs, dendritic cells.  
Studies using the murine model of NTN have allowed the dissection of key 
processes contributing to the formation of glomerular thrombosis and crescent 
formation. Crescentic GN can develop in the absence of B cells and immunoglobulin 
(Li et al., 1997) and it is the balance of T helper cell subset activation that 
determines the severity of the resultant glomerular injury (Huang et al., 1997). Th1 
and Th17 subsets both contribute to renal injury, but their respective cytokine 
responses can inhibit the other subset; IL-17 can exacerbate acute kidney injury but 
plays a protective role in established disease through the inhibition of the Th1 
response (Paust et al., 2009, Odobasic et al., 2011, Turner et al., 2012). 
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Experiments using the murine model of NTN have shown the capacity of particular 
cytokines to attenuate (IL-4, IL-10) or exacerbate (IL-12) the development of 
crescentic glomerulonephritis by modulating the T cell response to the deposited 
antigen (Kitching et al., 1999b, Kitching et al., 2000, Tipping et al., 1998, Tipping et 
al., 1997). Interferon-gamma (IFN-γ), produced by Th1 cells, directs cell-mediated 
renal injury (Kitching et al., 1999a) and tumour necrosis factor (TNF), also a key Th1 
cytokine, is essential in the upregulation of adhesion molecule expression (ICAM-1 
and VCAM-1) and the recruitment of inflammatory cells after the injection of NTS, 
leading to the formation of glomerular crescents (Le Hir et al., 1998). 
In addition to infiltrating leukocytes, intrinsic renal cells play an important role in the 
development of renal injury in crescentic glomerulonephritis; IL-12-producing non-
bone marrow derived cells significantly contribute to the glomerular accumulation of 
leukocytes (Timoshanko et al., 2001) and CD40-expressing intrinsic renal cells are 
involved in the development of disease through the induction of Th1 cytokines (Ruth 
et al., 2003, Timoshanko et al., 2002). Major histocompatibility complex class II 
(MHC II)-expressing intrinsic renal cells are also essential for the development of 
glomerular injury via their interaction with CD4+ T cells (Li et al., 1998). 
Experiments using the NTN model first described the vital role of Fc receptors in the 
acute phase of crescentic GN (Suzuki et al., 1998). The function of circulating 
leukocytes in the disease manifested in NTN has shown to be mediated through 
Fcgamma receptor I and III interactions (Tarzi et al., 2002, Tarzi et al., 2003) and a 
role has been revealed for the mannose receptor (MR; a pattern recognition 
receptor) in the Fc-mediated functions of macrophages and their survival, promoting 
glomerular injury, independent of the adaptive immune response (Chavele et al., 
2010). 
1.3.2 Murine experimental vasculitis  
Several murine models have been developed in an attempt to replicate MPO-
associated AAV. The models used in the following experiments successfully 
reproduce a pauci-immune crescentic glomerulonephritis as seen in the human 
disease (see Figure 1-6). 
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Figure 1-6 Cellular effectors in two models of anti-MPO associated 
glomerulonephritis 
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Two murine models of anti-MPO associated glomerulonephritis. The passive transfer model 
is generated by an acute cellular response to injected anti-MPO IgG combined with adjuvant. 
This leads to glomerular injury and the crescentic accumulation of macrophages and T 
lymphocytes. The DTH-like injury model is initiated by the injection of MPO and low dose 
NTS, causing glomerular accumulation of neutrophils, leading to a breaking of immune 
tolerance to MPO and subsequent adaptive immune response. 
1.3.2.1 Rodent models of myeloperoxidase anti-neutrophil cytoplasm 
antibody disease 
Xiao et al. published the first example of a murine model of severe focal necrotising 
and crescentic glomerulonephritis caused by the transfer of anti-MPO antibodies 
into wild-type mice (Xiao et al., 2002). The disease induced by purified IgG transfer 
is pauci-immune in nature, lacking glomerular immune deposits, and is histologically 
identical to the human disease, making it an ideal experimental model. The disease 
severity in this model of anti-myeloperoxidase antibody-induced crescentic 
glomerulonephritis can be enhanced by the administration of granulocyte colony 
stimulating factor (GCSF) and bacterial LPS, the latter mimicking the effect of an 
infection (Huugen et al., 2005, Freeley et al., 2013). Neutrophils are essential 
effector cells in this murine model of glomerulonephritis and mice depleted of 
neutrophils are completely protected from disease (Xiao et al., 2005). The model 
has been used to demonstrate the critical role of the alternative complement 
pathway in disease and has led to the development of a clinical trial testing the 
efficacy of a C5aR inhibitor in AAV (Xiao et al., 2007, Xiao et al., 2014). A 
modification of this model, where MPO knockout (Mpo−/−) mice that are immunized 
with mouse MPO are irradiated and bone marrow (BM) is replaced with Mpo+/+ or 
Mpo-/- BM has revealed the essential expression of MPO on haematopoietic cells 
for disease development as mice engrafted with Mpo-/- bone marrow do not develop 
disease (Schreiber et al., 2006). 
An alternative model of myeloperoxidase anti-neutrophil cytoplasm antibody disease 
has been developed by the group of Holdsworth and Kitching (Gan et al., 2010, 
Ruth et al., 2006). In this model, mice are injected with human or mouse MPO in 
adjuvant and subsequently administered a subnephritogenic dose of NTS, directing 
the immune response to the kidney. This model is unique in replicating the DTH-like 
response to planted MPO, seen in AAV. CD4+ T cells are a significant contributor to 
crescentic renal injury in this model, a mechanism which is independent of ANCA. 
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Experiments using this model have revealed the essential role of IL-17 in disease 
induction; IL-17 deficient mice are significantly protected from disease and show a 
marked reduction in neutrophil and macrophage accumulation independent of 
antibody titres (Gan et al., 2010). The importance of TLR stimulation as a co-
stimulus for disease induction has been demonstrated in this model, supporting a 
link between infection and disease (Summers et al., 2011). 
The homology between human and rat MPO has allowed the development of a rat 
model of crescentic pauci-immune glomerulonephritis through the immunization of 
Wistar-Kyoto (WKY) rats with human MPO in adjuvant. Cross-reactivity between the 
anti-human MPO antibodies and rat MPO induces crescentic nephritis and lung 
haemorrhage. This model of disease is more reproducible than murine models of 
anti-neutrophil cytoplasm antibody disease and has highlighted the contribution of 
innate immune stimuli (within the adjuvant) and genetic background to disease 
(Little et al., 2005, Little et al., 2009). However, rat models do not have the 
advantage of being transferrable to such a wide range of genetic modifications that 
are available in mice. 
1.3.2.2 Murine models of anti-proteinase 3 anti-neutrophil cytoplasm 
antibody disease 
Although there is a substantial body of evidence to indicate the direct pathogenicity 
of MPO-ANCA in animal models, a lack of homology between human and murine 
PR3 and an absence of surface expression of PR3 on mouse neutrophils has 
hindered the development of a murine model of anti-PR3 anti-neutrophil cytoplasm 
antibody disease. There is one mention of a direct pathogenic role of PR3-ANCA 
recently described by Little et al. in 2012 (Little et al., 2012). In Little et al.’s model, 
irradiated NOD-scid-IL2Rγ−/− mice are rescued with the infusion of human 
haematopoietic stem cells. These chimeric mice develop a mild to severe 
glomerulonephritis with lung haemmorhage when injected with IgG from PR3-ANCA 
vasculitis patients. Although this model is crucial in demonstrating a direct 
pathogenic role for human PR3-ANCA, there is no current reproducible model of the 
granulomatous inflammation found PR3-associated vasculitis and this model has not 
been replicated since. 
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1.4 Project hypothesis 
Annexin 1 has emerged as a key mediator in the resolution of inflammation (see 
Figure 1-7). The protein plays a regulatory role in neutrophil trafficking to 
inflammatory sites and promotes PMN clearance in a nonphlogistic manner, 
promoting the return of the tissue to homeostasis. Annexin 1 deficient mice are more 
susceptible to a number of acute and chronic models of inflammation and Annexin 1 
derived peptides can resolve an established inflammatory reaction. 
 
Figure 1-7 Annexin 1 is a key player in the active process of inflammation 
resolution  
Resolution of inflammation is understood to be an active process involving several 
endogenous protein and lipid mediators including lipoxins, resolvins and Annexin 1. 
Dysregulation of these resolution mediators may contribute to chronic inflammatory states.  
AAV is characterised by a necrotising glomerulonephritis, driven by the 
accumulation of neutrophils and macrophages leading to chronic, non-resolving 
inflammation. Current treatment strategies in AAV encompass a general immune-
suppressive approach with treatment-associated complications and relapse 
incidence of significant concern. ‘Resolution’-based therapy may offer a new avenue 
of treatment options.  
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Recent understanding of the pathogenesis of AAV has demonstrated an important 
role of PR3 in disease. A higher neutrophil expression of PR3 correlates with a risk 
of relapse and is an indicator for poor treatment response. PR3 cleaves Annexin 1 
and my hypothesis is that an abundance of PR3 expressing neutrophils at the 
inflammatory site in AAV leads to an increase in Annexin 1 cleavage, preventing the 
proteins’ pro-resolution actions, contributing to the chronic inflammatory state. 
1.4.1 Thesis aims 
The primary aims of this thesis are: 
 To examine the effect of the genetic absence of Annexin 1 on the disease 
manifested in a murine model of immune-complex mediated crescentic 
glomerulonephritis. Chapter 3. 
 
 To investigate whether cleavage–resistant forms of Annexin 1 might   
modulate disease in a murine model of immune-complex mediated 
crescentic glomerulonephritis. Chapter 3. 
 
 To determine whether any effects of glucocorticoid treatment in a murine 
model of immune-complex mediated crescentic glomerulonephritis are 
mediated by Annexin 1. Chapter 3. 
 
 To examine the effect of the genetic absence of Annexin 1 on the disease 
manifested in murine models of anti-MPO associated glomerulonephritis. 
Chapter 4. 
 
 To compare 
i. the neutrophil surface expression of PR3 
and 
ii. proportion of intact Annexin 1 compared to its cleavage products in 
neutrophils 
between healthy controls and PR3-positive GPA patients and observe any 
correlations between the two. Chapter 5. 
 
 To investigate whether cleavage–resistant forms of Annexin 1 might   
modulate the ANCA-induced activation of human neutrophils. Chapter 5. 
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Chapter 2 Materials and Methods 
2.1 Reagents, Antibodies and Animals 
2.1.1 Reagents 
All oligonucleotides were from Sigma. 
Immunodominant MPO peptide was synthesised by Activotec, Cambridge, UK with 
acetyl/amide termini. 
Table 2 Reagents 
Company Reagent 
Catalogue 
number 
Andwin Scientific, Illinois, 
U.S.A. 
Diff-Quick stain kit NC9943455 
AppliChem GmbH, 
Connecticut, U.S.A. 
Cetyltrimethyl ammonium bromide A0805 
BD Biosciences, 
California, U.S.A. 
BD Horizon Fixable Viability Stain 
450 
562247 
 BD CompBeads anti-Rat IgG 552844 
 Annexin V FITC 556419 
Biolegend, California, 
U.S.A. 
1X RBC Lysis Buffer 420301 
Bio-Rad Laboratories, 
California, U.S.A. 
Recombinant human TNF-ɑ PHP051 
Citifluor, London, UK Antifadant mount solution AF1 
GE Healthcare, 
Buckinghamshire, UK 
HiTrap Protein G Sepharose 
columns 
GZ17040403 
 
HiTrap ConA 4B sepharose 
columns 
28-9549-01 AA 
 PD-10 columns 17-0851-01 
KPL, Maryland, U.S.A. 
LumiGlo chemiluminescent 
substrate system 
54-61-00 
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Company Reagent 
Catalogue 
number 
Life Technologies, 
California, U.S.A. 
Microplate Immuno MaxiSorp 96 
well flat bottom polystyrene plate 
DIS-971-010P 
 Trypan Blue Solution, 0.4% 15250-061 
 DMEM with GlutaMAX™ 31966047 
Merck Millipore, 
Darmstadt, Germany 
Human myeloperoxidase 475911 
Newmarket Scientific, 
Newmarket, UK 
Polink-2 HRP Plus kit D46 
PAA Laboratories, 
Somerset, UK 
Iscove's Modified Dulbecco's 
Media (IMDM) 
E15-819 
PeproTech EC, London, 
UK 
GM-CSF 315-03-1000 
Sartorius Stedim 
Biotechnology, Surrey, 
UK 
Vivaspin centrifugal concentrator 85030-511-57 
Siemens AG, D-91052 
Erlangen, Germany 
Multistix 8 SG urine urinary 
dipsticks 
2146 
Sigma-Aldrich, Poole, 
Dorset, UK 
Lipopolysaccharide from Ecoli 
serotype 026:B6 
L8274 
 Complete Freund’s Adjuvant F5881 
 Incomplete Freund’s Adjuvant F5506 
 Sheep IgG I5131 
 Fetal Calf Serum F9665 
 10% neutral buffered formalin HT501128 
 
REDTaq® ReadyMix™ PCR 
Reaction Mix with MgCl2 
R2523 
 
SIGMAFAST
™
 OPD (o-
Phenylenediamine dihydrochloride) 
tablets 
P9187 
 p-nitrophenyl phosphate tablets N2770-50SET 
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Company Reagent 
Catalogue 
number 
 
Dexamethasone 21-phosphate 
disodium 
D1159 
 Percoll P1644 
 Histopaque 1119 11191 
 5-sulphosalycyclic acid dihydrate 247006 
 
Cytochalasin B from Drechslera 
dematioidea 
C2743 
 N-Formyl-Met-Leu-Phe (fMLP) 47729 
Thermo Fisher Scientific, 
Illinois, U.S.A. 
Detoxi-Gel Endotoxin Removing 
Gel 
PN20344 
 BCA Protein Assay Kit 23227 
 OCT SDLAMB/OCT 
 
Thermo Scientific Spectra 
Multicolor Broad Range Protein 
Ladder 
26634 
 Alpha-methyl-d-mannopyranoside 10023170 
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Table 3 Antibodies 
Company Reagent Catalogue number 
Kind gift from Professor  
M. Perretti, Queen Mary 
University of London, 
London, UK 
 
Monoclonal mouse anti-
human Annexin 1 
antibody 
 
Kind gift from Professor 
P. Heeringa, University of 
Groningen, Groningen, 
The Netherlands 
Murine MPO and anti-
MPO antibody 
 
ABCAM, Cambridge, UK 
Rat anti-mouse Ly6G (for 
immunostaining) 
AB25273 
Bio-Rad Laboratories, 
California, U.S.A. 
Rat anti-mouse CD68 MCA1957GA 
BD Biosciences, 
California, U.S.A. 
Mouse anti-human CD54 
(ICAM-1) – PE 
560971 
 Mouse IgG1k PE isotype 556650 
 
Rat anti-mouse Ly6G – 
PE 
551461 
 Rat IgG2a k PE isotype 553930 
 
Rat anti-mouse CD11b –
PerCP/Cy5.5 
550993 
 
Rat IgG2b k PerCP/Cy5.5 
isotype 
550764 
 
Rat anti-mouse Ly6C – 
APC 
560595 
 Rat IgM k APC isotype 400810 
   
   
Biolegend, California, 
U.S.A. 
Mouse anti-human CD15 -
APC 
323007 
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Mouse IgG1 k APC 
isotype 
400122 
 
Rat anti-mouse PE/Cy7 -
F4/80 
123114 
 Rat IgG2a k F4/80 isotype 400521 
 Rat anti-mouse CD41 PE 133905 
Bio-Rad Laboratories, 
California, U.S.A. 
Rat anti-mouse CD45 - 
FITC 
MCA1031FA 
 Rat IgG2b FITC isotype  MCA1125FT 
Santa Cruz Biotechnology, 
Texas, U.S.A. 
Mouse anti-human PR3 
FITC 
sc-52716 
 Normal mouse IgG1 FITC sc-2855 
Sigma-Aldrich, Poole, 
Dorset, UK 
Monoclonal mouse anti-
goat/sheep IgG FITC 
F4891 
 
Goat anti-mouse IgG – 
alkaline phosphatase 
antibody 
A9316 
2.1.2 Animals 
C57BL/6-Annexin-/- were obtained from Charles River Laboratories (Margate, UK). 
B6.129X1-Mpotm1Lus/J mice were obtained from The Jackson Laboratory (Maine, 
USA). Mice used in the experiments were between 8-15 weeks of age and gender 
matched. Controls used were either littermate wild-type mice or C57BL/6 mice bred 
in-house (strain originally from Charles River Laboratories). All mice were housed 
under pathogen-free conditions and kept according to the animal facility guidelines. 
Experiments were carried out under project licence number 40/3228 and followed 
the regulations set out by the UK Home Office Animals (Scientific Procedures) Act, 
UK (1986). Animal group sizes for experiments were minimised by the use of a 
sample size calculation based on preliminary results. 
2.2 In vivo techniques 
2.2.1 Induction of accelerated nephrotoxic nephritis 
NTS was generated from the injection of sheep with isolated mouse glomeruli 
emulsified in Complete Freund’s Adjuvant (CFA), followed by two boosters of 
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glomeruli in Incomplete Freund’s Adjuvant (IFA). Then a terminal bleed was 
performed and serum isolated. NTS was precipitated by Professor Alan Salama, 
UCL Centre for Nephrology, UCL, London, using ammonium sulphate. To induce 
NTN, mice were pre-immunised with a subcutaneous injection of 0.25mg sheep IgG 
(Sigma) on day -5. 1 part sheep IgG was mixed with 4 parts CFA and 3 parts sterile 
0.9% saline. On day 0 mice were given an IV tail injection of 200μl NTS, diluted 1:1 
in sterile 0.9% saline, mixed with or without varying doses of LPS. Mice were 
sacrificed on Day 7 or 8. 
2.2.2 Generation of anti-MPO antibodies in MPO-/- mice 
MPO-/- mice over 6 weeks of age were given a total dose of 40µg mMPO over 36 
days (injections on day 0, 21 and 36). The first injection of 20µg was given IP in 
CFA, the second and third injections of 10ug were given IP in Incomplete Freund’s 
Adjuvant (IFA). Animals were sacrificed on day 42 and blood was obtained by 
cardiac puncture. Blood was collected into untreated eppendorfs and kept on ice 
before obtaining serum by centrifuging at 5000rpm for 10 mins at 4°C. Serum was 
stored at -20°C prior to antibody isolation. 
Additional dosing of MPO immunodominant peptide  
A subset of MPO-/- mice were injected with mouse immunodominant peptide 
MPO409–428 (PRWNGEKLYQEARKIVGAMV) (Ooi et al., 2012). This peptide was 
administered at a dose of 50µg with the first and second injections of mMPO, within 
the emulsion. 
2.2.3 Induction of anti-myeloperoxidase associated glomerulonephritis 
Either C57BL/6 wild-type mice or Annexin-/- mice were injected with 100µg/g anti-
MPO IgG by IV tail injection day 0, t=0hr, followed by an IP injection of 0.1µg LPS at 
t=1hr. Additional IP injections of 26µg GCSF were administered at day -4, 0 and +4. 
2.2.4 Assessment of disease 
2.2.4.1 Measurement of haematuria and proteinuria 
Urine was collected over 18 hours using murine metabolic cages. Haematuria was 
estimated using urine dipstick analysis (Siemens) and urine was collected into 
eppendorfs for subsequent measurement of proteinuria, serum urea and creatinine. 
Proteinuria was measured using a sulphosalicyclic acid (Sigma) assay against a 
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standard curve of BSA and read at 450nm. Urine samples were measured in 
triplicate and diluted at 1:10 in water or 1:100 if nephrotic (classified as +++ on a 
urine dipstick scale of proteinuria). Serum urea and creatinine were measured by 
Clinical Chemistry, MRC, Harwell. 
2.2.4.2 Preparation of histology 
After sacrifice, the murine circulation was flushed with ice cold PBS using a 
peristaltic pump by injection into left ventricle, after cutting the inferior vena cava, to 
remove any circulating leukocytes. Hemi-kidney, liver and spleen were fixed in 10% 
neutral buffered formalin (Sigma) and hemi-kidney and spleen were snap-frozen in 
liquid nitrogen with OCT on a cork disc for subsequent cryo-sectioning. 
Fixed sections were processed and stained with periodic acid Schiff (PAS) and 
haematoxylin-eosin (H&E) by The Department of Cellular Pathology, The Royal 
Free Hampstead NHS Trust. 
2.2.4.3 Histological assessment 
Histological assessment was carried out blinded to the experimental conditions. 
PAS stained sections were scored on a scale of 0-2 (mild, moderate or severe) for 
the degree of glomerular proliferation and a score of 0-4 for the number of 
thrombotic quadrants. 25 glomeruli were scored per sample. 
2.2.4.4 Cryosectioning 
Frozen samples were cut into 6μm sections using a cryostat and were left to air dry, 
protected from light, overnight before being stored at -80°C until subsequent 
staining. 
2.2.4.5 Immunostaining of frozen tissue sections 
Direct immunofluorescence was performed on frozen kidney sections to detect 
sheep IgG. Samples were fixed in acetone for 10 minutes, before rehydrating in 
PBS and incubating with monoclonal mouse anti-goat/sheep IgG FITC (Sigma) at 
1/200 dilution for 1hr at room temperature in a humidified chamber. Sections were 
then washed in PBS and mounted using an anti-fadant mount solution (Citifluor). 
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Indirect immunostaining to detect CD68 and Ly6G was performed on frozen 
sections using a Polink-2 HRP Plus kit (Newmarket Scientific). Tissue was fixed in 
pre-cooled acetone for 10 minutes before incubating in 0.3% hydrogen peroxide 
solution for 10 minutes to block endogenous peroxidase activity. After blocking in 
10% semi-skimmed dry milk powder (Marvel) for 30 minutes, slides were incubated 
with rat anti-mouse CD68 (Bio-Rad Laboratories) at 1/200 or rat-anti mouse Ly6G 
(ABCAM) at 1/200, diluted in PBS with 10% normal goat serum for 1hr at room 
temperature in a humidified chamber. Control sections were incubated in PBS with 
10% normal goat serum only. Spleen was included as a positive control for CD68. 
The subsequent steps followed the manufacturers’ instructions and colour 
development was stopped after identifying positive staining on the spleen by 
microscopic visualisation. Slides were counterstained with Mayer’s haematoxylin 
and mounted using DePeX mounting medium. 
2.2.4.6 Assessment of immune response to sheep IgG (ELISA) 
Systemic immune response to Sheep IgG was measured by ELISA using serum 
samples. Flat-bottomed 96-well plates (Nunc Maxisorb, Life Technologies) were 
coated with sheep IgG at 0.1mg/ml, diluted in borate buffered solution (BBS; 100mM 
boric acid, 25mM sodium tetraborate anhydrous, pH 8.3-8.5) or BBS alone, 
overnight at 4°C. Plates were washed three times in PBS/0.075% Tween-20 and 
blocked with 3% BSA in PBS/0.075% for 1 hr at 37°C. Total IgG was measured by 
incubating samples at a 1:1000 dilution for 1 hr at 37°C, followed by incubation with 
an alkaline phosphatase secondary antibody (goat anti-mouse IgG, Sigma) at a 1 in 
1000 dilution for 1 hr at 37°C. Plates were developed with p-nitrophenyl phosphate 
(Sigma), 50µl per well and read at 405nm on an ELISA plate reader. 
2.3 In vitro techniques 
Informed written consent was obtained from patients and controls included in the 
following experiments. Clinical sample collection and use received ethical approval 
from the Royal Free Hospital, London. 
2.3.1 Cellular techniques 
2.3.1.1 Generation of murine MPO from MPRO cell line 
Induced-differentiated mouse promyleocyte cell line (MPRO; ATCC CRL-11422) 
was cultured at 37°C, 5% C02 in Iscove's Modified Dulbecco's Media (IMDM, PAA 
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Laboratories) with 20% heat-inactivated fetal calf serum (FCS), 1% penicillin and 
streptomycin (p/s) and supplemented with either 6-10ng/ml GM-CSF (PeproTech) or 
10-15% HM-5 conditioned medium (filter-sterilised). MPRO cells were grown to 
approximately 2 x 106 cells/ml before harvesting and freezing down in Buffer A 
(6.7mM sodium dihydrogen phosphate pH 6, 1mM MgCl2, 3mM NaCl, protease 
inhibitor, ddH20). Pellets were frozen and stored at -80°C prior to MPO extraction. 
HM-5 cells were maintained at 37°C, 5% C02 in Dulbecco's Modified Eagle Medium 
(DMEM) with GlutaMAX™ (Life Technologies), 10% heat-inactivated FCS, 1% p/s 
and cultured for 5-6 days past 100% confluency to produce conditioned medium 
containing GM-CSF. Cells were initially cultured personally and then grown by Dr 
Margaret Goodall, School of Immunity and Infection, University of Birmingham, UK.  
2.3.1.2 Isolation of leukocytes from murine whole blood 
Blood from cardiac puncture was anti-coagulated using 1:5 ratio of 3.8% tri-sodium 
citrate solution. Red cells were lysed for 10 minutes at room temperature using 2ml 
1X RBC Lysis Buffer (Biolegend) per 100ul whole blood. Cells were washed in 
FACS wash buffer (0.1% sodium azide, 1% heat-inactivated fetal calf serum (FCS) 
in PBS) before counting and staining for FACS analysis. 
2.3.1.3 Isolation of microparticles from murine whole blood 
Blood from cardiac puncture was anti-coagulated using 1:5 ratio of 3.8% tri-sodium 
citrate solution. Platelet-poor plasma was isolated from anti-coagulated blood by 
centrifuging at 2400rpm for 5 minutes, followed two further centrifugations at 
>10,000rpm for 5 minutes to purify the supernatant containing the microparticles. 
Plasma was stored at -80°C prior to staining for FACS analysis. 
2.3.1.4 Separation of mononuclear cells from kidney 
After sacrifice, the murine circulation was flushed with ice cold PBS using a 
peristaltic pump by injection into left ventricle, after cutting the inferior vena cava, to 
remove any circulating leukocytes. Kidney was cut into small pieces and placed in 
cold sterile PBS before being transferred into a 0.5mg/ml collagenase solution for 
digestion. The tissue was then digested for 25 minutes at 37°C before further 
mashing and an additional digestion time of 5 minutes. Digests were then sieved 
through 70μm and 30μm cell strainers before washing and staining for FACS 
analysis. 
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2.3.1.5 PMN isolation from human blood 
5-7mls of peripheral blood anticoagulated with EDTA was layered onto 6ml 
Histopaque 1119 (Sigma) and centrifuged at 800g for 20 minutes with no brake. The 
lower, reddish layer containing the granulocytes was washed in PBS (centrifuged at 
300g for 10 min) and transferred onto a discontinuous Percoll (Sigma) gradient 
made up of 2mls each of the following percentages; 85%, 80%, 75%, 70%, 65%. 
After centrifugation at 800g for 20 minutes with no brake, the layers between 65% 
and 85% were collected, washed and counted for subsequent manipulation or 
analysis. Viability was ≥95%, assessed by trypan blue exclusion (Life Technologies).  
2.3.1.6 Generation of whole cell lysates 
Neutrophils were resuspended at 10 x 106 cells / ml in a non-denaturing lysis buffer 
(20mM Tris-HCl pH8, 137mM NaCl, 10% glycerol, 1% Triton-X 100, 2mM EDTA) on 
ice for 30 minutes in the presence of protease inhibitors. Cells were centrifuged at 
≥10,000g for 10 minutes at 4°C and supernatants were stored at -20°C. 
2.3.1.7 Purity assessment of PMN population by cytospin and subsequent 
staining 
To assess purity of isolated PMN population, cells were resuspended at a 
concentration of 0.75 x 106 cells / ml in PBS and 100μl was added to the cytospin 
apparatus. Slide chambers were spun at 450rpm for 6 minutes before disassembling 
and leaving to air dry for 10 minutes. Cells were then fixed in 100% ethanol for 10 
minutes before staining with Diff-Quick (Andwin Scientific); 30 seconds in solution I 
(red) followed by 30 seconds in solution II (blue). 
2.3.1.8 FACS techniques 
2.3.1.8.1 Immunofluorescent staining of isolated cells 
Leukocytes from blood or kidney single cell suspensions were washed in FACS 
wash buffer (0.1% sodium azide, 1% fetal calf serum (FCS) in PBS) and 
resuspended at a concentration of 1 x 106 cells in 100µl wash buffer for staining. 
When monocytes or macrophages were included in the cell suspension, cells were 
stained in the presence of 5% FCS to reduce non-specific staining. Antibodies were 
used at the recommended concentration, or titrated to an optimum level of staining 
before use, and incubated with the cells for 30 minutes on ice before washing, 
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fixation with 1% paraformaldehyde and storage at 4°C prior to acquisition within 1 
week.  
2.3.1.8.2 Viability assessment of cells by FACS 
Cell viability was assessed using a fixable viability stain (BD Biosciences) that 
allows the discrimination between live and dead cells based on the fluorescence 
intensity at 450nm. Cells were stained as directed by the manufacturer. 
2.3.1.8.3 FACS acquisition 
BD CompBeads (BD Biosciences) were used for compensation controls. Data was 
acquired using the BD LSRFortessa and between 100,000 and 1 x 106 events were 
collected per sample.  
2.3.1.9 In vitro activation of human neutrophils 
by patient ANCA 
Human neutrophils were resuspended at 2.5 x 106 cells / ml and primed with 
cytochalasin b (Sigma) and TNF-ɑ (Bio-Rad Laboratories) at a concentration of 
5µg/ml and 2ng/ml respectively for 15 minutes at 37°C, with or without a specified 
concentration of SuperAnnexinA1. Subsequently, 100μl of cells were delivered to 
wells of a U-bottomed 96-well plate and incubated with either PBS, 1μM fMLP 
(Sigma), endotoxin-depleted ANCA or normal human IgG, both at 0.2mg/ml, for 15 
minutes at 37°C. Then, the plate was spun at 1500rpm for 5 minutes before 
transferring 75μl of the supernatant to a flat-bottomed 96-well plate for 
measurement of MPO release.  
by TNF-α  
Human neutrophils were resuspended at 10 x 106 cells / ml in HBSS and plated in a 
48-well plate. Cells were incubated with/without TNF-α at 10ng/ml for 30min at 
37°C.  
2.3.2 Molecular Biology 
2.3.2.1 Genotyping of mice 
Genomic DNA was obtained from the digestion of ear clips overnight in 100ul DNA 
lysis buffer (100mM Tris HCl pH 8.5, 5mM EDTA, 0.2% sodium dodecyl sulphate 
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(SDS), 200mM NaCl) at 55°C with 100μg/ml proteinase K. Samples were then 
diluted with 300μl of distilled water and heat inactivated for 15 minutes at 75°C. 
PCR was carried out using REDTaq® ReadyMix™ PCR Reaction Mix with MgCl2 
(Sigma) and 2μl of the crude lysate template, using the standard protocol.  
MPO-/- genotyping 
See Appendix Figure 6-3 for MPO-/- genotyping example 
Primers: MPO1 (5’ TGA-CAC-CTG-CTC-AGC-TGA-AT 3’), MPO2 (5’ TGC-AGG-
CAG-CTG-GTC-TCG-CA- 3’), MPO3 (5’ CTA-CCG-GTG-GAT-GTG-GAA-TGT- 3’). 
PCR conditions: 
95°C for 5 minutes, 1 cycle 
94°C for 1 minute, 35 cycles 
60°C for 1 minute, 35 cycles 
72°C for 1 minute, 35 cycles 
72°C for 5 minutes, 1 cycle 
10°C hold 
2.3.2.2 Gel electrophoresis 
PCR products were analysed by gel electrophoresis on a 2% agarose gel with 1μl 
ethidium bromide (10mg/ml) per 50ml volume. Gels were run at 100V for 30 minutes 
and visualised using a UV light source. 
2.3.3 Protein Biochemistry 
2.3.3.1 Degranulation assay / MPO release 
75ul of supernatants from neutrophil activation assays were incubated 100μl MPO 
substrate (SIGMAFAST™ OPD tablets, Sigma) per well for 30 minutes in the dark at 
room temperature. The reaction was stopped by adding 100μl acetic acid and the 
OD was read at 450nm on a plate reader. 
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2.3.3.2 Assessment of protein concentration 
Total protein concentration of cell lysates was determined by a bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific). Bovine serum albumin (BSA) standards 
were made up in the lysis buffer used to create cell lysates and standards and 
samples were run in triplicate. Standard protocols were followed. 
2.3.3.3 SDS-PAGE 
10% SDS polyacrylamide gels were made and equal amounts of total protein per 
sample were loaded and separated by electrophoresis alongside a multicolour broad 
range protein ladder (Thermo Fisher Scientific). For straightforward protein 
visualisation, gels were stained with Coomassie blue. 
2.3.3.4  Western blotting 
Western blotting was used to examine Annexin 1 cleavage products in neutrophil 
whole cell lysates. Protein was transferred from SDS gels using a semi-dry 
technique to a nitrocellulose membrane and blocked overnight in blocking buffer 
(5% semi-skimmed dry milk powder (Marvel), 1X TBS, 0.1% Tween-20). 
Membranes were washed and incubated with the primary antibody at appropriate 
concentrations in blocking buffer for 2 hours at room temperature and then washed 
and incubated in the appropriate secondary antibody conjugated to horse radish 
peroxidase (HRP) for 1 hour at room temperature in blocking buffer. LumiGlo 
chemiluminescent substrate system (KPL) was used to visualize the protein. 
2.3.3.5 Purification of human and mouse IgG 
Human IgG containing ANCA or mouse IgG containing anti-MPO IgG was isolated 
from plasma exchange fluid or serum, respectively, using a Protein G Sepharose 
column (GE Healthcare) on a fast protein liquid chromatography FPLC machine. 
Columns were washed with 10 column volumes of binding buffer (20mM sodium 
phosphate pH 7.0) before applying the sample, adjusted with an equal volume of 
binding buffer. Unbound protein was washed through the column with further 
volumes of binding buffer until no material appeared in the effluent. IgG was eluted 
in 1 ml fractions with 0.1M glycine-HCl pH 2.7 into eppendorfs containing 40µl Tris-
HCl pH9.0 to neutralise the solution. The IgG concentration of each fraction was 
determined by the absorbance at 280nm and selected fractions were pooled and 
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dialysed against PBS overnight. Final concentration was determined by the above 
mentioned method and samples were stored at -20°C for future use. 
2.3.3.6 Removal of endotoxin 
LPS-depletion of IgG preparations was achieved by applying the samples to a 
polymyxin B column (Detoxi-Gel Endotoxin Removing Gel, Thermo Scientific). 
Columns were firstly regenerated with 1% sodium deoxycholate, before equilibrating 
with pyrogen-free water and applying the sample. IgG was incubated for 1 hour on 
the column to maximise endotoxin depletion efficiency, eluted with pyrogen-free 
water and stored at -20°C. 
2.3.3.7 Anti-MPO IgG ELISA 
NUNC maxisorb plates (eBioScience) were coated with 0.5µg/ml mMPO in coating 
buffer (0.1M carbonate-bicarbonate pH9.6) overnight at 4°C. Plate washed 5 times 
with wash buffer (10mM Tris, 75mM NaCl, 0.05% Tween 20, pH8) before blocking in 
1% BSA in PBS for 1hr at room temperature. Wash x5. Samples diluted 1:100 in 
incubation buffer (PBS with 0.2% BSA, 0.05% Tween-20) and added to plate. 
Standard and samples pipetted across the plate in a 4-fold titration curve. Incubated 
for 1hr at room temperature before wash x5. Incubated with alkaline phosphatase 
labelled goat anti-mouse IgG diluted 1/000 in incubation buffer for 1hr at room 
temperature before wash x5 and developed with p-nitrophenyl phosphate (Sigma). 
Plates scanned at 405nm and reaction stopped by adding 100µl/well NaOH 5M 
when a plateau for the lower dilutions is reached. 
2.3.3.8 MPO extraction from MPRO cell line 
All steps were carried out on ice to avoid protein degradation. MPRO cell pellets 
were resuspended in 10mls Buffer A (see Appendix) (0.5mM PMSF) per 1ml cell 
pellet and lysed using dounce homogenisation. Vesicles were then ruptured by 
mixing cell pellets end-over-end with 1% cetyltrimethyl ammonium bromide (CTAB) 
(AppliChem GmbH) for 2h. Insoluble material was removed by centrifugation at 
20,000g for 20 minutes at 4°C. Soluble material was dialysed against Buffer B (see 
Appendix) overnight at 4°C. The following day, MPO was purified using fast protein 
liquid chromatography over a HiTrap ConA 4B sepharose column (GE Healthcare) 
and eluted using 750mM methyl-d-mannopyranoside (Thermo Fisher Scientific). 
Fractions were analysed using a spectrophotometer and measured at 280nm and 
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430nm to determine purity before being pooled. Pooled fractions were buffer 
exchanged into sterile PBS using PD-10 columns (GE Healthcare) and concentrated 
to 1mg/ml using Vivaspin centrifugal concentrator (Sartorius Stedim Biotechnology). 
2.3.3.9 MPO activity assay 
The MPO content of the MPRO cells was monitored over time using an MPO activity 
assay. A standard curve of MPO was made with human MPO (Merck Millipore), 
diluted in PBS. MPRO cells were lysed with a non-denaturing lysis buffer (as 
mentioned in section 2.3.1.6) on ice for 30 minutes. Serial dilutions of test samples 
were added to wells in duplicate. The samples were incubated with OPD substrate 
(Sigma) and H202 for 30 minutes at room temperature, protected from light. The 
reaction was stopped with sulphuric acid and read at 490nm on a plate reader. 
2.3.4 Statistical analysis 
2.3.4.1 FlowJo 
FACS files were analysed using FlowJo version 7.6.5 - 10.0.7 (Tree Star Inc., 
Ashland, Oregon, USA). 
2.3.4.2 Prism  
Statistical analysis was performed using GraphPad Prism 4.0 - 6.0 (GraphPad 
software, San Diego, CA, USA). Data were assessed for normality using a 
D'Agostino & Pearson omnibus normality test to choose the appropriate statistical 
test. A student’s t-test was used to determine any difference between two 
parametrically distributed sets of unpaired data. A Mann-Whitney test was used 
when unpaired data were non-parametrically distributed. Paired data were analysed 
using a paired t-test when data were parametrically distributed and a Wilcoxon 
matched-pairs signed rank test when data were non-parametrically distributed. A 
Kruskal-Wallis test was used to compare two or more groups of non-parametrically 
distributed data when there was a single independent variable and a two-way 
analysis of variance (ANOVA) was used to compare two or more groups of non-
parametrically distributed data when there were two independent variables. 
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2.3.4.3 ImageJ 
Image J was used to calculate densitometry measurements on Western blot 
(National Institutes of Health, USA). 
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Chapter 3 The effect of Annexin 1 in a murine model of 
accelerated nephrotoxic nephritis 
3.1 Introduction 
The murine model of nephrotoxic nephritis (NTN) is used successfully as a model of 
crescentic glomerulonephritis to determine the underlying pathology of glomerular 
thrombosis and crescent formation that can be found in AAV. The disease 
generated in C57BL/6 mice is characterised by a Th1-response; dependent on the 
glomerular accumulation of macrophages and T lymphocytes and deposition of fibrin 
leading to renal injury. 
Annexin 1 has been shown to play a protective role in a number of Th1-driven 
models of inflammation; Annexin 1 deficient mice exhibit exacerbated disease 
phenotypes in mouse models of antigen- and collagen-induced arthritis, 
accompanied by increased cellular infiltration, T cell proliferation and expression of 
proinflammatory cytokines within the synovial joint (TNF-α, IL-1β, IL-6 and MIF). In T 
cell-mediated dermal contact hypersensitivity there is an increase in neutrophil and 
CD4+ T cell adhesion in the absence of Annexin 1, accompanied by increased T cell 
proliferation and IL-17A mRNA. In ovalbumin (OVA)-induced dermal delayed type 
hypersensitivity (DTH) response there is also increased T cell proliferation and IFN-γ 
and IL-17A levels detected in Annexin 1 deficient mice (Yang et al., 2004, Yang et 
al., 2013).  
Steroid treatment is an important element in the management of AAV and 
dexamethasone has been shown to attenuate disease in NTN (Nagai et al., 1982). A 
number of the anti-inflammatory actions of glucocorticoids have been attributed to 
Annexin 1 (Hannon et al., 2003, Wallner et al., 1986) and Annexin 1 deficient mice 
are resistant to the pro-resolving effects of dexamethasone in two models of 
inflammatory arthritis (Patel et al., 2012, Yang et al., 2004). A serine protease-
cleavage-resistant form of Annexin 1 (SuperAnxA1) has been shown to inhibit the 
adhesion and infiltration of neutrophils in an in vivo model of inflammation 
(Pederzoli-Ribeil et al., 2010) and has been used successfully to accelerate the 
resolution of inflammation in a model of serum-induced inflammatory arthritis (Patel 
et al., 2012), revealing the potential for Annexin 1 peptidomimetics in the treatment 
of chronic inflammation. 
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Microparticles (MPs) have been implicated in the pathogenesis of AAV; neutrophil-
derived MPs can activate endothelial cells and platelet-derived MPs can activate 
neutrophils in vitro. In addition, levels of neutrophil-, platelet- and endothelial-derived 
MPs are elevated in active disease. Microparticle numbers have not been 
investigated in murine models of crescentic glomerulonephritis, and with a 
potentially emerging role in vascular injury it is important to characterise them in 
these models and examine any parallels between their abundance in murine and 
human vascular disease. 
3.2 Aim 
This chapter investigates the role of Annexin 1 in the murine model of accelerated 
NTN. Disease was compared between wild-type and Annexin 1 deficient mice, while 
the effect of SuperAnxA1 and dexamethasone on disease was examined. In 
addition to histological readouts for disease, neutrophil and macrophage infiltration 
into the kidney was analysed, peripheral and infiltrating leukocytes were phenotyped 
for inflammatory markers and microparticle numbers were determined in blood 
plasma. 
3.3 Experimental Design 
C57BL/6 and Annexin 1 -/- mice used were sex- and age-matched and between 8-
15 weeks of age. Initial experiments to generate NTN in wild-type mice were 
performed with varying doses of LPS. Disease severity was assessed by renal 
function; haematuria and proteinuria estimated by urinary dipstick, proteinuria 
measured by sulphosalicyclic acid method and serum urea and creatinine measured 
by Clinical Chemistry, MRC, Harwell. Glomerular thrombosis was scored on PAS 
stained kidney sections. Neutrophil and macrophage infiltration into the intra-
glomerular space was quantified by Ly6G and CD68 staining of frozen kidney 
sections, respectively. Phenotyping of blood leukocytes and renal macrophages was 
achieved using FACS. Blood plasma samples were stored for microparticle analysis. 
The systemic immune response to pre-immunisation with Sheep IgG was assessed 
by ELISA. 
Statistical analysis was performed using GraphPad Prism. 
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3.4 Results 
3.4.1 Establishing the murine model of accelerated nephrotoxic nephritis 
Murine models are notoriously variable in terms of the degree of disease induced 
when generated in different animal units with varying degrees of pathogen levels 
and when different sources of adjuvant or stimulus are used. 
The aim was to replicate the model of accelerated NTN in a new animal house and 
establish a moderate degree of disease that could be influenced by treatment with 
particular reagents or the genetic absence of specific proteins. 
Nephrotoxic serum (NTS) used in the following experiments had been used 
successfully to induce disease at the Hammersmith Hospital Campus in the 
presence and absence of additional endotoxin. NTS was diluted 1:1 in sterile saline 
for injection. 
PAS-stained kidney was scored blinded, 25 glomeruli were counted per section. 
Experiments to establish the mouse model of NTN are summarised in Table 4.  
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Table 4 Table describing the preliminary experiments performed to establish the nephrotoxic nephritis model 
Experiment ID 
Experimental 
groups 
Number of mice in 
experimental group 
Dose of NTS and 
route administered 
Dose of LPS and 
route administered 
Thrombosis score 
(0-4) 
1 
Control 2 N/A* None 0, 0 
NTN 3 200μl IP None 0, 0, 0 
2 
Control 2 N/A None 0, 0 
NTN 3 100μl IV None 2.7,  0.6 , 0 
3 
Control 6 N/A None 0, 0, 0, 0, 0, 0 
NTN 6 100μl IV None 0, 0, 0, 0, 0, 0 
4 
Control 8 N/A None 0, 0, 0, 0, 0, 0, 0, 0 
NTN 9 100μl IV None 
0, 0, 0, 0, 0, 0, 0, 0, 
0 
5 NTN 8 100μl IV None 0, 0, 0, 0, 0, 0, 0, 0 
6 
Control + 0.025μg 
LPS 
3 N/A 0.025μg IP 0, 0, 0 
Control + 0.5μg LPS 6 N/A 0.5μg IP 0, 0, 0, 0, 0, 0 
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NTS + 0.025μg LPS 1 100μl IV 0.025μg IP 1.56 
NTS + 0.5μg LPS 1 100μl IV 0.5μg IP 0 
7 
Control + 0.5μg LPS 4 N/A 0.5μg IP 0, 0, 0, 0 
Control + 1μg LPS 3 N/A 1μg IP 0, 0, 0 
NTS + 0.5μg LPS 3 100μl IV 0.5μg IP 0, 0, 0 
NTS + 1μg LPS 3 100μl IV 1μg IP 0, 0, 0 
8 NTN 4 100μl IV 0.625μg IV with NTS 
3.76, 3.80, 2.16, 
3.60 
      
* Control animals were injected with an equivalent volume of sterile saline  
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Attempts to establish NTN with NTS alone 
The first experiment to establish the NTN model (experiment ID 1, see Table 4) was 
trialled through the intraperitoneal (IP) injection of 200μl NTS alone, into mice pre-
immunised with Sheep IgG, as a straightforward route of administration. When 
proteinuria was estimated by urinary dipstick 7 days after NTS, there was some 
proteinuria evident in all three animals that were given NTS; however no glomerular 
disease was evident on PAS-stained kidney sections. The second experiment 
(experiment ID 2) replicated the protocol previously established at the Hammersmith 
Hospital Campus and involved the injection of 100μl NTS intravenously (IV). One of 
the three animals that was administered NTS displayed an elevated level of 
haematuria when estimated by urinary dipstick, 7 days after NTS, and a thrombosis 
score of 2.7 when glomerular disease was quantified (see Figure 3-1 for scoring 
classification); however the other two animals that received NTS displayed little or 
no glomerular disease. Repeats of this protocol (experiment IDs 3, 4 & 5) to account 
for any shortcomings in the IV injection route yielded little or no proteinuria and no 
haematuria when estimated by urinary dipstick, 7 days after NTS. Glomerular 
disease was not evident in any animals when visualised on PAS-stained kidney 
sections. 
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Figure 3-1 Images to demonstrate glomerular thrombosis scoring system 
PAS stained kidney sections were visualised at x630 magnification and 25 individual glomeruli were scored per section. Score 0: capillary loops intact within 
glomerulus. Score 1: glomerular structure disrupted but no evidence of thrombosis. Score 2: glomerular thrombosis detected. Score 3: majority of glomerulus 
thrombosed, some structure still intact and cells still visible. Score 4: glomerulus totally thrombosed, minimal cells visible. 
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Determination of LPS dose to exacerbate response to NTS 
Lipopolysaccharide (LPS) has historically been administered alongside NTS to 
exacerbate disease in the murine model of NTN. A pilot experiment to determine a 
dose of LPS that caused neutrophilia was undertaken using mice pre-immunised 
with CFA 5 days previously. Mice were injected IP with either 0.025μg or 0.05μg 
LPS alone. FACS analysis of peripheral blood samples stained with anti-Ly6G 
antibody 18 hours after administration of LPS revealed that a dose of 0.05μg LPS 
compared to 0.025μg LPS resulted in an increased median neutrophil percentage 
compared to total leukocyte events (median 22% versus 13%, Figure 3-2). 
 
Figure 3-2 LPS administration leads to an increase in the percentage of 
neutrophils compared to total leukocytes in the peripheral blood  
FACS analysis of tail bleeds from mice pre-immunised with CFA alone that had been 
administered 0.025μg and 0.5μg LPS IP revealed an increased median percentage of 
neutrophils, compared to total leukocyte events, 18hrs after LPS, when a higher dose of LPS 
was given. Total leukocytes were determined by FSC/SSC profile and neutrophils were 
determined by Ly6G
+
 expression. Data are expressed as median with interquartile range. 
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Injection of mice with NTS + LPS 
When mice pre-immunised with CFA and sheep IgG were injected IP with 0.05μg 
LPS, alongside NTS IV, 4 hours after administration the percentage of neutrophils in 
the peripheral blood was increased when compared with the injection of 0.05μg LPS 
in the absence of NTS (median 86% versus 79%) (Figure 3-3).  
 
Figure 3-3 NTS administration alongside LPS leads to an increase in the 
percentage of neutrophils compared to total leukocytes in the peripheral blood 
FACS analysis of tail bleeds from mice pre-immunised with CFA and sheep IgG, 4 hrs after 
IP administration of saline alone, 0.5μg or 1μg LPS alone or in combination with 100μl NTS 
IV. Total leukocytes were determined by FSC/SSC profile and neutrophils were determined 
by Ly6G
+
 expression. There was an increased percentage of neutrophils, compared to total 
leukocytes, when LPS was administered compared to saline alone. When NTS was 
administered in parallel with 0.5μg LPS, compared to 0.5μg LPS alone, there was an 
increase in the percentage of neutrophils, compared to total CD45
+
 events. Data are 
expressed as median with interquartile range. 
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Although the neutrophil proportion was increased within the total leukocyte 
population 4 hours after the administration of LPS, in mice where LPS was injected 
IP alongside the IV injection of NTS there was no haematuria evident when 
estimated by urinary dipstick and on examining PAS stained kidney sections there 
was no glomerular disease evident apart from a single animal with a small amount 
of glomerular thrombosis, 7 days after NTS injection. 
A subsequent experiment replicating an LPS dose given in combination with NTS 
established at the Hammersmith Hospital Campus involved the addition of 0.625μg 
LPS to the NTS solution and the injection of this suspension IV. 7 days after 
NTS/LPS proteinuria and haematuria were strongly elevated when estimated by 
urinary dipstick in all 3 mice tested. Glomerular thrombosis score ranged from 2.2-
3.8 in all 4 mice when quantified on PAS stained kidney sections. 
3.4.2 The absence of Annexin 1 exacerbates disease in a mouse model of 
nephrotoxic nephritis 
The Annexin 1 knockout mouse developed by Hannon et al. (Hannon et al., 2003) is 
more susceptible to a number of models of inflammatory disease (Yang et al., 2004, 
Yang et al., 2013, Liu et al., 2015). I previously described the establishment of the 
accelerated NTN model in wild-type mice with a dose of 0.625µg LPS given in 
combination with NTS IV. This dose resulted in a relatively severe disease 
phenotype when scored on glomerular thrombosis. My hypothesis was that Annexin 
1 would attenuate disease in NTN and therefore a lower LPS dose of 0.1µg was 
administered in the following experiments to avoid potential lethality of disease in 
Annexin 1 deficient mice. 
To investigate whether the absence of Annexin 1 in C57BL/6 mice confers a greater 
susceptibility to the development and severity of glomerular inflammation in a mouse 
model of immune complex glomerulonephritis, I induced NTN in wild-type (WT) and 
Annexin 1 deficient (Anx-/-) mice. Animals pre-immunised with Sheep IgG 5 days 
previously were injected with 0.1μg LPS in combination with NTS IV on day 0. A 
subset of WT and Anx-/- mice (n=3 per group) were culled on day 3 to allow the 
investigation of early effects of the absence of Annexin 1. The remaining mice were 
culled equally across experimental groups on day 7 or 8 and end-point data were 
combined from two experiments; n=8 per group and n=5 per group, respectively. 
Two WT animals and one Anx-/- animal died between day 1 and day 3 of unknown 
causes. 
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In this model of NTN, FACS analysis of cells isolated from cardiac puncture blood 
on day 3 did not reveal a difference in the absolute leukocyte counts or total number 
of neutrophils between WT and Anx-/- mice (Figure 3-4). 
(iii) 
Strain Sample Average cell 
count per 50μl 
blood 
 Percentage 
neutrophils / 
CD45+ events 
Number of 
neutrophils per 
50μl blood 
wt A 816667 28.7 234383 
B 800000 18.5 148000 
C 766667 18.3 140300 
Anx-/- A 800000 9.54 76320 
B 316667 10.2 32300 
C 800000 33.2 265600 
Figure 3-4 Day 3 analysis of numbers of peripheral blood leukocytes and 
neutrophils in NTN 
Blood samples were taken on day 3 of NTN. (i) Total leukocytes isolated from a set volume 
of peripheral blood were visualised using trypan blue and counted. (ii) Subsequent 
calculations of total neutrophil counts were determined by FACS. (iii) Raw data to illustrate 
the graphs derived for (i) and (ii). 
FACS analysis of kidney single cell suspensions generated at day 3 suggested that 
the infiltrating macrophages in the Anx-/- kidney on day 3 were of a less 
inflammatory phenotype, based on their Ly6C MFI (median 270 versus 732) (Figure 
3-5). There were no differences evident in the percentages of infiltrating neutrophils 
or macrophages compared to CD45+ events, or the CD11b expression of the 
macrophages, when comparing experimental groups. 
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Figure 3-5 Day 3 analysis of Ly6C expression of infiltrating macrophages in 
NTN 
FACS analysis of kidney single cell suspensions. (i) Leukocytes were determined by their 
positive expression of CD45. (ii) Macrophages and neutrophils were gated based on their 
expression of CD11b and Ly6G within the CD45+ gate. (iii) Infiltrating and resident 
macrophages were identified within the macrophage gate as F4/80
low
 and F4/80
high
 
respectively. (iv) The median Ly6C MFI of the F4/80
low
 macrophages was lower in Anx-/- 
mice compared to WT mice. Data are expressed as median with interquartile range. 
 80 
 
Ly6G immunostaining of frozen kidney sections 3 days after LPS/NTS did not reveal 
a difference in the number of infiltrating neutrophils between the Anx-/- kidney and 
WT kidney (Figure 3-6). 
 
Figure 3-6 Ly6G staining of NTN day 3 frozen kidney  
(i) Representative field of WT NTN day 3 kidney, x200 magnification. (ii) Representative 
field of Anx-/- NTN day 3 kidney, x200 magnification. (iii) Ly6G positive events were 
scored over 5x fields of x200 magnification to compare neutrophil infiltration between WT 
and Anx-/- mice on day 3 of NTN. (iv) High resolution image of Ly6G staining x630 
magnification. 
At day 7/8 after LPS/NTS Anx-/- mice exhibited a significantly elevated level of 
haematuria estimated by urinary dipstick (median 3 versus 1.5; p=0.03) and serum 
urea (89.8mmol/L versus 12.5mmol/L; p=0.029) compared to WT mice. The urine 
protein/creatinine ratio was not significantly different between experimental groups 
(0.3 mg/mmol versus 0.5mg/mmol) (Figure 3-7).  
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Figure 3-7 Annexin 1 deficient mice exhibit decreased renal function compared 
to wild-type mice in a mouse model of nephrotoxic nephritis 
(i) Haematuria estimated by urinary dipstick was significantly elevated in the Anx-/- mice 
compared to WT mice (p=0.03). (ii) Serum urea was also significantly increased in the Anx-
/- mice compared to WT mice (p=0.029). (ii) Urine protein/creatinine ratio was not 
significantly different between groups. All results were analysed using a Mann-Whitney t-
test. Data are shown as median with interquartile range. 
The degree of glomerular thrombosis, quantified on PAS-stained kidney sections, in 
the Anx-/- mice was significantly increased when compared to the WT mice at the 
experiment end (median 2.2 thrombosed quadrants versus 1.2 thrombosed 
quadrants; p=0.009) (Figure 3-8). 
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Figure 3-8 Glomerular thrombosis is significantly elevated in Annexin 1 
deficient mice when compared to wild-type mice, in a model of nephrotoxic 
nephritis 
(i) Glomerular thrombosis, scored on the number of quadrants involved, was significantly 
increased in the Anx-/- mice when compared to the WT mice, on day 7/8 of disease. Data are 
expressed as median with interquartile range. (ii) a typical PAS-stained glomerulus from a 
WT mouse, thrombosis score of 1. (iii) a typical PAS-stained glomerulus from an Anx-/- 
mouse, thrombosis score of 3. 
There was no difference in the number of macrophages infiltrating into the 
glomerular space on day 7/8 between experimental groups when assessed by CD68 
immunostaining of frozen kidney sections (Figure 3-9).  
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Figure 3-9 Infiltration of macrophages into the glomerular space remains 
unchanged when comparing wild-type mice and Annexin 1 deficient mice on 
day 7/8 of NTN 
(i) CD68 immunostaining of frozen kidney section demonstrating infiltration of 
macrophages into the glomerular space on day 7 of NTN. (ii) When 25 glomeruli were 
scored, the average number of infiltrating macrophages into the glomerular space was no 
different between WT and Anx-/- mice on day 7/8 of NTN. Data are expressed as median 
with interquartile range. 
The adaptive immune response, assessed by the response to Sheep IgG, between 
the Anx-/- mice and WT mice was comparable, when measured by ELISA.  
 
Figure 3-10 There is no difference in the adaptive immune response to Sheep 
IgG between wild-type mice and Annexin 1 deficient mice, when measured by 
ELISA 
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Systemic immune response to Sheep IgG was measured by ELISA using serum samples. 
Plates were coated with 0.1mg/ml sheep IgG overnight at 4°C. Plates were washed and 
blocked before incubating samples at a 1:1000 dilution for 1 hr at 37°C, followed by 
incubation with an alkaline phosphatase secondary antibody (1 in 1000 dilution) for 1 hr at 
37°C. Plates were developed with p-nitrophenyl phosphate and read at 405nm. 
FACS analysis of kidney single cell suspensions at day 7/8 did not reveal any 
differences between the percentages of infiltrating neutrophils or macrophages 
when comparing WT and Anx-/- mice. The CD11b and Ly6C phenotypes of the 
infiltrating macrophages were comparable between experimental groups. 
3.4.2.1 Microparticles in NTN 
Human neutrophil- and platelet-derived MPs (NMPs and PMPs) have pro-
inflammatory capacity in vitro and correlate with disease activity in AAV.  
I previously demonstrated that Annexin 1 deficient mice have aggravated disease, 
compared to wild-type mice in a murine model of NTN. In order to investigate 
whether MP numbers are altered in Annexin 1 deficient mice compared to wild-type 
mice in NTN, blood plasma was stained for FACS analysis with Annexin V and 
antibodies to Ly6G or CD41, to identify total MPs, NMPs and PMPs (staining and 
FACS performed by Dr Ying Hong, UCL). MP numbers were compared between 
wild-type and Annexin 1 deficient mice, n=7 per group. Mice pre-immunised with 
Sheep IgG were injected with 0.1μg LPS in combination with NTS IV on day 0. Mice 
were culled equally across experimental groups on day 7 or 8. One wild-type animal 
died between day 1 and day 3 of unknown causes. 
In this NTN model total MP numbers and NMP numbers were significantly lower in 
the Anx-/- mice, compared to the WT mice (median total MPs 1.4x106 versus 
3.5x106; p=0.035, NMPs 0.8x104 versus 2.6x104; p=0.0058, Figure 3-11). PMP 
numbers were comparable between the experimental groups. 
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Figure 3-11 Total microparticle numbers and neutrophil-derived MPs are significantly less in Annexin 1 deficient mice in NTN 
Microparticles were isolated from blood plasma at the experiment end. Cells were incubated with Annexin V and then stained with Ly6G or CD41 to identify 
total microparticles (i), and those derived from neutrophils (ii) or platelets (iii), respectively. MPs were analysed by FACS and latex beads (Sigma) were run 
concurrently with the samples to determine absolute MP numbers. Data are expressed as median with interquartile range. 
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3.4.3 Daily treatment of mice with 10µg dexamethasone does not reduce 
disease in this model of nephrotoxic nephritis 
Annexin 1 has been demonstrated to mediate the anti-inflammatory effects of 
dexamethasone in two models of inflammatory arthritis (Patel et al., 2012, Yang et 
al., 2004). 
To investigate whether the treatment of C57BL/6 mice with dexamethasone 
accelerates the resolution of nephrotoxic nephritis, animals were injected with 0.1μg 
LPS in combination with NTS IV on day 0 and 10μg dexamethasone (or vehicle) 
was administered by IP injection, daily, from 3 days post-NTS injection until mice 
were culled on day 7/8. To examine whether any effects of dexamethasone were 
mediated by Annexin 1, two groups of mice were used in the experiment; wild-type 
and Annexin 1 deficient mice (n=5 per group, dexamethasone or vehicle treated). 
One animal from the Anx-/- control group died due to unidentified causes 6 days 
post-NTS so no data was available to add to the following analysis. 
The degree of haematuria estimated by urinary dipstick day 7/8 after NTS was no 
different when comparing WT control and WT dexamethasone-treated, or Anx-/- 
control and Anx-/- dexamethasone treated animals. It was unclear whether serum 
urea and urine protein/creatinine ratio were different between treated and untreated 
groups due to sample collection difficulties (Figure 3-12).  
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Figure 3-12 Treatment of wild-type and Annexin 1 deficient mice with 10µg 
dexamethasone has no effect on renal function, in this model of nephrotoxic 
nephritis. 
(i) Haematuria estimated by urinary dipstick analysis was no different between WT or Anx-/- 
mice. Problems with serum isolation and measurement meant that it was unclear whether 
protein/creatinine ratio (ii) and serum urea (iii) were different between treated and untreated 
groups. Data are expressed as median with interquartile range. 
When glomerular thrombosis was quantified on PAS-stained kidney sections, 
treatment of WT and Anx-/- mice with 10µg dexamethasone had no effect on renal 
injury (Figure 3-13).  
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Figure 3-13 Treatment of wild-type and Annexin 1 deficient mice with 10µg 
dexamethasone has no effect on glomerular thrombosis, in this model of 
nephrotoxic nephritis. 
When glomerular thrombosis was scored on PAS stained kidney sections, there was no 
difference evident between treated and untreated groups, in WT or Anx-/- mice. Data are 
expressed as median with interquartile range. 
Glomerular macrophage infiltration on day 7/8 of NTN, determined by CD68 
immunostaining of frozen kidney sections, was also similar when comparing treated 
and untreated groups (Figure 3-14). 
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Figure 3-14 Treatment of wild-type and Annexin 1 deficient mice with 10µg 
dexamethasone has no effect on total macrophage infiltration into glomeruli, in 
this model of nephrotoxic nephritis. 
CD68 immunostaining did not reveal a difference in macrophage infiltration into the 
glomerular space between treated and untreated groups, in WT or Anx-/- mice. Data are 
expressed as median with interquartile range. 
3.4.4 Daily dosing of 1µg SuperAnxA1 has no effect on glomerular injury in 
this mouse model of accelerated nephrotoxic nephritis 
Patel et al. demonstrated that treatment of mice with protease-resistant Annexin 1 
(SuperAnxA1/SAnxA1) accelerates the resolution of inflammatory arthritis, when 
compared to the injection of human recombinant Annexin 1 or vehicle control (Patel 
et al., 2012).  
As I had previously demonstrated a protective role for Annexin 1 in disease I 
reasoned to test SAnxA1 as an effector of resolution in NTN. I utilised the same 
dosing strategy as Patel et al. and injected mice with 1μg SAnxA1, or vehicle 
control, from day -2 (before NTS) to day 7 or 8 at which point mice were culled 
equally across experimental groups (control n=7, SAnxA1 n=7) (see Figure 3-15). 
Following the establishment of the NTN model in my hands, I hypothesised that a 
less severe degree of disease should be utilised for the assessment of cleavage-
resistant Annexin 1 peptides in order to observe any effect, so the dose of LPS was 
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reduced to 0.3μg/mouse, administered IV with the NTS. After performing an initial 
experiment with this dose of LPS, the experiment was repeated with a lower dose of 
LPS (0.1μg) to test whether a less severe disease phenotype would unmask any 
subtle effects of SAnxA1. 
 
Figure 3-15 Dosing schedule for SuperAnnexinA1 in accelerated NTN 
C57BL/6 mice were pre-immunised with 0.25mg sheep IgG in CFA on day -5. On day 0 
mice were injected IV with NTS combined with LPS (0.1μg or 0.3μg per mouse). SAnxA1 
was administered IP 1μg daily from day -2 until experiment end. 
With this dosing strategy, when mice were given doses of 0.3μg or 0.1μg LPS in 
combination with NTS IV, haematuria and proteinuria estimated by urinary dipstick 
were no different between the control or SAnxA1 groups (Figure 3-16, i and ii). 
Serum urea and protein/creatinine ratio were also no different between the control 
and SAnxA1 groups (Figure 3-16, iii and iv). Glomerular thrombosis, scored on PAS 
stained kidney sections, exhibited a variable spread in both control and SAnxA1 
groups (Figure 3-16, v). This dose of SAnxA1 did not have any effect on 
macrophage infiltration into the glomerulus on day 7/8, when mice were given doses 
of 0.3μg or 0.1μg in combination with NTS IV, although a lower dose of LPS was 
associated with a significantly lower number of infiltrating glomerular macrophages 
in the absence of SAnxA1 (1 versus 2 infiltrating macrophages; p=0.0157) (Figure 
3-16, vi). 
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Figure 3-16 Daily dosing of 1µg SuperAnnexinA1 has no effect on renal injury 
or total macrophage infiltration in this mouse model of NTN 
WT mice were administered 1µg SAnxA1 daily alongside the NTN injection schedule. 
Experiments with two different doses of LPS were performed (0.3μg or 0.1μg). Where urine 
was successfully collected, haematuria (i) and proteinuria (ii) estimated by urinary dipstick 
were no different between the control or SAnxA1 groups. Renal function, assessed by serum 
urea (iii) and protein/creatinine ratio (iv) was also no different between the control and 
SAnxA1 groups. Glomerular thrombosis (v) exhibited a variable spread in both control and 
SAnxA1 groups. (vi) The number of infiltrating macrophages into the glomerular space at 
day 7 was not different between control and SAnxA1 groups but was significantly reduced in 
 92 
 
the control group when 0.1μg LPS was administered with the NTS, rather than 0.3μg 
(p=0.0157, Mann-Whitney t-test). Data are expressed as median with interquartile range.  
3.4.4.1 Surface CD11b expression is reduced in infiltrating macrophages in 
mice treated with SuperAnnxinA1 in a model of NTN 
To explore any subtle physiological effects of SAnxA1 in this model of NTN, cells 
were isolated from cardiac puncture blood and kidney single cell suspensions for 
FACS analysis at the experiment end. Cells were stained with antibodies to CD45, 
Ly6G, CD11b, Ly6C and F4/80 to enable the detection and phenotyping of 
neutrophils, monocytes and macrophages. 
When NTS was given with low dose LPS (0.1μg) there were no differences in the 
relative percentages of neutrophils or monocytes, compared to total leukocyte 
events, between the control and SAnxA1 groups in the blood. When the phenotype 
of the blood monocyte population was examined by means of Ly6C expression, a 
bimodal population of Ly6C-expressing monocytes was revealed (Figure 3-17). 
These two populations, designated Ly6Cmid and Ly6Chigh did not differ in their 
relative abundance, or as a fraction of the total leukocyte population when 
comparing the control and SAnxA1-treated animals. The MFIs of the Ly6Cmid and 
Ly6Chigh populations were no different when comparing experimental groups. 
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Figure 3-17 FACS analysis reveals two distinct populations of mouse monocytes in the blood based on surface expression of Ly6C 
Anticoagulated blood from mouse cardiac puncture was red-cell lysed and stained with antibodies to CD11b and Ly6C. (i) Leukocyte events were gated based 
on their FSC/SSC profile to exclude cell debris. (ii) Monocytes were determined by their positive CD11b expression within the leukocyte gate and exhibited a 
bimodal pattern of Ly6C expression. These two populations were designated Ly6C
mid
 and Ly6C
high
. 
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When NTS was given with low dose LPS (0.1μg) there was no difference in the 
percentage of infiltrating neutrophils detected by FACS in the kidney at day 7/8 
when comparing the control and SAnxA1-treated groups. The percentages of 
infiltrating and resident macrophages, determined by their F4/80low and F4/80high 
phenotypes respectively, were comparable between experimental groups, when 
compared to total CD45+CD11b+Ly6G- events and when considered relative to each 
other. The Ly6C expression of the infiltrating macrophages was no different when 
comparing the control and SAnxA1-treated groups. The CD11b expression of the 
infiltrating macrophages was significantly lower in the SAnxA1 group (1.0x104 
versus 1.1x104; p<0.04) when compared with the control group (Figure 3-18).  
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Figure 3-18 Surface CD11b expression is reduced in infiltrating macrophages in 
mice treated with SuperAnxA1 in a model of NTN 
FACS analysis of kidney single cell suspensions. (i) Leukocytes were determined by their 
positive expression of CD45. (ii) Macrophages and neutrophils were gated based on their 
expression of CD11b and Ly6G within the CD45+ gate. (iii) Infiltrating and resident 
macrophages were identified within the macrophage gate as F4/80
low
 and F4/80
high
 
respectively. (iv) The CD11b MFI of the F4/80
low
 macrophages was significantly lower in 
mice treated with SAnxA1 (p=0.037, Mann-Whitney t-test). Data are expressed as median 
with interquartile range. 
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3.5 Discussion 
Success in generating the murine model of accelerated nephrotoxic nephritis in 
C57BL/6 mice was achieved when additional endotoxin was administered in the 
form of LPS IV combined with NTS solution. LPS has been used historically as an 
adjuvant to enhance the immune response to NTS and may reflect infectious stimuli 
found naturally in the environment, which might be absent in the sanitised 
surroundings of a Comparative Biology Unit. 
The genetic absence of Annexin 1 resulted in significantly more severe disease in 
this model of NTN. Serum urea was elevated in Annexin 1 deficient mice and 
glomerular thrombosis was increased from an average of 1.2 to 2 (score 0-4 
involved quadrants). FACS analysis of leukocyte activation markers early in disease 
suggested that infiltrating macrophages were of a less inflammatory phenotype in 
the Annexin 1 deficient animals, based on their Ly6C expression. The CD11b 
expression of the infiltrating macrophages was unchanged between experimental 
groups. Blood neutrophil counts have been shown to be significantly lower in 
Annexin 1 deficient mice 24hrs post LPS and Annexin 1 deficient leukocytes display 
an increased activation state (Damazo et al., 2005), however analysis of peripheral 
blood 3 days after NTS injection did not reveal any differences in the total numbers 
of circulating leukocytes or neutrophils between wild-type and Annexin 1 deficient 
animals. There were also no differences observed in the numbers of infiltrating 
neutrophils into the glomerulus early in disease when comparing experimental 
groups. At the disease end point, although renal impairment was more severe in 
Annexin 1 deficient mice, there was no apparent effect on total numbers of 
infiltrating glomerular macrophages. The absence of Annexin 1 did not appear to 
have a significant effect on the humoral immune response to pre-sensitization with 
Sheep IgG. I hypothesised that an Annexin 1 deficiency in NTN would lead to an 
increased early neutrophil influx, exacerbating the immune response to NTS, and 
resulting glomerular injury. It is possible that the early timepoint data examining 
neutrophil infiltration was lacking in experimental numbers. There were also not 
many neutrophils detected on the kidney immunostaining, indicating that neutrophil 
infiltration may have peaked prior to day 3. Alternatively, Annexin 1 has been shown 
to augment Th1 responses, and the Annexin 1 deficiency could be affecting the 
DTH-like response seen in this model, leading to an increased accumulation of Th1 
cells. There was no TNF-α or IL-6 detectable by ELISA in the remaining serum 
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samples, so these cytokines could not be compared between the experimental 
groups.  
There was a significant reduction in overall MP numbers and neutrophil-derived MPs 
in Annexin 1 deficient mice in this NTN model, compared to wild-type mice. Due to 
the significantly decreased renal function, and increased degree of glomerular 
thrombosis found in Annexin 1 deficient animals in this model, this would suggest 
that overall MP numbers are not a reliable reflection of vascular injury in mice, in 
contrast to what has been demonstrated in human AAV. Neutrophil-derived MPs 
have also been described to mediate anti-inflammatory effects (Dalli et al., 2008), so 
a reduction of these in NTN could be a mechanism by which disease is aggravated 
in Annexin 1 deficient mice, although there is no published evidence to suggest that 
Annexin 1 influences MP release directly. 
Daily administration of 10µg dexamethasone did not appear to have any effect on 
renal injury or glomerular macrophage infiltration in this model of NTN; so the impact 
of this drug could not be compared between wild-type and Annexin 1 deficient mice. 
The dose of dexamethasone given here was based on previously published doses 
demonstrated to attenuate disease in accelerated NTN (see Table 5) and resolve 
inflammation in other disease models and was equivalent to an average of 4mg/kg 
according to the size of the mice. The administration of dexamethasone 3 days after 
NTS/LPS was intended to resolve inflammation after disease onset, reflecting how 
AAV would be treated in a clinical setting. It is possible that in this disease model, 
Annexin 1 is primarily important in the early neutrophil influx and the administration 
of dexamethasone after disease has initiated was too late to have an effect on 
resulting glomerular injury. In any future experiments, it would be important to 
establish an appropriate dose and timing schedule of dexamethasone administration 
before comparing experimental groups. 
Table 5 Previously published dexamethasone doses for treatment of 
experimental inflammation 
Author Year Experimental 
model 
Dose of 
dexamethasone 
Administration 
routine 
Nagai et al.  1982 Accelerated 
NTN 
1 or 5 mg/kg IP Daily for 14 
days post NTS 
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Mancuso et 
al.  
1995 Zymosan 
peritonitis  
1 mg/kg s/c One dose 2hr 
prior to 
zymosan 
Yang et al.  2004 Antigen-
induced 
arthritis 
0.5mg/kg IP Daily from day 
20 following 
disease onset  
Patel et al.  2012 Serum-
induced 
arthritis 
10µg/animal IP Daily from day 
2 following 
disease onset 
     
s/c: subcutaneous 
When mice were injected with 1µg SAnxA1 prophylactically and during the disease 
timecourse there was a significant reduction observed in the CD11b expression of 
infiltrating macrophages. It was unexpected to find CD11b expression reduced in the 
SAnxA1-treated group as CD11b expression is reduced in Annexin 1 deficient 
monocytes and macrophages (Hannon et al., 2003, Yona et al., 2004, Yona et al., 
2006). This has been postulated to account for an impaired phagocytic mechanism 
in Annexin 1 deficient cells. However, CD11b also plays an important role in 
adherence of monocytes to activated endothelium, so a reduction of macrophage 
CD11b expression could play an anti-inflammatory role through reduced monocyte 
trafficking. GCs reduce CD11b expression and as a regulator of Annexin 1, this 
could agree with these SAnxA1 data (Burton et al., 1995, Das et al., 1997, Lim et al., 
2000). There was no observed effect of this dosing of SAnxA1 on renal injury or 
glomerular macrophage infiltration at the experiment end, when mice were given 
doses of 0.3μg or 0.1μg LPS in combination with NTS IV. Although, lower doses of 
LPS did not lead to reduced disease severity as assessed by urinary dipstick 
findings or glomerular thrombosis score. While SAnxA1 has been shown to reduce 
leukocyte infiltration in vivo, in an experimental model of resolving arthritis, SAnxA1 
administration did not affect the initial neutrophil and mononuclear cell-driven stage 
of disease but did accelerate the resolution-phase. The disease manifested this 
model of accelerated NTN may be too robust to allow any pro-resolving effects of 
this dose of SAnxA1.  
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Summary: 
 The genetic absence of Annexin 1 results in significantly more severe 
disease in a murine model of immune complex-mediated crescentic 
glomerulonephritis, nephrotoxic nephritis (NTN). 
 Total microparticle and neutrophil-derived microparticle numbers are 
reduced in Annexin 1 deficient mice, compared to wild-type mice in this NTN 
model. 
 Daily administration of 10µg dexamethasone did not have any impact on 
disease in this NTN model, so the impact of this drug in Annexin 1 deficient 
mice could not be studied. 
 There was no effect on disease severity when SuperAnnexinA1 was 
administered according to this dosing schedule in this NTN model, however 
there was a significant reduction in the CD11b expression of infiltrating 
macrophages. 
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Chapter 4 The effect of Annexin 1 in murine models of MPO-
related glomerulonephritis 
4.1 Introduction 
The data in Chapter 3 demonstrate that Annexin 1 plays a protective role in a 
murine model of crescentic glomerulonephritis (NTN). To investigate further what 
role Annexin 1 might have in AAV, the effect of the protein was examined in murine 
models of MPO-related glomerulonephritis. 
Murine models of myeloperoxidase anti-neutrophil cytoplasm antibody disease have 
been essential in determining key pathogenic pathways involved in the development 
of AAV. The passive transfer model of anti-myeloperoxidase associated 
glomerulonephritis developed by Xiao et al. is dependent on the infiltration of 
neutrophils for the development of crescentic GN which is apparent 3 days post-IgG. 
Recombinase-activating gene-2–deficient (Rag2–/–) mice, lacking functional T and 
B lymphocytes are equally susceptible to disease development (Xiao et al., 2005). 
The disease penetrance in this model can be exacerbated by the injection of LPS 
and granulocyte-colony stimulating factor (GCSF), which in combination leads to an 
increased number of circulating neutrophils early in disease, followed by an 
exacerbated infiltration of glomerular macrophages and a higher incidence of 
glomerular crescents (Freeley et al., 2013, Huugen et al., 2005). An alternative 
model of anti-myeloperoxidase associated glomerulonephritis developed by the 
group of Holdsworth and Kitching is generated by delivering a subnephritogenic 
dose of NTS to mice sensitised with mouse MPO in adjuvant. This model is unique 
in replicating the DTH-like response to planted MPO, seen in AAV and is useful in 
examining both the humoral and cellular response to anti-MPO as both neutrophils 
and CD4+ T cells play a key role in disease (Gan et al., 2010, Ruth et al., 2006). 
The same group has recently identified an immunodominant MPO T-cell epitope that 
when injected in place of native mouse MPO produces an equivalent immune 
response and focal crescentic glomerulonephritis (FCGN) (Ooi et al., 2012).  
Annexin 1 regulates neutrophil and monocyte accumulation in vivo and has a 
particular role in moderating leukocyte/endothelial interactions in the 
microvasculature. The genetic absence of Annexin 1 in murine models of acute and 
chronic inflammation results in augmented neutrophil and monocyte accumulation 
(Getting et al., 1997, Lim et al., 1998, Damazo et al., 2005, Yang et al., 1997). In 
models of chronic inflammation, Annexin 1 deficient mice display enhanced 
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macrophage recruitment, extracellular matrix deposition and fibrosis (Damazo et al., 
2011, Locatelli et al., 2014). Annexin 1 can also play a protective role within a DTH 
response, limiting T cell proliferation and the production of IFN-γ and IL-17A (Yang 
et al., 2013). 
Microparticles (MPs) may play a role in vascular injury and heightened levels of 
neutrophil- and platelet-derived MPs correlate with disease activity in AAV. I 
demonstrated in the previous chapter that total MP numbers and NMP numbers are 
significantly reduced in Annexin 1 deficient mice in model of NTN, but their 
abundance in other models of crescentic glomerulonephritis is yet to be addressed.  
4.2 Aim 
This chapter investigates the role of Annexin 1 in murine models of MPO-related 
glomerulonephritis. The primary aim was to establish a model of anti-
myeloperoxidase glomerulonephritis, with which the absence of Annexin 1 could be 
examined by comparing disease in wild-type and Annexin 1 deficient mice. Attempts 
were made to induce anti-MPO IgG in MPO-deficient mice using two different 
antigens; murine MPO (mMPO) alone or with the additional injection of 
immunodominant MPO CD4+ T-cell epitope (MPO409-428). Anti-MPO IgG was 
isolated from pooled MPO-deficient serum and assessed for purity and titre against 
purified anti-MPO IgG with previously established pathogenicity. Initially steps were 
taken to establish a model of anti-myeloperoxidase glomerulonephritis based on the 
original passive transfer approach described by Xiao et al. (2002). Once 
successfully set up, this model was used to compare disease between wild-type and 
Annexin 1 deficient mice. A further attempt at modelling MPO-associated 
glomerulonephritis was intended to reproduce the model described by Holdsworth 
and Kitching (Ruth et al., 2006) with the accompaniment of additional doses of 
immunodominant MPO peptide. 
4.3 Experimental Design 
Wild-type and Annexin 1 deficient mice used were sex- and age-matched and 
between 8-20 weeks of age. Initial optimisation of the anti-myeloperoxidase 
glomerulonephritis model was carried out trialling the passive transfer of varying 
doses of anti-MPO IgG isolated from MPO deficient mice immunised with purified 
mMPO. Accompanying injections of LPS and GCSF were used to exacerbate 
disease. An additional attempt to model MPO-associated glomerulonephritis 
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involved the injection of two doses of mMPO combined with MPO immunodominant 
peptide in adjuvant followed by the transfer of subnephritogenic doses of 
nephrotoxic serum (NTS). MPO antibody titres were determined by ELISA on serum 
or plasma isolated from peripheral or cardiac blood. Disease severity was assessed 
by renal function; haematuria and proteinuria estimated by urinary dipstick of 24 
hour urine collection, proteinuria quantified by sulphosalicyclic acid method and 
serum urea measured by Clinical Chemistry, MRC, Harwell. Glomerular crescent 
formation was scored on PAS stained kidney sections. Macrophage infiltration into 
the intra-glomerular space was quantified by CD68 immunostaining of frozen kidney 
sections. Plasma samples were stored for microparticle analysis. 
4.4 Results 
Circulating anti-MPO IgG was induced in MPO-deficient mice by the injection of 
mMPO in adjuvant. Anti-MPO IgG was isolated from MPO-deficient serum but was 
relatively low in titre compared to anti-MPO IgG with previously established 
pathogenicity. A murine model of anti-myeloperoxidase associated 
glomerulonephritis was ultimately established through the IV injection of 100µg/g 
bodyweight anti-MPO IgG followed by an IP injection of 0.1µg LPS/animal 1hr after 
IgG transfer. IP injections of 26µg GCSF were given in addition; 4 days prior to IgG, 
alongside the IgG injection and 4 days after IgG. An alternative model of anti-
myeloperoxidase associated glomerulonephritis based on the injection of mMPO 
and MPO immunodominant peptide followed by NTS failed to induce an immune 
response and any associated renal injury. Comparison of the passive-transfer model 
of anti-myeloperoxidase associated glomerulonephritis between wild-type and 
Annexin 1 deficient mice did not reveal any significant differences in renal function 
or glomerular disease at the experiment end.  
4.4.1 Generation of anti-MPO IgG in MPO-deficient mice 
Xiao et al. (2002) originally described the generation of circulating anti-MPO specific 
antibodies in MPO-deficient mice through the injection of mouse MPO in adjuvant 
over a course of 36 days. Purified IgG from these mice is then injected into recipient 
mice to induce a pauci-immune crescentic glomerulonephritis that develops over a 
course of 6 days. 
To generate a source of anti-MPO IgG, MPO-deficient (B6.129X1-Mpotm1Lus/J, MPO-
/-) mice were initially injected IP with 20μg mMPO on day 0 in a Complete Freund’s 
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Adjuvant (CFA) emulsion, followed by an IP injection of 10μg mMPO on day 21 and 
day 36 in an Incomplete Freund’s Adjuvant (IF) emulsion. Control age-matched 
MPO-/- mice were injected with an eqimolar concentration of bovine serum albumin 
(BSA) in CFA (or IF) emulsion over the course of 36 days. Anti-MPO IgG titres were 
determined before sacrifice from peripheral blood samples by ELISA. Animals were 
sacrificed on day 42 for serum collection and subsequent IgG purification. Table 6 
summarises the experiments to induce circulating anti-MPO IgG in MPO-/- mice.  
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Table 6 Table detailing the induction of anti-MPO IgG in MPO deficient mice 
Experiment ID 
Experimental 
groups 
Number of 
mice in 
experimental 
group 
Average age at 
injection start 
date (wks) 
Gender 
(M/F) 
Source of 
mMPO 
Additional 
immunodominant 
peptide (Y/N) 
Normalised 
mean 
antibody titre 
A 
Mpo-/-
_mMPO 
8 11 7/1 P.Heeringa N 0.02 
Mpo-/-_BSA 7 8 4/3 - N 0.00 
B 
Mpo-/-
_mMPO 
13 12 5/8 P.Heeringa N 0.77 
C 
Mpo-/-
_mMPO 
8 7 8/0 P.Heeringa N 0.27 
D 
Mpo-/-
_mMPO 
17 13 9/8 Mine N 0.76 
E 
Mpo-/-
_mMPO 
8 11 3/5 Mine Y 0.12 
        
All mice were injected with a total of 40µg mMPO or BSA over a course of 36 days. Additional 50µg immunodominant peptide MPO409–428 was combined 
with mMPO on day 0 and day 21 in experiment E. Anti-MPO IgG titres were determined by ELISA from MPO-/- serum on day 40. 
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Titres were normalised to the Ec50 of purified anti-MPO IgG provided by P.Heeringa run 
alongside as a way to control for inter-experimental variation (see Figure 4-1). 
The first injections of mMPO were carried out using protein kindly donated by 
P.Heeringa (University of Groningen, Netherlands) that had previously been proven 
to induce circulating anti-MPO IgG in MPO-deficient mice. When circulating antibody 
titres were ascertained by ELISA on day 40, the anti-MPO IgG levels were very low 
when compared to purified anti-MPO IgG (also donated by P.Heeringa) (Figure 4-1, 
experiment A). Repeats of the experimental protocol described above, injecting 
either mMPO from P.Heeringa or isolated by myself (from a mouse promyelocytic 
cell line) produced varying circulating anti-MPO IgG titres (Figure 4-1, experiment B-
D). The addition of 50μg immunodominant peptide MPO409–428 combined with the 
mMPO injection at day 0 and day 21 did not appear to increase antibody titres by 
the experiment end (Figure 4-1, experiment E).  
 
Figure 4-1 Circulating antibody titres from MPO-deficient mice injected with 
mMPO with or without MPO immunodominant peptide MPO409–428 
Graph shows anti-MPO IgG titres from consecutive experiments A-E. All mice were injected 
with a total of 40µg mMPO over a course of 36 days. Additional 50µg immunodominant 
peptide MPO409–428 was combined with mMPO on day 0 and day 21 in experiment E. Anti-
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MPO IgG titres were determined by ELISA from MPO-/- serum on day 40. Titres were 
normalised to the Ec50 of purified anti-MPO IgG provided by P.Heeringa run alongside as a 
way to control for inter-experimental variation. Anti-MPO IgG titres were variable when 
either mMPO from P.Heeringa or our lab was used to inject MPO-/- mice and did not rise 
when immunodominant peptide MPO409–428 was combined with the mMPO. Single data 
points represent pooled serum values. 
Serum isolated from the first MPO-/-s injected (experiment A) and the subsequent 
experiments with the highest anti-MPO IgG titres (experiments B and D) were 
selected for IgG purification. Purified anti-MPO IgG titres ranged from 7-30% of the 
concentration of purified anti-MPO IgG supplied by P.Heeringa (Figure 4-2). The 
titre of the anti-MPO IgG isolated from the batch of MPO-/- serum with the highest 
concentration (experiment D) was 10 times less that the purified anti-MPO IgG 
supplied by P.Heeringa. 
 
Figure 4-2 Anti-MPO IgG titres of purified IgG from serum 
Anti-MPO IgG titres were determined by ELISA from purified IgG (pooled from previous 
experiments A, B & D (see Figure 4-1). Titres were normalised to the Ec50 of purified anti-
MPO IgG provided by P.Heeringa run alongside as a way to control for inter-experimental 
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variation. Anti-MPO IgG titres were very low in my purified IgG product compared to 
purified anti-MPO IgG supplied by P.Heeringa. 
To assess the purity of my isolated anti-MPO IgG an aliquot was run on a 
polyacrylamide gel alongside commercially-sourced purified sheep IgG and the 
unbound fraction from the purification (Figure 4-3). Coomassie blue-staining of the 
gel revealed that my isolated anti-MPO IgG product was largely free from other 
contaminating proteins and was the expected size corresponding to ~50kDa. The 
unbound fraction from the purification process did not appear to contain any IgG and 
the main fragment was likely albumin (~67kDa). 
 
Figure 4-3 Coomassie blue stained SDS-PAGE reveals that purified anti-MPO 
IgG is largely free from other contaminating proteins 
5μg total protein was loaded per lane. Lane 1: Purified sheep IgG, lane 2: isolated anti-MPO 
IgG, lane 3: unbound fraction from anti-MPO IgG purification. 
As my isolated anti-MPO IgG was determined to be largely pure it was used in the 
following passive transfer model of anti-myeloperoxidase associated 
glomerulonephritis. Due to the titre of my purified anti-MPO IgG being very low 
compared to the purified anti-MPO IgG supplied by P.Heeringa, any of my anti-MPO 
IgG used in the following experiments was adjusted according to the titre compared 
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to the purified anti-MPO IgG supplied by P.Heeringa which had been successfully 
used to induce disease. 
4.4.2 Establishing the passive transfer model of anti-myeloperoxidase 
associated glomerulonephritis 
Experimental use of the passive transfer model of anti-myeloperoxidase associated 
glomerulonephritis developed by Xiao et al. has been crucial in identifying the non-
redundant role of neutrophils in the development of crescentic GN and the 
importance of the alternative complement pathway in disease pathogenesis (Xiao et 
al., 2005, Xiao et al., 2007). The model has also exposed the potential for disease to 
be aggravated in the presence of bacterial LPS and GCSF (Huugen et al., 2005, 
Freeley et al., 2013). I intended to use this model to investigate the role of Annexin 1 
in the anti-MPO mediated renal injury present in anti-myeloperoxidase associated 
glomerulonephritis. 
The aim was to establish a model of anti-myeloperoxidase associated 
glomerulonephritis in order to test the effect of the absence of Annexin 1 on disease. 
I attempted to replicate the passive transfer model developed by Xiao et al. (Xiao et 
al., 2002) in which mice are intravenously injected with antibody isolated from MPO-
deficient mice immunised with purified murine MPO. I used additional injections of 
LPS and GCSF as described by Freeley et al. (Freeley et al., 2013) to exacerbate 
the disease phenotype. Experiments to generate the passive transfer model of anti-
myeloperoxidase associated glomerulonephritis are summarised in Table 7. 
Table 7 Table detailing the generation of the passive transfer model of anti-
myeloperoxidase associated glomerulonephritis 
Experiment ID I II III IV V 
Number of mice in 
experimental group 
5 3 3 3 3 
Gender M F M M F 
Average age at 
injection start date 
(wks) 
8 8 8 20 8 
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Dose of anti-MPO 
IgG (µg/g 
bodyweight) 
50 50 50 100 100 
Source of anti-MPO 
IgG 
P.Heering
a 
P.Heering
a 
P.Heering
a 
Mine 
P.Heering
a 
LPS dose 150 EU/g 0.1µg 0.1µg 0.1µg 0.1µg 
Route of LPS 
injection 
IP IV IP IP IP 
Time of LPS 
injection according 
to IgG 
t=1hr t=0hr t=1hr t=1hr t=1hr 
GCSF injection No 
Day -4, 0, 
+4 
Day -4, 0, 
+4 
Day -8, 
-4, 0, +4 
Day -4, 0, 
+4 
Haematuria 
day 
1 
N/A 
1
 0, 0, 2 0, 0, 0 0, 0, 0  3, 3, 2 
day 
7 
0, 0 
2
 0, 0, 0 0, 0, 0 0, 0, 0 0, 0, N/A
3
 
Proteinuria day 7 
(mg/ml) 
not measured 
2.3, 0.6, 
2.1 
0.1, 1.0, 
N/A
3
 
Mean                   
antibody titre 
(Ec50) 
day 
1 
N/A 
4
 61.07 171.3 N/A 
4
 133.2 
day 
7 
53.70 41.67 239.1 57.2 151.0 
Glomerular 
crescents (%) 
0, 0, 0 0, 0, 0 0, 0, 0 0, 0, 0 
4.2 
23.4 
5.7 
      
Haematuria was estimated by urine dipstick. 
1 
Urine was not available for day 1 analysis in 
experiment I. 
2 
3/5 mice died of LPS toxicity between 1 and 3 days post LPS/IgG in 
experiment I. 
3
 Urine was not available for day 7 analysis from one animal in experiment V. 
4 
Blood not available for antibody titre determination. 
A preliminary attempt to trial the passive-transfer model of anti-myeloperoxidase 
associated glomerulonephritis in mice encompassed the IV injection of 50µg/g 
bodyweight anti-MPO IgG (donated by P.Heeringa) accompanied by 150 EU/g LPS 
injected IP 1hr after IgG (experiment I). Of a total of five 8 week old male C57BL/6 
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mice, three of five animals succumbed to LPS-toxicity between 1 and 3 days post 
IgG/LPS. Of the two mice that survived, 7 days post IgG there was no evidence of 
renal injury estimated by urinary dipstick analysis or observed on PAS-stained 
kidney sections and MPO antibody titres were very low (Figure 4-4). 
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Figure 4-4 Anti-MPO antibody ELISA titres from anti-myeloperoxidase associated glomerulonephritis trial experiments 
Anti-MPO antibody titres were measured by ELISA in serum collected 1 or 7 days after anti-MPO IgG injection. Data are shown as mean + SEM.
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To avoid any further mortalities due to LPS-related toxicity, a subsequent attempt at 
establishing disease was made using a dose of LPS established in the NTN model; 
the IV injection of 50µg/g bodyweight anti-MPO IgG was combined with 0.1µg 
LPS/animal (experiment II). Of a total of three 8 week old female C57BL/6 mice, one 
animal exhibited raised haematuria estimated by urinary dipstick 1 day post IgG but 
renal injury estimated by urinary dipstick on day 7 was not apparent in any of the 
three animals. There was no kidney injury observed on histology and antibody titres 
were relatively low on day 1 and day 7 (Figure 4-4). 
To replicate the protocol described by Freeley et al. (Freeley et al., 2013) the next 
attempt to induce anti-myeloperoxidase associated glomerulonephritis involved the 
IV injection of 50µg/g bodyweight anti-MPO IgG followed by an IP injection of 0.1µg 
LPS/animal 1hr after IgG (experiment III). IP injections of 26µg GCSF were also 
given 4 days prior to IgG, at the time of the IgG injection and 4 days after IgG. None 
of the three male 8 week old C57BL/6 mice demonstrated any renal abnormalities 
estimated by urinary dipstick although antibody titres were significantly elevated on 
day 1 and day 7 after IgG compared to previous experiments (Figure 4-4). There no 
significant glomerular abnormalities evident on PAS-stained kidney sections in any 
of the three mice injected with anti-MPO IgG (Figure 4-5).  
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Figure 4-5 No significant glomerular abnormalities observed in an attempt to 
establish the passive-transfer model of anti-myeloperoxidase associated 
glomerulonephritis 
C57BL/6 mice were injected IV with 50µg/g bodyweight anti-MPO IgG followed by an IP 
injection of 0.1µg LPS/animal 1hr after IgG. IP injections of 26µg GCSF were also given 4 
days prior to IgG, at the time of the IgG injection and 4 days after IgG (experiment III). No 
significant renal abnormalities were observed on PAS-stained kidney sections in any of the 
three mice 7 days after receiving anti-MPO IgG. Magnification x400. 
As the antibody titres in the animals in the experiments thus far were relatively low 
and  there was no significant renal injury observed, the following experiment used 
100µg/g bodyweight anti-MPO IgG (my stock) followed by an IP injection of 0.1µg 
LPS/animal 1hr after IgG (experiment IV). IP injections of 26µg GCSF were also 
given 8 and 4 days prior to IgG, at the time of the IgG injection and 4 days after IgG. 
There was no evidence of renal injury estimated by urinary dipstick analysis or 
observed on histology in any three of the 20 week old male C57BL/6 mice injected. 
Proteinuria was low in all three animals with a mean of 1.7mg/ml and antibody titres 
were still consistently low on day 7 (Figure 4-4). 
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Success in inducing anti-myeloperoxidase associated glomerulonephritis was 
ultimately achieved through the IV injection of 100µg/g bodyweight anti-MPO IgG 
(from P.Heeringa) followed by an IP injection of 0.1µg LPS/animal 1hr after IgG 
(experiment V). IP injections of 26µg GCSF were also given 4 days prior to IgG, 
alongside the IgG injection and 4 days after IgG. All three female 8 week old mice 
injected exhibited enhanced haematuria estimated by urinary dipstick analysis on 
day 1, indicating acute kidney injury, which resolved by day 7. Proteinuria was low in 
all three animals with a mean of 0.6mg/ml. Anti-MPO antibody titres averaged 133 
(EC50) on day 1 and were maintained to day 7; averaging 151 (Figure 4-4). 
Glomerular crescents were visible on PAS stained kidney sections in all three 
animals 7 days after receiving anti-MPO IgG; ranging through 4.2%, 5.7% and 
23.4%. There was also some focal fibrinoid necrosis and a degree of peri-glomerular 
leukocyte accumulation observed (Figure 4-6). 
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Figure 4-6 Significant renal injury observed in mouse model of anti-myeloperoxidase associated glomerulonephritis 
C57BL/6 mice were injected IV with 100µg/g bodyweight anti-MPO IgG (from P.Heeringa) followed by an IP injection of 0.1µg LPS/animal 1hr after IgG. 
IP injections of 26µg GCSF were also given 4 days prior to IgG, alongside the IgG injection and 4 days after IgG. Glomerular crescents were observed on 
PAS-stained kidney sections in all 3 animals 7 days after receiving anti-MPO IgG. There was also some focal fibrinoid necrosis (right arrow) and a degree of 
peri-glomerular leukocyte accumulation (left arrow). Magnification x400 (left image) x630 (right image). 
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4.4.3 Effect of the absence of Annexin 1 in anti-myeloperoxidase associated 
glomerulonephritis 
With a model of anti-myeloperoxidase associated glomerulonephritis set up in my 
hands, an experiment was carried out to examine any differences in disease 
penetrance between wild-type and Annexin 1 deficient mice. Annexin 1 -/- mice 
have shown increased susceptibility to murine models of acute and chronic 
inflammation, demonstrating increased neutrophil and monocyte infiltration and 
excessive macrophage recruitment, extracellular matrix deposition and fibrosis 
(Damazo et al., 2011, Locatelli et al., 2014).  
To investigate whether the absence of Annexin 1 in C57BL/6 mice confers a greater 
susceptibility to the development and severity of glomerular inflammation in a mouse 
model of anti-myeloperoxidase associated glomerulonephritis, I induced disease in 
wild-type and Annexin 1 -/- mice. 8 week old female wild-type and Annexin 1 -/- mice 
(n=4 per group) were injected IV with 100μg/g bodyweight anti-MPO IgG (from 
P.Heeringa) or a saline control (wild-type n=4) on day 0. In conjunction with this, all 
mice received an IP injection of 0.1μg LPS one hour after IgG or saline 
administration and IP injections of 26μg GCSF on day -4, 0 and +4. 24 hour urine 
collections were carried out in metabolic cages on day 0 and day 6 and tail bleeds 
were performed on day 1 for determination of anti-MPO antibody titres. Mice were 
sacrificed on day 7. 
In this passive transfer model of anti-myeloperoxidase associated 
glomerulonephritis, antibody titres on day 1 and day 7 from the experiment 
comparing disease in wild-type and Annexin 1 -/- mice were comparable to those in 
the pilot experiment trialling the same disease induction protocol in wild-type mice 
(n=3) (Figure 4-7). Therefore additional readouts relating to disease were combined 
across experiments. 
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Figure 4-7 Administration of anti-MPO IgG in combination with 
intraperitoneal injections of LPS and GCSF, into wild-type and Annexin 1 
deficient mice results in sustained anti-MPO IgG titres from day 1 to day 7 after 
injection of IgG  
Plasma or serum was isolated from blood collected on day 1 or day 7 to determine anti-MPO 
titre by ELISA. Anti-MPO IgG titres were sustained between day 1 and day 7 in both wild-
type and Annexin 1 -/- mice. The titres across experiment 1 (wild-type n=3) and experiment 
2 (wild-type n=4, Annexin 1 -/- n=4) did not show significant variation. Data are shown as 
mean with standard error of the mean.  
Haematuria estimated by urinary dipstick was negative for all animals on day 7. 
When combining the data across experiments, at day 7 proteinuria and serum urea 
levels were very low in all animals; less than 1mg/ml, and less than 10mmol/l 
respectively. There was no difference in serum urea or protein/creatinine ratio 
between wild-type and Annexin 1 -/- mice (Figure 4-8, i and ii).  
On examination of PAS stained kidney sections on day 7 there were between 2-23% 
crescentic glomeruli found in 5 of 7 wild-type mice but there was no glomerular 
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crescent formation observed in the Annexin 1 -/- mice. Due to the small 
experimental group numbers, this difference did not reach statistical significance. 
There was no difference in the number of infiltrating macrophages into the 
glomerulus between experimental groups (Figure 4-8, iii and iv). 
 
Figure 4-8 Renal injury is no different between wild-type and Annexin 1 
deficient mice in this murine model of anti-myeloperoxidase associated 
glomerulonephritis 
7 days after anti-MPO IgG injection, serum urea levels were low (i) and no different between 
the wild-type and Annexin 1 -/- mice. (ii) Protein/creatinine ratio was also no different 
between the wild-type and Annexin 1 -/- mice. Quantification of PAS-stained kidney 
sections (iii) revealed that compared to an average of 3% crescentic glomeruli in wild-type 
mice, Annexin 1 -/- mice did not develop any glomerular crescents. This difference was not 
statistically significant when analysed with a Mann-Whitney test. The number of infiltrating 
macrophages into the glomerular space at day 7 was no different between the experimental 
groups (iv). N.B. Data from two experiments were combined due to comparable antibody 
titres as demonstrated in Figure 4-7. Wild-type animals from the pilot experiment are 
indicated in orange. Data are shown as median with interquartile range. 
 119 
 
4.4.3.1 Microparticles in MEV 
Microparticles have a potential role in vascular injury and I demonstrated in the 
previous chapter that total MP numbers and NMP numbers are significantly 
diminished in Annexin 1 deficient animals in a murine model of NTN. 
In order to investigate MP numbers in MEV and whether these are affected by the 
absence of Annexin 1, blood plasma was stained for FACS analysis with Annexin V 
and antibodies to Ly6G or CD41, to identify total MPs, NMPs and PMPs (staining 
and FACS performed by Dr Ying Hong, UCL). 8 week old female wild-type and 
Annexin 1 -/- mice (n=4 per group) were injected intravenously with 100μg/g 
bodyweight anti-MPO IgG (from P.Heeringa) or a saline control (wild-type n=4) on 
day 0. In conjunction with this, all mice received an IP injection of 0.1μg LPS one 
hour after IgG or saline administration and IP injections of 26μg GCSF on day -4, 0 
and +4. Mice were sacrificed on day 7. 
In this MEV model total MP numbers were significantly elevated in the Annexin 1 
deficient mice, compared to the wild-type mice (p=0.0286) but did not differ from the 
LPS control group (Figure 4-9). Numbers of NMPs and PMPs did not differ between 
experimental groups. 
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Figure 4-9 Total microparticle numbers are significantly elevated in Annexin 1 deficient mice a model of MEV 
Microparticles were isolated from blood plasma at the experiment end. Cells were incubated with Annexin V before staining with Ly6G or CD41 to identify 
total microparticles (i), and those derived from neutrophils (ii) or platelets (iii), respectively. MPs were analysed by FACS and latex beads (Sigma) were run 
concurrently with the samples to determine absolute MP numbers. 8 week old female wild-type and Annexin 1 -/- mice (n=4 per group) were injected IV with 
100μg/g bodyweight anti-MPO IgG (from P.Heeringa) [MEV] or a saline control (wild-type n=4) on day 0 [wt LPS control]. In conjunction with this, all mice 
received an IP injection of 0.1μg LPS one hour after IgG or saline administration and IP injections of 26μg GCSF on day -4, 0 and +4. Data are expressed as 
median with interquartile range. Dotted line represents equivalent median value for NTN control (see Figure 3-11). 
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4.4.4 Attempt to model anti-myeloperoxidase associated glomerulonephritis 
using mMPO in adjuvant and nephrotoxic serum with additional MPO 
immunodominant peptide 
A further attempt was made to induce anti-myeloperoxidase associated 
glomerulonephritis using a protocol based on the experimental model described by 
Holdsworth and Kitching (Ruth et al., 2006). This model is based on the hypothesis 
that MPO acts as an autoantigen in the kidney and cell-mediated immunity plays a 
key role in disease pathogenesis. It has been has been successfully used in 
demonstrating the importance of CD4+ effector T cells and IL-17 in the development 
of crescentic GN. A specific immunodominant MPO CD4+ T-cell epitope (MPO409-
428) was recently identified by the same group and has been shown to induce 
disease in a similar capacity to that of the native protein, when low dose anti-GBM 
antibody is used to direct the immune response to the glomerulus (Ooi et al., 2012). 
I used this immunodominant peptide in conjunction with injection of whole murine 
MPO in an effort to accentuate the immune response to the deposited whole MPO. I 
intended to use this experimental model to investigate the role of Annexin 1 in both 
the humoral and cellular arms of the immune response within the development of 
crescentic glomerulonephritis. 
9 week old female C57BL/6 mice (n=6) and Annexin 1 -/- mice (n=6) were injected 
subcutaneously in the left flank with 40μg murine MPO + 50μg MPO 
immunodominant peptide in CFA. This injection was repeated in the right flank 7 
days later in IFA. Control animals (C57BL/6 n=6) were injected with saline in CFA or 
IFA. After a further 7 days, all mice were injected IV with 100µl NTS diluted 1:1 in 
saline, 200µl total volume. This injection was repeated the following day. After 4 
days, mice were culled after collecting urine overnight in metabolic cages. 
No renal injury was evident when estimated by urine dipstick analysis 4 days after 
the final NTS injection and anti-MPO antibody titres assessed by ELISA from 
cardiac puncture serum were negative in all animals. There was no renal injury 
apparent on examination of PAS-stained kidney sections, with the exception of one 
Annexin 1 -/- animal that exhibited some localised tubular damage. 
4.4.5 Discussion 
Injection of MPO deficient mice with murine MPO in adjuvant as previously 
described by Xiao et al. (2002) produced varying antibody titres. Additional 
administration of immunodominant peptide MPO409–428, designed to encourage loss 
 122 
 
of tolerance to the native MPO, did not appear to increase the immune response as 
reflected in the anti-MPO IgG titres. This lack of, and variation in, immune response 
to MPO may have resulted from low purity of the injected protein as subsequent 
mMPO immunisations in our lab have been more successful and required less 
protein to produce an immune response in MPO deficient mice. 
Total IgG was isolated from serum from the MPO deficient mice with the highest 
anti-MPO IgG titres. Anti-MPO IgG titres of purified IgG were very low when 
compared with IgG with previously established pathogenicity, although the protein 
product was largely uncontaminated. There were technical issues with the 
purification of IgG from serum resulting from fibrin clotting, disrupting the isolation 
which may have resulted in the loss of antibody.  
I attempted to replicate the passive transfer model of anti-myeloperoxidase 
associated glomerulonephritis developed by Xiao et al. (2002) with additional 
injections of LPS and GCSF. LPS has historically been used to exacerbate the 
disease phenotype in this model and leads to an early increase in neutrophil influx 
and a late increase in glomerular macrophage infiltration (Huugen et al., 2005). 
Recently GCSF has also been used in conjunction with LPS to increase disease 
penetrance as this glycoprotein is thought to prime neutrophils for MPO-ANCA 
induced activation (Freeley et al., 2013). Although purified IgG from MPO deficient 
mice was adjusted according to titre against IgG with previously established 
pathogenicity, it failed to produce a sustained circulating antibody response in wild-
type mice. FCGN was achieved when mice were injected IV with 100µg anti-MPO 
IgG (from P.Heeringa) followed by an IP injection of 0.1µg LPS/animal 1hr after IgG. 
IP injections of 26µg GCSF were also given 4 days prior to IgG, alongside the IgG 
injection and 4 days after IgG. The degree of glomerular crescent formation 
averaged 5% (range 0-23%), there was also some focal fibrinoid necrosis visible 
and a degree of peri-glomerular leukocyte inflammation. Using this passive transfer 
model of anti-myeloperoxidase associated glomerulonephritis Xiao et al. have 
reported a variable penetrance of disease with the average number of crescentic 
glomeruli ranging from 3-11.5% in the absence of additional endotoxin or 
inflammatory agents. Although LPS and GCSF injections were given in this model, 
the disease severity fell short of 29% crescentic glomeruli reported by Freeley et al. 
where both of these agents were used. 
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In this passive transfer model of anti-myeloperoxidase associated 
glomerulonephritis Annexin 1 deficient mice maintained an equivalent antibody titre 
to wild-type mice over the experimental time course, however they did not develop 
any glomerular crescents compared to an average of 5% glomerular crescents in 
wild-type mice. Glomerular macrophage infiltration was comparable in Annexin 1 
deficient and wild-type mice as were serum urea readings and protein/creatinine 
ratios at the experiment end. However, 1 day following anti-MPO IgG injection, 
haematuria estimated by urinary dipstick was elevated in the wild-type mice in the 
pilot experiment, compared with all wild-type and Annexin 1 deficient mice in the 
second experiment, which exhibited low or negative levels of haematuria. This is a 
crude measurement but could indicate lower disease penetrance in the second 
experiment when compared to the pilot experiment as antibody titres are not always 
reflected in disease severity. Annexin 1 plays a protective role in a number of 
inflammatory disease models and regulates neutrophil/endothelial interactions in the 
microcirculation (Damazo et al., 2005, Locatelli et al., 2014). As glomerular injury in 
the passive-transfer model is primarily mediated by the influx and degranulation of 
neutrophils, accompanied by the infiltration of mononuclear cells, I hypothesised that 
Annexin 1 deficiency would exacerbate disease. It is likely that the difference 
observed in glomerular histology between the wild-type and Annexin 1 deficient 
animals is due to experimental variation, and the disease penetrance was not 
substantial enough across the experimental groups to demonstrate a protective 
effect of Annexin 1. In experimental autoimmune encephalomyelitis (EAE) Annexin 1 
deficient mice have impaired capacity to develop disease, although unlike the 
murine model of anti-myeloperoxidase associated glomerulonephritis, this disease is 
T-cell mediated (Paschalidis et al., 2009).  
There was a significant increase in overall MP numbers in Annexin 1 deficient mice, 
compared to wild-type mice, in this MEV model. As there was no significant 
difference detected in disease between Annexin 1 deficient and wild-type mice in 
MEV, it is difficult to comment on the relationship of these MPs to vascular injury in 
mice. However, an increase in overall MP numbers in Annexin 1 deficient mice is 
opposite to what was observed in NTN, where there was exacerbation of disease, 
suggesting that MPs could be protective in MEV. Much of the research on neutrophil 
MPs has indicated that they are of an anti-inflammatory nature, however there is 
also research to suggest that PMN-derived MPs can be pro-inflammatory and 
activate endothelial cells (Mesri and Altieri, 1998). The nature of MPs may 
influenced by their activation stimulus. The average total MP numbers in the LPS 
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control were higher than in the wild-type MEV group. This was unexpected and 
could be a reflection of a lack of disease penetrance in the wild-type animals and 
general variation in MP numbers in the experimental groups after LPS treatment. It 
is possible that the higher MP numbers in the Annexin 1 deficient animals are due to 
a lack of TNF-α inhibition, exacerbating the inflammatory effects of LPS and release 
of pro-inflammatory MPs. Inclusion of an Annexin 1 deficient LPS control group 
would assess this hypothesis.  
I attempted to replicate the anti-myeloperoxidase associated glomerulonephritis 
model developed by the group of Holdsworth and Kitching (Ruth et al., 2006). 
Although additional MPO immunodominant peptide was combined with the murine 
MPO, designed to enhance the immune response to the deposited protein, no 
evidence of disease was found in wild-type mice and circulating anti-MPO antibody 
was undetectable. There was limited success inducing anti-MPO IgG in MPO 
deficient mice with my purified mMPO and this failure to induce an immune 
response could also be reflective of a deficiency in mMPO purity. 
Summary: 
 In this instance, the passive transfer model of anti-myeloperoxidase 
associated glomerulonephritis required additional injections of LPS and 
GCSF to generate a pauci-immune crescentic glomerulonephritis in C57BL/6 
mice. 
 The disease penetrance across experimental groups in this MEV model 
prevented the conclusion to whether the absence of Annexin 1 had an effect 
on disease. 
 An attempt to replicate the DTH-like response to planted antigen in the 
mouse kidney as described by Ruth et al. (2006) was unsuccessful, despite 
the fact that additional immunodominant MPO CD4+ T-cell epitope was 
injected alongside the native protein. 
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Chapter 5 The effect of Annexin 1 on human neutrophil 
responses to ANCA 
5.1 Introduction 
Chapters 3 and 4 describe potentially opposing roles for Annexin 1 in two alternative 
models of crescentic glomerulonephritis. To investigate the cellular mechanisms that 
might account for either a protective or injurious role for Annexin 1 in AAV, the 
following chapter investigates Annexin 1 in the context of patient and healthy control 
neutrophils in vitro. 
There is previous evidence that a higher neutrophil membrane expression of 
proteinase 3 (PR3) is associated with AAV and correlates with risk of disease 
relapse (Rarok et al., 2002, Witko-Sarsat et al., 1999). Also transcriptional 
expression of PR3 has been shown to relate to disease activity and higher levels 
can be an indicator of subsequent poor response to treatment (Cheadle et al., 2010, 
Grayson et al., 2015). PR3 and Annexin 1 co-localize on the neutrophil surface on 
activation, allowing the cleavage of Annexin 1 by PR3, putatively preventing the 
proteins’ pro-resolution functions. Annexin 1 cleavage products can be detected in 
the BALF of patients with abnormal lungs and in experimental-colitis in rats and 
increased Annexin 1 cleavage has been associated particularly with a heightened 
degree of neutrophil infiltration (Muller Kobold et al., 1998, Vong et al., 2007). 
Seminal work by Falk et al. (1990) revealed that neutrophils are activated by ANCA, 
which results in the release of free radicals and primary granule contents causing 
direct damage to the endothelium as well as depositing MPO in the kidney as a 
planted autoantigen. This binding of ANCA to neutrophils is understood to occur 
through FcRγ engagement (Mulder et al., 1994). Annexin 1 has been shown to 
inhibit binding of IgG to Fcγ receptors on peripheral blood monocytes and 
neutrophils in vitro and neutrophil FcγR-mediated respiratory burst can be inhibited 
by treatment with the Annexin 1 N-terminal peptide Ac2-26 (Goulding and Guyre, 
1993, Goulding et al., 1998). A PR3 cleavage-resistant form of Annexin 1, SAnxA1, 
has a longer sequence and a higher affinity for FPR2/ALXR than the peptide Ac2-
26. This peptide can inhibit PMN accumulation in vivo and accelerate the resolution 
of inflammation within the arthritic joint, but its’ direct actions on neutrophil activation 
have not been investigated (Pederzoli-Ribeil et al., 2010, Patel et al., 2012, Perretti 
and Dalli, 2009). 
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5.2 Aim 
The initial aim of this chapter is to investigate whether the expression of PR3 on the 
neutrophil surface is altered in this PR3-positive GPA patient group when compared 
to healthy controls. The second objective is to observe any associations between 
neutrophil surface PR3 expression and Annexin 1 cleavage. Finally, the ability of 
cleavage-resistant forms of Annexin 1 to inhibit ANCA-induced activation of primed 
neutrophils is explored. 
5.3 Experimental Design 
Neutrophils were isolated from whole blood anti-coagulated with EDTA from patients 
and healthy controls by layering on Histopaque 1119 followed by a discontinuous 
Percoll gradient. For the investigation of membrane PR3 expression and Annexin 1 
cleavage, neutrophils were stimulated with/without TNF-α (10ng/ml) for 30 minutes 
at 37°C before separating into cells for FACS and whole cell lysates for Western 
blotting. Cells for FACS analysis were stained with anti-PR3 FITC antibody or 
isotype control. Whole cell lysates were generated by resuspending cells at 10 x 106 
cells/ml in a non-denaturing lysis buffer (20mM Tris HCl pH 8.0, 137mM NaCl, 10% 
glycerol, 1% Triton X-100, 2mM EDTA) with protease inhibitors and incubating on 
ice for 30 minutes before centrifuging ≥10,000g at 4°C for 10 minutes. The ability of 
cleavage-resistant forms of Annexin 1 to inhibit ANCA-induced activation of primed 
neutrophils was trialled using varying concentrations of SAnxA1 and CR-AnxA12–50. 
Neutrophils were primed with cytochalasin b and TNF-α alongside the relevant 
peptide or control before activation with ANCA or fMLP was assessed by the 
detection of MPO release. 
Table 8 Experimental groups 
 Healthy controls PR3-positive GPA 
patients 
Number 10 12 
Gender (M/F) 3/7 7/5 
Mean age (yr) 44 (25-70) 53 (20-78) 
Median ANCA titre 
(U/ml) 
N/A 26 (<1 – >177) 
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Steriod treatment 
(percentage of patients 
receiving prednisolone) 
N/A 75% (Mean dose 14mg/d; 
range 3mg/d – 60mg/d) 
   
Age, median ANCA titre and steroid dose are all reflective of the date at which the blood 
sample was taken. 
5.4 Results 
5.4.1 Isolation of neutrophils from peripheral whole blood 
To enable the detection of surface PR3 expression and Annexin 1 cleavage 
products, neutrophils were isolated as described. Neutrophils were assessed for 
purity by generating a cytospin and averaged greater than 95% (Figure 5-1). 
 
Figure 5-1 Diff-Quick staining of a cytospin reveals that isolated neutrophil 
purity is greater than 95%  
Neutrophils isolated from peripheral blood were assessed for purity by loading 150μl of a 
0.75x10
6
 cells/ml cell suspension into a cuvette and spinning at 450rpm for 6 minutes in a 
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cytocentrifuge. Cells were immediately fixed and stained with Diff-Quik before 
visualisation. Magnification is x100. 
5.4.2 Neutrophil surface expression of PR3 is bimodal 
To determine neutrophil surface expression of PR3 (mPR3), purified cells were 
stained with anti-PR3 FITC antibody. FACS analysis revealed a bimodal expression 
pattern of PR3 on the neutrophil surface across all healthy controls and GPA patient 
cells (Figure 5-2). Hereafter, these two distinct neutrophil populations will be referred 
to as mPR3low and mPR3high, based on their surface PR3 expression. 
 
Figure 5-2 Neutrophil surface expression of PR3 is bimodal 
Neutrophils isolated from peripheral blood were incubated with anti-PR3 FITC antibody for 
30 minutes on ice in the dark before washing and fixing with 1% PFA. One-colour flow 
cytometry was performed on a BD FACSCalibur and 10,000 neutrophil events were 
collected based on their forward- and side-scatter (FSC/SSC) profile. Subsequent analysis 
revealed a discrete population of neutrophils based on their FSC/SSC (i). These cells 
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exhibited a bimodal pattern of PR3 expression (ii) which I have designated mPR3
low
 and 
mPR3
high 
based on their SSC vs PR3 MFI profile. (iii) Representative histograms of the range 
of neutrophil surface PR3 expression displayed across healthy controls and GPA patients 
(anti-PR3 stained samples in black, isotype control in grey). 
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5.4.3 Surface PR3 expression is higher in neutrophils from GPA patients 
when compared with healthy controls 
To validate whether neutrophil surface PR3 expression was inherently different 
between my healthy control and GPA patient groups, isolated neutrophils were 
stained for FACS analysis with and without in vitro stimulation by TNF-α (10ng/ml). 
The mPR3 expression of the neutrophil population as a whole was significantly 
higher (p=0.03) in the patients when compared with healthy controls within the TNF-
α treatment condition. There was also a trend (that did not reach statistical 
significance) toward the mPR3 expression of the neutrophil population being 
elevated in the GPA patients when compared with healthy controls in the absence of 
TNF-α stimulation (Figure 5-3). There was no difference between the mPR3 
expression of the neutrophil population with/without TNF-α treatment within the 
healthy control group, but there was a suggestion that the mPR3 expression of the 
neutrophil population may increase within the GPA patient group with in vitro 
stimulation; however this value did not reach statistical significance. 
 
Figure 5-3 Neutrophil surface expression of PR3 is elevated in GPA patients 
when compared with healthy controls after in vitro neutrophil activation 
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Neutrophils stimulated with/without TNF-α (10ng/ml) for 30 minutes at 37°C were 
incubated with anti-PR3 FITC antibody or isotype control. The MFI of the PR3-stained 
neutrophil population as a whole, was divided by the MFI of the equivalent population 
stained with the isotype control antibody to produce a value for relative mPR3 expression. 
The neutrophil surface expression of PR3 (mPR3) was significantly higher in GPA patients 
than healthy controls when treated with TNF-α (10ng/ml) (p=0.03, unpaired t-test). 
There have been differences reported in the PR3 expression of the mPR3high subset 
when comparing neutrophils from healthy controls and GPA patients (Rarok et al., 
2002). When neutrophils were split into mPR3high and mPR3low subsets based on 
their PR3 MFI and SSC profile (see Figure 5-2) the surface expression of PR3 in the 
mPR3high subset significantly increased (p=0.005) with TNF-α stimulation in healthy 
control neutrophils when compared to unstimulated neutrophils (Figure 5-4). This 
effect was not observed in neutrophils from GPA patients. When comparing the 
surface expression of PR3 in the mPR3high subset from neutrophils from healthy 
controls and GPA patients there was a trend towards the MFI being higher in the 
GPA patients in unstimulated cells, although the p value fell short of statistical 
significance. This trend was not seen in the presence of TNF-α stimulation. 
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Figure 5-4 Surface PR3 expression of mPR3
high
 neutrophil subset is increased 
with in vitro neutrophil activation in healthy controls 
Neutrophils were stimulated and stained as Figure 5-3. The MFI of the mPR3
high
 neutrophil 
subset, stained with anti-PR3, was divided by the MFI of the equivalent population stained 
with the isotype control antibody to produce a value for relative mPR3 expression. Gates to 
distinguish mPR3
high
 and mPR3
low
 neutrophil populations were set on unstimulated 
conditions for anti-PR3 stained or isotype stained samples and transferred to the TNF-α 
treatment condition. The surface expression of PR3 was significantly higher in the mPR3
high
 
neutrophil subset in healthy controls when treated with TNF-α (10ng/ml), compared to 
untreated cells (p=0.005, paired t-test).  
The surface PR3 expression of the mPR3low subset was significantly higher (p=0.03) 
in the GPA patients with TNF-α stimulation when compared to untreated neutrophils. 
There was a trend towards this phenomenon in the healthy control neutrophils but 
the p value did not reach significance. There was no difference between the surface 
PR3 expression of the mPR3low subset when comparing unstimulated or TNF-α 
stimulated cells between healthy controls and GPA patients (Figure 5-5). 
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Figure 5-5 Surface PR3 expression of mPR3
low
 neutrophil subset is increased 
with in vitro neutrophil activation in GPA patients 
Neutrophils were stimulated and stained as Figure 5-3. The MFI of the mPR3
low
 neutrophil 
subset, stained with anti-PR3, was divided by the MFI of the equivalent population stained 
with the isotype control antibody to produce a value for relative mPR3 expression. Gates to 
distinguish mPR3
high
 and mPR3
low
 neutrophil populations were set on unstimulated 
conditions for anti-PR3 stained or isotype stained samples and transferred to the TNF-α 
treatment condition. The surface expression of PR3 was significantly higher in the mPR3
low
 
neutrophil subset in GPA patients when treated with TNF-α (10ng/ml), compared to 
untreated cells (p=0.03, paired t-test). 
When examining the relative abundance of the mPR3high neutrophil subset 
compared to the mPR3low neutrophil subset, TNF-α-stimulated neutrophils from the 
healthy controls had significantly less mPR3high neutrophils (mean= 62.0%) 
compared to unstimulated cells (mean= 67.8%, p=0.01). The abundance of the 
mPR3high subset was unchanged in GPA patient neutrophils when comparing 
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stimulated and unstimulated cells and when comparing healthy control and GPA 
patient neutrophils under either experimental condition (Figure 5-6). 
 
Figure 5-6 Abundance of mPR3
high
 subset decreases with in vitro neutrophil 
activation in healthy controls 
Neutrophils were stimulated and stained as Figure 5-3. Neutrophils were determined as 
mPR3
high 
or mPR3
low 
as depicted in Figure 5-2. The percentage of the mPR3
high 
subset 
decreased in healthy controls when treated with TNF-α (10ng/ml), compared to untreated 
cells (p=0.01, paired t-test). 
5.4.4 Annexin cleavage products can be detected by Western blotting in 
whole cell lysates of neutrophils treated with/without TNF-α in vitro 
In order to investigate Annexin 1 cleavage in neutrophils and any differences 
between healthy controls and patients, whole cell lysates were generated from 
unstimulated neutrophils and neutrophils stimulated with TNF-α (10ng/ml). Protein 
from unstimulated or stimulated cells was detected by Western blotting using a 
monoclonal mouse anti-human Annexin 1 antibody. 
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Annexin 1 protein was detected in neutrophil whole cell lysates from healthy controls 
and GPA patients by Western blotting. There was no protein detectable in the cell 
supernatants recovered from the experiments when determined by BCA assay. 
Within the whole cell lysates a ~37kDa band corresponding to intact Annexin 1 was 
revealed alongside two smaller bands corresponding to ~30kDa and ~28kDa (Figure 
5-7).  
 
Figure 5-7 Annexin 1 cleavage products can be detected by Western blotting in 
whole cell lysates of neutrophils treated with/without TNF-α in vitro 
Neutrophil whole cell lysates were generated by resuspending cells at 10 x 10
6
 cells/ml in a 
non-denaturing lysis buffer (20mM Tris HCl pH 8.0, 137mM NaCl, 10% glycerol, 1% Triton 
X-100, 2mM EDTA) with protease inhibitors and incubating on ice for 30 minutes before 
centrifuging ≥10,000g at 4°C for 10 minutes. 10μg protein (determined by BCA assay) was 
loaded from each sample onto a reducing SDS-polyacrylamide gel. Protein was detected by 
Western blotting using mouse anti-human Annexin 1 antibody. An expected band of ~37kDa 
was observed for intact Annexin 1 in addition to two smaller cleavage products 
corresponding to ~30kDa and ~28kDa. 
Image J software was used to quantify the proportions of intact and cleaved Annexin 
1 products detected by Western blotting in each sample (Figure 5-8, i). When 
examining the amount of total cleaved Annexin 1 in whole neutrophil lysates 
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compared to total Annexin 1 protein detected in each sample, there was no 
significant difference observed between healthy control and GPA patient cells under 
control or TNF-α treatment conditions, although the median percentage of cleaved 
Annexin 1 was lower in GPA patient neutrophils (Figure 5-8, ii, iv). The proportion of 
cleaved Annexin 1 was unchanged when comparing unstimulated cells to cells 
stimulated with TNF-α (10ng/ml). When investigating the 30kDa and 28kDa 
cleavage products in relation to each other, there was no significant difference 
between the abundance of the 30kDa peptide when comparing healthy control and 
GPA patient neutrophils in both control and treatment conditions, although the 
median percentage of the 30kDa peptide was higher in GPA patient neutrophils 
overall (2-way ANOVA: healthy control/patient group accounting for 15% of variation 
p=0.08). 
 137 
 
 
Figure 5-8 There are no significant differences in the abundance of Annexin 1 
cleavage products detected in neutrophil whole cell lysates when comparing 
GPA patient and healthy control cells 
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(i) Image J software was used to quantify the proportion of intact and cleaved Annexin 1 
detected by Western blotting in each sample (ii) total cleaved Annexin 1 was expressed as a 
percentage of total Annexin 1 detected in each sample (iii) the proportion of 30kDa cleavage 
product was expressed as a percentage of 30kDa and 28kDa areas combined (iv,v) 
interleaved box and whisker plots indicating the minimum and maximum as an alternative 
representation of graphs (ii) and (iii).  
There was not enough neutrophil whole cell lysate available to probe for a loading 
control (β-actin, GAPDH etc.) to determine total Annexin 1 content across every 
sample. As a standard amount of whole cell lysate was loaded per well (determined 
by BCA assay), a ratio was determined within each sample to compare the 
abundance of intact Annexin 1 with and without TNF-α stimulation. The ratio was 
created by expressing each area of the intact Annexin 1 band determined by ImageJ 
as a percentage of the bands combined. i.e. if the TNF-α band was twice as strong 
as the control band, the TNF-α condition would read as 0.7 and the control band 
0.3. This ratio allowed the investigation of whether the total amount of intact Annexin 
1 varied with TNF-α stimulation within each sample, and whether this variation 
differed between healthy controls and GPA patients. When a ratio of intact Annexin 
1 between the two conditions was expressed, there was no significant difference 
observed in the total amount of intact Annexin 1 detected with and without TNF-α 
treatment in either healthy controls or GPA patients (Figure 5-9). 
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Figure 5-9 There is no observed effect on total amounts of intact Annexin 1 with 
TNF-α stimulation in healthy controls or GPA patient neutrophils, when 
detected in whole cell lysates by Western blotting 
Image J software was used to quantify the amount of intact Annexin 1 detected by Western 
blotting and data were expressed as a ratio of intact Annexin 1 detected in each sample with 
and without TNF-α stimulation. 
5.4.5 Neutrophil surface expression of PR3 is associated with Annexin 1 
cleavage 
To explore any relationship between neutrophil surface PR3 expression and 
Annexin 1 cleavage, correlations were investigated between neutrophil surface PR3 
expression determined by FACS analysis and the abundance of Annexin 1 cleavage 
products in proportion to the intact 37kDa protein, established by Western blotting. 
Correlations were considered between unstimulated cells and cells stimulated in 
vitro with TNF-α, as described previously. 
Neutrophil surface PR3 expression (a relative value determined by FACS analysis, 
as previously described) showed a trend towards a positive correlation with the 
abundance of total cleaved Annexin 1 in healthy control cells treated with TNF-α 
(10ng/ml), although this correlation did not meet statistical significance (Spearman 
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correlation coefficient = 0.65, p=0.067) (Figure 5-10). This trend was not observed 
for GPA patient neutrophils (Spearman correlation coefficient = 0.32, p=0.30) or 
when cells were untreated. 
 
Figure 5-10 Association between neutrophil surface PR3 expression and 
quantity of Annexin 1 cleavage products detected in whole cell lysates after in 
vitro activation 
Neutrophils were stimulated and stained as Figure 5-3. A higher surface expression of PR3 
determined by FACS analysis loosely correlated with a higher proportion of total cleaved 
Annexin 1 detected by Western blotting in whole cell lysates from healthy control 
neutrophils when treated with TNF-α (10ng/ml) (Spearman correlation coefficient = 0.65, 
p=0.067). There was no correlation between surface expression of PR3 and the proportion of 
total cleaved Annexin 1 in GPA patients when treated with TNF-α (Spearman correlation 
coefficient = 0.32, p=0.30). ■ Healthy controls ○ GPA patients. 
The relative abundance of the mPR3high subset compared to the mPR3low subset 
within the total neutrophil population showed a trend towards a positive correlation 
with the amount of total cleaved Annexin 1 found in neutrophil whole cell lysates 
from healthy controls with and without TNF-α stimulation (unstimulated: Spearman 
correlation coefficient = 0.68, p=0.0503; stimulated: Spearman correlation coefficient 
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= 0.62, p=0.0857) (Figure 5-11, i and ii). This correlation became significant in 
stimulated cells when both healthy control and GPA patient groups were analysed in 
combination (unstimulated combined groups: Spearman correlation coefficient = 
0.41, p=0.06; stimulated combined groups: Spearman correlation coefficient = 
0.475, p<0.03), but was not observed in GPA patient neutrophils alone. 
The percentage of the 28kDa Annexin 1 cleavage product in relation to the 30kDa 
peptide significantly positively correlated with the percentage of mPR3high 
neutrophils in unstimulated cells when whole cell lysates from healthy controls and 
GPA patients were analysed together (Spearman correlation coefficient = 0.47, 
*p=0.04) (Figure 5-11, iii). There was no correlation observed in healthy controls or 
GPA patients when cells were stimulated with TNF-α (Figure 5-11, iv). 
 
Figure 5-11 The abundance of the mPR3
high 
neutrophil subset positively 
correlates with the detection of Annexin 1 cleavage products detected in whole 
 142 
 
cell lysates from healthy control cells and GPA patients with and without in 
vitro activation 
Neutrophils were stimulated and stained as Figure 5-3. (i) The relative abundance of the 
mPR3
high
 subset within the total neutrophil population, determined by FACS analysis, 
showed a trend towards a positive correlation with a higher proportion of total cleaved 
Annexin 1 detected by Western blotting in whole cell lysates from unstimulated healthy 
control neutrophils (Spearman correlation coefficient = 0.68, p=0.0503). This trend was also 
observed when healthy control and GPA patient groups were analysed together (Spearman 
correlation coefficient = 0.41, p=0.06). (ii) When cells were stimulated with TNF-α 
(10ng/ml), there was a trend towards this same correlation in the healthy control neutrophils 
(Spearman correlation coefficient = 0.6167, p=0.0857). When healthy control and GPA 
patient neutrophils were analysed in combination, the correlation reached statistical 
significance (Spearman correlation coefficient = 0.4753, p<0.03). (iii) There was a 
significant positive correlation between the abundance of the 28kDa Annexin 1 cleavage 
product, compared to the 30kDa peptide, and the relative abundance of the mPR3
high
 subset 
in unstimulated cells when whole cell lysates from healthy controls and GPA patients were 
analysed together (Spearman correlation coefficient = 0.47, p=0.04). (iv) There was no 
correlation between the abundance of the 28kDa Annexin 1 cleavage product, and the 
relative abundance of the mPR3
high
 subset when cells were stimulated with TNF-α. ■ 
Healthy controls ○ GPA patients. 
There were no correlations between the MFI of the mPR3high population and the 
amount of total cleaved Annexin 1 found in neutrophil whole cell lysates from 
healthy control or GPA patient neutrophils, with and without TNF-α stimulation. The 
MFI of the mPR3high population exhibited a significant negative correlation with the 
abundance of the 28kDa Annexin 1 cleavage product when compared with the 
30kDa cleavage product, in unstimulated neutrophils from healthy controls 
(Spearman correlation coefficient = -0.86, p=0.02) (Figure 5-12, iii). There were no 
correlations between these two factors in GPA patients, or when cells were 
stimulated with TNF-α. 
There were no correlations observed between the MFI of the mPR3low population 
and the abundance of Annexin 1 cleavage products. 
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Figure 5-12 The MFI of the mPR3
high 
neutrophil subset negatively correlates 
with the detection of the 28kDa Annexin 1 cleavage product detected in whole 
cell lysates from healthy control cells in the absence of in vitro activation 
Neutrophils were stimulated and stained as Figure 5-3. The MFI of the mPR3
high
 subset 
within the total neutrophil population, determined by FACS analysis, was compared with 
cleaved Annexin 1 detected by Western blotting in whole cell lysates. There were no 
correlations between the mPR3
high
 MFI and total cleaved Annexin 1 in healthy control or 
GPA patient neutrophils when cells were untreated (i) or stimulated with TNF-α (ii). There 
was a significant negative correlation between the mPR3
high
 MFI and the percentage of 
28kDa peptide in unstimulated healthy control neutrophils (Spearman correlation coefficient 
= -0.86, p=0.02) (iii), but not in unstimulated GPA patient neutrophils. There was no 
correlation between the mPR3
high
 MFI and the percentage of 28kDa peptide in TNF-α 
stimulated neutrophils. ■ Healthy controls ○ GPA patients. 
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The previous analyses in this section compared neutrophil surface PR3 expression 
with the abundance of Annexin 1 cleavage products, in relation to total Annexin 1 
detected in each individual sample. In order to determine whether neutrophil surface 
PR3 expression relates to total Annexin 1 expression, the above analyses were 
repeated with the data for total intact Annexin 1 generated in Figure 5-9. These data 
are a ratio of intact Annexin 1 with and without TNF-α stimulation within each 
sample. When this ratio was compared to the abundance of mPR3high neutrophils in 
relation to mPR3low neutrophils detected by FACS, in the relevant condition, there 
was a trend towards a correlation between an increased abundance of mPR3high 
neutrophils and decreased total amount of intact Annexin detected in whole cell 
lysates from GPA patient cells in the presence of in vitro activation (Spearman 
correlation coefficient = -0.51, p=0.0507) (Figure 5-9). There was no correlation 
between these two factors in healthy control cells, or when cells were unstimulated. 
 
Figure 5-13 Association between the abundance of mPR3
high
 neutrophils and 
total amount of intact Annexin detected in whole cell lysates in the presence of 
in vitro activation 
Image J analysis of amounts of intact Annexin 1 was performed as Figure 5-9. The ratio of 
mPR3
high
 to mPR3
low
 neutrophils was compared to the ratio of intact Annexin detected in 
neutrophil lysates with or without TNF-α stimulation. In GPA patient cells, there was a trend 
 145 
 
towards a negative correlation between the two factors (Spearman correlation coefficient = -
0.5052, p=0.0507). There was no correlation in healthy control cells. ■ Healthy controls ○ 
GPA patients. 
5.4.6 Activation of primed human neutrophils by patient ANCA is modulated 
by a cleavage-resistant form of Annexin 1 in vitro 
To investigate whether cleavage-resistant forms of Annexin 1 might moderate the 
ANCA-induced activation of human neutrophils, neutrophils were isolated from an 
individual healthy control and primed with cytochalasin b and TNF-α, with or without 
SAnxA1, before incubating with either IgG isolated from a healthy control, or a PR3- 
or MPO-positive AAV patient. fMLP was used as a positive control and individual 
experiments were normalised to PBS controls, allowing data to be combined. MPO-
release was measured as an indicator of neutrophil degranulation. 
Incubation of neutrophils with SAnxA1 appeared to inhibit the activation of human 
neutrophils by patient MPO- and PR3-ANCA in a dose-dependent manner when 
measured by MPO-release (Figure 5-14), although experimental replicates were not 
high enough to reach statistical significance. Increasing concentrations of SAnxA1 
also inhibited MPO-release in fMLP stimulated and control IgG conditions, indicating 
that this inhibition was not ANCA-specific. 
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.  
Figure 5-14 The activation of human neutrophils is inhibited in a dose-
dependent manner by increasing concentrations of SuperAnnexinA1 
Neutrophils were primed with 5µg/ml cytochalasin b and 2ng/ml TNF-α at 2.5 x 10⁶ 
cells/ml, with or without SuperAnnexinA1 (SAnxA1) before stimulation with endotoxin-
depleted patient or normal human IgG (0.2mg/ml). fMLP (1μM) was used as a positive 
control for activation. Degranulation was quantified by MPO production using a colorimetric 
assay and normalised to PBS controls; n=3 experiments. 
5.5 Discussion 
FACS analysis of neutrophil surface PR3 expression revealed a bimodal population 
of neutrophils in both healthy controls and PR3-positive GPA patients in remission. 
This was in line with previous reports of neutrophil surface PR3 expression 
consisting of a PR3high and PR3low subset (Schreiber et al., 2003, Witko-Sarsat et al., 
1999). When comparing the surface PR3 expression of isolated peripheral blood 
neutrophils between patients and healthy controls, when neutrophils were stimulated 
with TNF-α, the overall neutrophil surface expression of PR3 was significantly higher 
in patient cells compared to healthy controls. When healthy control cells were 
stimulated with TNF-α, the neutrophil surface PR3 expression of the PR3high subset 
significantly increased, although the fraction of this population decreased, leaving 
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the overall neutrophil surface PR3 expression unchanged. In patient cells, the 
neutrophil surface PR3 expression of the PR3low subset significantly increased with 
TNF-α stimulation, leading to a trend towards an increase in overall PR3 expression 
that did not reach statistical significance. The ratios of PR3high and PR3low subsets 
were unchanged with TNF-α stimulation in patient neutrophils. Under control 
conditions there was no statistically significant difference in neutrophil surface PR3 
expression between healthy controls’ and patients’ cells, although there was a trend 
towards a higher overall expression of PR3 in patient neutrophils. When examining 
the PR3high and PR3low subsets individually, this phenomenon was revealed to 
originate from a trend towards a higher PR3 expression in the PR3high patient 
neutrophils. The observations reported here agree with previous accounts of a 
higher overall PR3 expression in GPA patients (Rarok et al., 2002, Schreiber et al., 
2003) although this was only found to be significant with TNF-α stimulation in this 
data set. The results described here elaborate on the specific contribution of the 
PR3high and PR3low subsets to the overall neutrophil surface PR3 expression. 
Previous reports of neutrophil  surface PR3 expression have been of the opinion 
that the proportions of PR3high and PR3low subsets are consistent over time in 
healthy controls and patients and do not change with in vitro neutrophil activation or 
disease activity, although an overall increase in MFI is observed when cells are 
activated with a combination of cytochalasin b and fMLP (Halbwachs-Mecarelli et 
al., 1995, Witko-Sarsat et al., 1999). The data here agree with the notion of an 
overall increase in neutrophil surface PR3 expression with cell stimulation, although 
this was only observed in patient cells and not in healthy control cells. These results 
also challenge the concept that the proportions of PR3high and PR3low subsets are 
predetermined. The results described here suggest that there could be a novel 
discrepancy between the reponse of healthy control and patient neutrophils to ex 
vivo stimulation. Monocyte expression of TNF-α is elevated in active AAV (Deguchi 
et al., 1990) and this could provide a physiological basis for augmented surface PR3 
expression in patient neutrophils; not only providing increased antigen for ANCA-
interaction but potentially supplying increased enzymatic capacity for Annexin 1 
cleavage. Three quarters of the patients in this data set were receiving steroid 
treatment with a mean dose of 14mg/d. There is anacedotal evidence that neutrophil 
surface PR3 expression is not influenced by steroid treatment but may be raised in 
other inflammatory diseases (Schreiber et al., 2003, Witko-Sarsat et al., 1999). 
There was no correlation between steroid dose and total neutrophil surface PR3 
expression either at baseline or after TNF-α treatment in this patient group 
(Appendix Figure 6-2). 
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The detection of Annexin 1 in neutrophil whole cell lysates by Western blotting 
revealed the intact protein (~37kDa) alongside two smaller cleavage products 
corresponding to ~30kDa and ~28kDa. Comparison of Annexin 1 cleavage between 
neutrophils isolated from PR3-positive GPA patients and healthy controls did not 
reveal any significant differences in the abundance of intact Annexin 1 or either of 
the smaller cleavage products, in the presence or absence of TNF-α. This is in 
contrast to previous data published by Vong et al. (2007) where an increase in 
Annexin 1 cleavage was detected in neutrophils with TNF-α stimulation (Vong et al., 
2007). It is possible that the neutrophil isolation process and subsequent steps 
leading to the creation of the whole cell lysate resulted in a level of Annexin 1 
cleavage that was unaffected by further TNF-α stimulation in my experiments. 
Neutrophils are short-lived and are ideally separated and used for in vitro activation 
assays within a 2-4hr window following blood collection. The nature of collecting and 
processing multiple patient samples from the clinic for FACS analysis alongside the 
generation of whole cell lysates resulted in some samples being processed after a 
delay of up to 1hr 30min, which could have led to the deterioration of the cells and 
potentially cleavage of Annexin 1 before in vitro stimulation. 
The initial analysis of Annexin 1 cleavage was a ratio of intact Annexin 1 to cleaved 
product within each neutrophil whole cell lysate. With the total amount of neutrophil 
whole cell lysate avaliable for Western blotting there was insufficient protein to 
detect a loading control (GAPDH, β-actin etc.) for calculating total protein 
abundance. Therefore as each lane was loaded with the same amount of total 
neutrophil whole cell lysate (determined by BCA assay), the density of each intact 
Annexin 1 band was compared with and without TNF-α within each patient/healthy 
control sample to produce a ratio of intact Annexin 1. There was no difference 
observed between the total amounts of intact Annexin 1 when comparing 
unstimulated and stimulated cells, in either healthy control or patient neutrophils. 
There may have been a degree of variation in the amount of protein loaded in each 
sample, which would have been accounted for if a standard was available, which 
may have masked any subtle changes in total intact Annexin 1 expressed in each 
condition. Glucocorticoids upregulate Annexin 1 expression and so I would expect to 
find increased levels of total Annexin 1 protein in the steroid-treated patient group, 
compared to the healthy controls. Whether this increased expression of Annexin 1 
would result in a disparity of cleavage between the patient and control group, or how 
neutrophils respond to TNF-α activation is unclear. 
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When associations were examined between surface PR3 expression and Annexin 1 
cleavage in neutrophil whole cell lysates, there was a significant correlation between 
an increased abundance of PR3high neutrophils and an increased proportion of 
cleaved Annexin 1, in TNF-α stimulated conditions, when both healthy control cells 
and patient cells were analysed in combination. There was also a significant 
correlation between an increased proportion of PR3high neutrophils and a higher 
percentage of the smaller 28kDa peptide, when compared to the total Annexin 1 
cleavage pool. This was observed in unstimulated cells when healthy control and 
patient cells were analysed together. Although the increased abundance of the 
28kDa peptide exhibited a positive correlation with the percentage of PR3high 
neutrophils, there was a significant negative correlation with the PR3 expression of 
the PR3high subset, in unstimulated neutrophils from healthy controls. Taken 
together, the correlations observed in this data set indicate that an increased 
proportion of PR3high neutrophils is associated with an increase in Annexin 1 
cleavage in vitro. These results suggest that the overall abundance of the PR3high 
subset might be of more importance than the PR3 MFI of each individual neutrophil 
subset in terms of association with Annexin 1 cleavage, although limited 
experimental group numbers may have prevented any observation of a correlation 
between overall neutrophil surface PR3 expression and Annexin 1 cleavage. 
In vitro experiments investigating the effect of increasing concentrations of a PR3 
cleavage-resistant peptide SuperAnnexinA1 (SAnxA1) in a neutrophil degranulation 
assay suggest that the peptide may be effective in inhibiting the activation of human 
neutrophils by MPO- and PR3-ANCA. This effect was also seen in the control IgG 
and fMLP conditions, suggesting that SAnxA1 has a general inhibitory effect on 
neutrophil activation, irrespective of stimulus. An inhibitory effect of SAnxA1 on 
neutrophil activation is consistent with reports of Annexin 1 and it’s N-terminal 
peptide Ac2-26 impeding FcγR-mediated neutrophil and monocyte activation 
(Euzger et al., 1999, Goulding et al., 1998, Goulding and Guyre, 1993). Annexin 1 
has been shown to have effects on the MAPK pathway and SAnxA1 may be 
inhibiting neutrophil degranulation through inhibition of MAPK activation (van der 
Veen et al., 2011, Yang et al., 2006). Unfortunately lack of avaliability of SAnxA1 
prevented the generation of further experimental replicates which may have pushed 
the data towards statistical significance. It would be also useful to establish whether 
this inhibitory effect on MPO-release here was related to cell toxicity/death. 
Experiments were attempted to replicate the data with proteolysis-resistant N-
terminal Annexin 1 peptide CR-AnxA12–50 but healthy control responses to ANCA 
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failed to exceed control IgG degranulation levels, preventing the investigation of any 
inhibitory effect on ANCA-induced neutrophil activation. 
Taken together, these results suggest that the neutrophil surface PR3 expression is 
higher in PR3-positive GPA patient cells compared to healthy controls, and an 
increase in the PR3high neutrophil fraction correlates with an increased detection of 
Annexin 1 cleavage products in whole cell lysates. In vitro experiments suggest a 
potential role for the PR3 cleavage-resistant peptide SAnxA1 in the general 
inhibition of neutrophil activation. 
Summary: 
 Neutrophil surface PR3 expression is significantly higher in PR3-positive 
GPA patient cells compared to healthy control cells when stimulated with 
TNF-α in vitro. 
 There is a significant correlation between an increased PR3high neutrophil 
fraction and an increased proportion of cleaved Annexin 1.  
 It is unclear whether there are different amounts of cleaved Annexin 1 in 
patient neutrophils compared to healthy controls. 
 The activation of human neutrophils is inhibited in a dose-dependent manner 
by increasing concentrations of SuperAnnexinA1 in vitro. 
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Chapter 6 Discussion 
6.1 Summary of results 
Chapter 3 investigated the role of Annexin 1 in a murine model of immune complex-
mediated crescentic glomerulonephritis (NTN). The effect of SuperAnnexinA1 on 
disease was examined and attempts were initiated to establish whether any effects 
of glucocorticoid treatment on disease were mediated by Annexin 1. The results in 
this chapter demonstrated that the genetic absence of Annexin 1 resulted in 
significantly more severe disease in the murine model of NTN, quantified by the 
degree of glomerular thrombosis. There were significantly less microparticles and 
neutrophil-derived microparticles found in the Annexin 1 deficient mice, compared to 
the wild-type mice. There was no observed effect on disease severity when 1µg 
SuperAnnexinA1 was administered daily in the NTN model; however the infiltrating 
macrophages in the treatment group had significantly reduced CD11b expression. 
The injection of 10µg dexamethasone did not have any impact on disease in this 
NTN model, preventing the exploration of glucocorticoid treatment in Annexin 1 
deficient mice. 
Chapter 4 went on to explore the role of Annexin 1 in murine models of anti-MPO 
associated glomerulonephritis. The passive transfer model of anti-myeloperoxidase 
associated glomerulonephritis required additional injections of LPS and GCSF to 
generate a pauci-immune crescentic glomerulonephritis in C57BL/6 mice. When 
comparing wild-type and Annexin 1 deficient mice, a lack of disease penetrance 
across experimental groups prevented the deduction as to whether the absence of 
Annexin 1 had an effect on disease. Attempts to reproduce the murine model of anti-
MPO associated glomerulonephritis developed by Ruth et al. (2006) were 
unsuccessful, despite the fact that additional immunodominant MPO CD4+ T-cell 
epitope was injected alongside the native protein to encourage the breaking of 
immune tolerance. 
Chapter 5 addressed the relationship between human neutrophil surface expression 
of PR3 and the degree of Annexin 1 cleavage; in neutrophils isolated from the 
peripheral blood of healthy controls and PR3-positive GPA patients in remission. In 
addition, the effect of a PR3 cleavage-resistant peptide (SuperAnnexinA1) on 
ANCA-induced neutrophil activation was investigated. The results in this chapter 
demonstrated that neutrophil surface PR3 expression is significantly higher in 
patient cells compared to healthy control cells when stimulated with TNF-α in vitro 
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and there is a significant correlation between an increased abundance of PR3high 
neutrophils and the detection of cleaved Annexin 1, in healthy control and patient 
cells, in TNF-α stimulated conditions. It was unclear from the data whether there are 
intrinsic differences in the amount of Annexin 1 cleavage in healthy control and 
patient neutrophils. In vitro experiments examining the activation of healthy human 
neutrophils by patient ANCA suggested a dose-dependent inhibition of 
degranulation responses by SuperAnnexinA1. 
6.2 Hypothesis for the role of Annexin 1 in human and experimental 
glomerulonephritis 
Annexin 1 is an endogenous inhibitor of inflammation, preventing inappropriate 
neutrophil extravasation into the tissues. When inflammatory stimuli are present 
Annexin 1 levels increase under glucocorticoid hormone control, allowing the protein 
to function as a pro-resolution mediator; promoting the apoptosis and efferocytosis 
of neutrophils, accelerating tissue repair and allowing the tissue to return to a 
homeostatic state. 
Annexin 1 plays a protective role in a number of murine models of acute and chronic 
inflammation, through the inhibition of innate and adaptive immune responses. The 
data in this thesis indicate that Annexin 1 deficient mice are more susceptible to 
disease in a mouse model of immune complex-mediated crescentic 
glomerulonephritis (NTN) and the PR3-cleavage resistant Annexin 1 peptide 
SuperAnnexinA1 has an anti-inflammatory effect on the phenotype of infiltrating 
macrophages in this model. Experiments addressing the role of Annexin 1 
deficiency in a murine model of anti-MPO associated glomerulonephritis were 
inconclusive, and the lack of disease penetrance may have masked the effect of 
Annexin 1. The pathogenesis of AAV involves important contributions from both the 
innate and adaptive immune responses. The two murine models used here address 
separate aspects of the immune response in the development of crescentic 
glomerulonephritis; the NTN model is Th1-driven whereas this passive-transfer 
model of anti-MPO associated glomerulonephritis relies primarily on the innate 
immune response to initiate an inflammatory response. 
PR3 cleaves Annexin 1, preventing interaction with its receptor FPR2/ALXR. The 
results in this thesis demonstrate that PR3 expression is significantly higher in 
neutrophils from PR3-positive GPA patients in remission compared to healthy 
controls when stimulated with TNF-α. Also, a higher neutrophil PR3 expression 
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correlates with increased Annexin 1 cleavage in healthy control and patient cells, in 
resting and TNF-α stimulated conditions. These results agree with previously 
published data indicating a higher neutrophil expression of PR3 in patient 
neutrophils and reveal a novel association between neutrophil PR3 expression and 
Annexin 1 cleavage in an ex vivo environment. Neutrophil infiltration is a 
fundamental component of disease pathogenesis in AAV and a high expression of 
PR3 on the neutrophil surface may not only act as an auto-antigen perpetuating the 
immune response to ANCA, but could lead to excessive cleavage of Annexin 1, 
preventing the proteins’ anti-inflammatory actions. The finding that neutrophil PR3 
expression is heightened in remission patients compared to healthy controls 
suggests a propensity for an inflammatory phenotype in these individuals which 
could contribute to the relapsing disease course often seen in PR3-positive GPA 
patients. The results in this thesis suggest that patient neutrophil PR3 expression 
might increase with cell activation. AAV patients with active disease display 
increased levels of TNF-α in peripheral blood mononuclear cells and anti-TNF 
inhibitors have shown some limited success in clinical trials (Deguchi et al., 1990, 
Morgan et al., 2011, Laurino et al., 2010). This heightened cytokine response in 
patients with active disease could contribute to an increase in neutrophil PR3 
expression and associated Annexin 1 cleavage, contributing to the chronic, non-
resolving phenotype characteristic of AAV.  
Annexin 1 peptidomimetics have been shown to exert a number of anti-inflammatory 
effects in vitro and in in vivo models of inflammation. The results presented in this 
thesis demonstrate that SuperAnnexinA1 may be effective in inhibiting the activation 
of human neutrophils by MPO- and PR3-ANCA. This hypothesis would agree with 
reports that Annexin 1 and its N-terminal peptide Ac2-26 impede FcγR-mediated 
neutrophil and monocyte activation (Euzger et al., 1999, Goulding et al., 1998, 
Goulding and Guyre, 1993) and provides insight into the ways in which Annexin 1 
peptidomimetics or FPR2/ALXR agonists could act as potential therapeutics in AAV. 
There are number of ways in which Annexin 1 deficiencies could potentially 
contribute to the pathology of AAV (see Figure 6-1). 
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Figure 6-1 Potential influence of Annexin 1 on the innate and adaptive immune 
mechanisms involved in the pathogenesis of AAV 
Annexin 1 may reduce IL-6 and IL-1β levels, inhibiting Th17 development and the 
contribution of this T cell subset to disease. Annexin 1 could reduce monocyte/macrophage 
infiltration, removing a major source of proinflammatory cytokine production. Annexin 1 
may play a homeostatic role preventing uncontrolled neutrophil chemotaxis to the 
inflammatory site. Annexin 1 may reduce circulating TNF-α and IL-1β, which contribute to 
neutrophil priming and the externalisation of ANCA antigens. Deficiencies in Annexin 1 
could contribute to Fcγ receptor mediated ANCA binding, causing full neutrophil activation, 
degranulation and release of free radicals, damaging the endothelium. Annexin 1 may 
promote shedding of adhesion molecules, reducing neutrophil-endothelial adhesion and 
subsequent damage to the endothelium. A C-terminal fragment of Annexin 1 may be 
responsible for the clustering of ICAM-1 in the formation of transmigratory cups. Cleavage 
of Annexin 1 at the neutrophil surface may remove the autocrine inhibition of neutrophil 
extravasation. 
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Neutrophil degranulation is a key pathological insult in AAV and MPO-expressing 
neutrophils are essential for the development of glomerulonephritis in mice. 
Increased cleavage of Annexin 1 in AAV could be a contributing factor to massive 
neutrophil influxes during acute disease due to the loss of Annexin 1 as a 
homeostatic mediator of neutrophil diapedesis (Schreiber et al., 2006). Annexin 1 
may also play a role in in inhibition of PI3Kγ activation which is involved in neutrophil 
activation and shown to play an essential role in the development of anti-MPO 
induced NCGN in mice (Schreiber et al., 2010). 
Research has demonstrated that Annexin 1 is upregulated in extravasated 
neutrophils and could play a role in promoting apoptosis of these cells, rather than 
allowing them to progress to a necrotic state. Focal segmental necrotising 
glomerulonephritis is a key feature of AAV and if there is a dysregulation of 
apoptosis in AAV, caused by increased cleavage of Annexin 1 by PR3, this could be 
contributing to the necrotising phenotype. 
As mentioned above, Annexin 1 has been shown to inhibit binding of IgG to Fcγ 
receptors on peripheral blood monocytes and neutrophils in vitro through a calcium-
dependent mechanism. Taken together with ex vivo evidence that neutrophil FcγR-
mediated respiratory burst can be inhibited by treatment with the Annexin 1 N-
terminal peptide Ac2-26, it is possible that Annexin 1 prevents Fcγ-mediated 
signalling through the MAPK pathway to prevent neutrophil activation (Goulding et 
al., 1998, Goulding and Guyre, 1993, van der Veen et al., 2011). If this is in fact the 
case in vivo, then Annexin 1 deficiencies in AAV could be contributing to ANCA 
binding to Fcγ receptors on neutrophils, leading to their activation and the 
subsequent inflammatory cascade. 
Annexin 1 can augment IL-10 production in vitro and in in vivo models of 
inflammation (Cooray et al., 2013, Guido et al., 2013). IL-10 competency is 
diminished in AAV patients during remission and active disease and a lack of Bregs 
secreting IL-10 may predispose a Th1 immune response (Todd et al., 2014, Wilde et 
al., 2013). IL-10 can also reduce T cell expression of IFN-γ in vitro via IL-12 
inhibition (Ludviksson et al., 1998). Excessive Annexin 1 cleavage in AAV may 
therefore reduce IL-10 production and contribute to disease pathogenesis. 
IL-1β has an important role in immune and inflammatory responses and PR3 is 
known to contribute to the serine-protease dependent processing of IL-1β from its 
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inactive to active form (Schreiber et al., 2012). Although a direct pathogenic role for 
IL-1β in AAV has not been identified and IL-1β serum levels do not differ in patients 
with AAV when compared to healthy controls, patients with active disease have an 
increased number of IL-1β-expressing macrophages infiltrating the glomerulus when 
compared with patients with inactive disease (Nogueira et al., 2010, Noronha et al., 
1993). Also, mice lacking dipeptidyl peptidase I (DPPI) which is required for PR3 
activation and subsequent IL-1β generation, are protected from anti-MPO induced 
necrotising crescentic glomerulonephritis (Schreiber et al., 2012). In terms of its 
pathophysiological effects, IL-1β can enhance leukocyte rolling, adhesion and 
migration in a mouse model when given in combination with ANCA, possibly through 
the upregulation of adhesion molecule expression (Myers et al., 1992, Nolan et al., 
2008). IL-1β may also contribute to Th17 cell differentiation and has thus been 
mentioned as a possible therapeutic target in AAV (Chung et al., 2009). In terms of 
Annexin 1 and IL-1β, murine models of antigen-induced arthritis and zymosan 
peritonitis have revealed increased levels of IL-1β in Annexin 1 deficient mice at the 
inflammatory site, an effect which can be rescued by administration of peptide Ac2-
26 in the zymosan peritonitis model (Damazo et al., 2006, Yang et al., 2004). 
However, full-length Annexin 1 does not reverse IL-1β induced neutrophil infiltration 
into a murine air pouch (Perretti and Flower, 1993). Increased levels of PR3 in AAV 
patients could contribute to the generation of, and pathological effects of IL-1β in 
disease, in addition to reducing levels of anti-inflammatory Annexin 1, meaning that 
targeting Annexin 1 could be beneficial in terms of IL-1β involvement in disease. 
A pathogenic link between IL-6 and AAV has not been proven, but as ANCA 
stimulate the release of IL-6 from B cells, driving the differentiation of Th0 to Th17 
cells, this cytokine no doubt has an important role in disease. Interestingly, an IL-6 
inhibitor has shown anecdotal success in the treatment of RA complicated with AAV 
(Sumida et al., 2011). Linking the documented effects of Annexin 1 on the MAPK 
pathway, a p38 MAPK inhibitor has been shown to reduce IL-6 production by 
glomerular epithelial cells, raising a potential role for Annexin 1 to influence not just 
the infiltrating cells but the microenvironment of the kidney glomerulus (van der 
Veen et al., 2011). In addition, in a comparison of diabetic patients with and without 
nephropathy, Annexin 1 levels are raised in the patients with nephropathy and 
positively correlate with IL-6 levels, suggesting a counter-regulatory mechanism for 
Annexin 1 on IL-6 levels (Pietrani et al., 2014). 
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Expression of the pro-inflammatory cytokine macrophage migration inhibitory factor 
(MIF) has recently been shown to associate with a number of inflammatory states 
and autoimmune diseases (Reviewed in (Asare et al., 2013)) and increased levels of 
MIF have been found to correlate with disease activity in AAV (Becker et al., 2006, 
Ohwatari et al., 2001). MIF has been found to counteract some of the anti-
inflammatory effects of GCs, including the expression of MAPK phosphatase 1 
(MKP-1) (Roger et al., 2005) and the regulation of phospholipase A2 activity. It has 
been suggested that endogenous MIF limits Annexin 1 expression and MIF can 
counteract the GC-dependent expression of Annexin 1 (Roger et al., 2005, Sun et 
al., 2013). In a mouse model of AIA, levels of IL-1β, TNFα, IL-6, and MIF were all 
found to be increased in Annexin 1 deficient mice when compared to their wild-type 
counterparts (Yang et al., 2004). Increased levels of MIF in active AAV could 
contribute to deficiencies in Annexin 1 caused by PR3 cleavage, making Annexin 1 
an even more interesting therapeutic target. 
Endogenous and exogenously-administered GCs have an established role in 
regulating Annexin 1 levels; glucocorticoids prevent generation of proteolytic 
enzymes which cleave Annexin 1 as well as increasing the production of Annexin 1 
and its receptor in cells of the human and mouse innate immune system and 
mobilizing Annexin 1 expression at the cell surface, enabling interaction with its 
receptor (Damazo et al., 2006, Ehrchen et al., 2007, Goulding et al., 1990, 
Hashimoto et al., 2007, Sawmynaden and Perretti, 2006). As well as regulating the 
innate immune response through Annexin 1, Perretti and D’Acquisto suggest that 
glucocorticoids may regulate the adaptive arm of the immune response by 
suppressing Annexin 1 expression, leading to reductions in T cell proliferation and 
activation (Perretti and D'Acquisto, 2009). Persistent T cell activation is 
characteristic in AAV, in active disease as well as in remission (Abdulahad et al., 
2006). GCs are used in AAV to induce and maintain disease remission and a 
number of these anti-inflammatory effects could be mediated through Annexin 1. As 
there is possible dysregulation of aspects of both the innate and adaptive immune 
system in AAV, direct manipulation of Annexin 1 could be therapeutically beneficial 
across different phases of disease and could avoid adverse side effects associated 
with GC treatment. 
6.2.1 Potential for the use of pro-resolving therapeutics in AAV 
Current treatment approaches in AAV are associated with adverse side effects due 
to non-specific immunosuppression while achieving sustained remission is a 
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challenge in a significant proportion of patients. Resolution pharmacology is an 
emerging concept in the treatment of chronic inflammatory diseases as a 
mechanism to actively augment resolution processes in conjunction with the 
suppression of inappropriate inflammatory responses. Evidence is accumulating for 
the efficacy of pro-resolving mediators in treating pathologies such as asthma, 
polycystic kidney disease and psoriatic arthritis (for a list of clinical trials see (Perretti 
et al., 2015)). 
Early studies utilising the N-terminal fragment of Annexin 1 (Ac2-26) in in vivo 
models of inflammation demonstrated anti-inflammatory effects (Getting et al., 1997, 
Perretti et al., 1993) and subsequent work has revealed the ability of Annexin 1 
cleavage-resistant peptides to act as pro-resolution mediators in several models of 
acute and chronic inflammation (Dalli et al., 2013, Patel et al., 2012). These newly 
developed cleavage-resistant peptides have longer sequences and higher affinity for 
FPR2/ALXR than the Annexin 1 N-terminal peptides and can therefore exert more 
potent and sustained effects in vivo (Perretti and Dalli, 2009). Recently, in a mouse 
model of RA, the stimulation of FPR2/ALXR has also been shown to be of 
therapeutic benefit and inhibits TNF-α mRNA expression in the joint (Kao et al., 
2014). 
Pro-resolving therapeutics might encompass potentiating endogenous pro-resolving 
pathways, the development of new agonists designed on pro-resolving mediators or 
mimetics of endogenous resolution mediators. There is exciting in vivo evidence for 
Annexin 1 peptidomimetics providing therapeutic benefit when delivered within 
targeted nanoparticles in experimental models of disease (Fredman et al., 2015, 
Headland et al., 2015, Leoni et al., 2015), endorsing therapeutic prospects for this 
type of peptide in chronic inflammatory diseases such as AAV. 
6.3 Thesis limitations 
The conclusions drawn from the in vitro investigations in this thesis are limited due 
to the nature of the experiments. These experiments allow the examination of direct 
links between neutrophil surface PR3 expression and Annexin 1 cleavage but are 
constrained by the absence of other cells which may influence either factor in the 
physiological environment. It is possible that neutrophil surface PR3 expression and 
Annexin 1 cleavage are altered during the neutrophil isolation process due to a 
degree of neutrophil activation and it is conceivable that the amount Annexin 1 
cleavage reached a maximum before cells were stimulated, masking any effect of in 
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vitro stimulation on Annexin 1 cleavage. The method of PMN isolation use for these 
studies would have excluded low-density granulocytes (LDGs) which co-localize 
with PBMCs in the separation gradient. LDGs have not yet been proven to exist in 
the blood of AAV patients but could play an important pro-inflammatory role in 
disease pathogenesis (Grayson et al., 2015). The analysis of Annexin 1 protein on 
Western blot was unable to encompass a loading control for calculating total protein 
so transcriptional/translational changes in Annexin 1 were not addressed and 
compared between patients and healthy controls. 
6.4 Limitations of the animal models used 
The use of animal models has been essential in delineating the pathology of AAV 
and has led to the development of novel therapeutics such as C5aR and TNF-α 
inhibitors. Alternative models are useful for defining separate aspects of the immune 
response, although do not address them all together. NTN is a straightforward 
model of crescentic glomerulonephritis; however the disease develops in the 
presence of immune-complexes unlike the pauci-immune nature of human AAV. In 
this model of NTN there were few crescentic glomeruli observed on histology, 
therefore disease was scored on glomerular thrombosis, in contrast with the fibrinoid 
necrosis seen in the human disease. The dose of SuperAnnexinA1 administered in 
NTN was based on previously published data reporting the acceleration of the 
resolution of inflammation in a model of inflammatory arthritis (Patel et al., 2012). 
Although the peptide did not affect disease severity in NTN, there was no 
physiological readout to demonstrate that this dose of SuperAnnexinA1 had entered 
the circulation or was having any systemic effect.  
The passive-transfer model of MPO-associated glomerulonephritis was used to 
address the effect of the absence of Annexin 1 on the innate immune contribution to 
disease. This model is useful in examining the acute stage of disease, but due to the 
lack of continuing antibody production is not suitable for studying the chronic phase 
of disease. This disease model is labour-intensive in terms of generating MPO to 
inject MPO deficient mice and subsequently isolating IgG to immunise experimental 
animals. There were challenges in isolating good quality MPO from the mouse 
promyelocytic cell line and inducing an antibody response in MPO deficient animals. 
There were also difficulties purifying IgG from MPO deficient serum and stimulating 
an immune response in recipient mice. The MEV model is notoriously variable in 
terms of disease penetrance and large animal groups are needed to reveal true 
differences between experimental groups. The passive transfer model described in 
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this thesis required additional injections of LPS and GCSF to generate disease, 
which was mild in severity compared to previously published data. Due to a lack of 
available anti-MPO IgG, experimental groups were small and data was combined 
across two experiments where the same reagents were used to generate disease. 
There was a suggestion from the results that Annexin 1 deficient mice might be 
protected from disease, however this may have resulted from a lack of disease 
penetrance in the second experiment, incorporating the Annexin 1 deficient mice, 
falling short of the first experiment. More animals would be needed in each group to 
define a true effect. 
6.5 Further questions to address 
Annexin 1 cleavage in AAV 
The results in this thesis revealed a skewing towards the detection of more Annexin 
1 cleavage products in healthy control neutrophils compared to patient cells. This 
was an unexpected result and it would be informative to add more samples to the 
analysis to observe if there is a true disparity between the two groups. It would be 
interesting to follow Annexin 1 cleavage over the disease time course and compare 
patients with active disease to those in remission, as well as adding in a disease 
control group to confirm whether Annexin 1 cleavage is a general feature of 
inflammation or is specifically altered in AAV patients. 
Human leukocyte elastase (HLE) also cleaves Annexin 1 by proteolysis and shares 
a cleavage site with PR3. Interestingly, both PR3 and HLE are externalised on 
neutrophil activation and antibodies to both proteins are found in AAV. The 
relevance of this is unclear, and it would be interesting to investigate whether 
elastase levels in neutrophils from AAV patients are also atypical and correlate with 
Annexin 1 cleavage. 
Total Annexin 1 expression 
The experiments in this thesis addressed ratios of intact to cleaved Annexin 1, but 
were unable to quantify total amounts of Annexin 1 in neutrophil whole cell lysates. It 
would be interesting to investigate whether total amounts of Annexin 1 differ 
between healthy controls and patients and whether total amounts of Annexin 1 
change between remission and active disease states, indicating control at a 
transcriptional or translational level. 
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Annexin 1 cleavage-resistant peptides 
The results described here suggest that ANCA-induced neutrophil degranulation 
may be inhibited by SuperAnnexinA1, however the neutrophil degranulation 
response to ANCA in these experiments was minimal compared to the background 
response to normal IgG. Compared to degranulation, intracellular ROS production is 
a more sensitive way of monitoring ANCA-induced activation and could provide a 
more robust way of measuring an inhibitory effect of cleavage-resistant Annexin 1 
peptides on ANCA-induced neutrophil activation. 
Nephrotoxic nephritis model 
The results in this thesis demonstrated a significant exacerbation of NTN in Annexin 
1 deficient animals compared to wild-type controls, but the mechanism of this 
protection by Annexin 1 was not apparent. It would be interesting to expand on the 
early time-point data to establish any effects of Annexin 1 deficiency on neutrophil 
infiltration early in disease and investigate Th1 responses which may have been 
augmented. The treatment of mice with 1µg SuperAnnexinA1 did not affect disease 
in this NTN model. Ultimately it would be interesting to see whether the 
administration of SuperAnnexinA1 could rescue the Annexin 1 deficient phenotype, 
providing a rationale for Annexin 1 peptidomimetics in the resolution of vascular 
injury.  
MEV models 
There were many challenges in attempting to establish MEV models for this work. It 
would be useful to develop on the passive transfer model of anti-MPO associated 
glomerulonephritis described here, adding animals to the experimental groups to 
observe any true effects of Annexin 1 deficiency on disease. If there was a 
significant effect on disease associated with the absence of Annexin 1 it would be 
interesting to explore whether this is due to the modulation of neutrophil trafficking in 
the early stage of disease. Use of alternative MEV models could provide insight into 
where Annexin 1 may play a role in different parts of the immune response in AAV; 
comparing the DTH-like injury model in wild-type and Annexin 1 animals would be 
informative on the effect of Annexin 1 in the adaptive immune component of disease 
and the BM transplant model could be utilised to determine whether Annexin 1 
expression is important in BM-derived cells or intrinsic renal cells. Both the DTH-like 
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injury model and the BM transplant model would also be useful in examining the 
importance of Annexin 1 in the chronic phase of disease as antibody levels are 
sustained over the experimental timecourse. Once established, these models could 
be used to investigate the therapeutic effects of cleavage-resistant Annexin 1 
apeptides on disease. It would be interesting to measure TNF-α levels in the serum 
and mRNA in the kidney to explore whether these change with treatment as this 
cytokine is relevant to AAV and has been shown to change with the presence and 
absence of Annexin 1. 
Establishing renal expression of Annexin 1 and FPR2/AXR is important in 
establishing if potential therapeutics might act locally in AAV and could be achieved 
with immunostaining of mouse and human kidney. 
6.6  Concluding remarks 
The results in this thesis indicate that neutrophil surface PR3 expression is 
significantly higher in PR3-positive GPA patient cells compared to healthy control 
cells when stimulated in vitro and reveal a novel correlation between an increased 
surface PR3 expression and the detection of Annexin 1 cleavage products in 
neutrophil whole cell lysates. 
In vivo, the genetic absence of Annexin 1 is demonstrated to result in significantly 
more severe disease in a murine model of immune complex-mediated crescentic 
glomerulonephritis, however the effect of Annexin 1 deficiency on disease in a 
murine model of anti-myeloperoxidase associated glomerulonephritis was 
inconclusive. 
The data presented here demonstrate that a PR3 cleavage-resistant Annexin 1 
peptide can skew infiltrating macrophages towards a less inflammatory phenotype in 
an in vivo model of crescentic glomerulonephritis and might inhibit neutrophil 
activation in vitro. 
Annexin 1 has recently emerged as a key mediator in the active process of the 
resolution of inflammation. The protein acts to limit neutrophil trafficking to 
inflammatory sites, promote their apoptosis and nonphlogistic clearance and can 
polarize macrophages to a pro-resolving phenotype. The data in this thesis 
demonstrate that Annexin 1 deficiencies could play an important role in the 
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pathogenesis of AAV and pro-resolving therapeutics based on Annexin 1 may have 
potential in the treatment of this chronic disease. 
This thesis is all original work. Where others have contributed it has been 
acknowledged. 
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Appendix 
 
Figure 6-2 Correlation of relative neutrophil mPR3 expression and steroid dose in PR3-positive GPA patients 
Neutrophils stimulated with/without TNF-α (10ng/ml) for 30 minutes at 37°C were incubated with anti-PR3 FITC antibody or isotype control. The MFI of the 
PR3-stained neutrophil population as a whole, was divided by the MFI of the equivalent population stained with the isotype control antibody to produce a 
value for relative mPR3 expression. There was no significant correlation observed between relative neutrophil PR3 expression and patient steroid dose either 
under unstimulated conditions (i) or with TNF-α treatment (ii). 
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Figure 6-3 MPO-/- genotyping 
Genomic DNA was obtained from the digestion of ear clips overnight in 100µl DNA lysis buffer at 55°C with 100μg/ml proteinase K. Samples were then 
diluted with 300μl of distilled water and heat inactivated for 15 minutes at 75°C. PCR was carried out using using REDTaq® ReadyMix™ PCR Reaction Mix 
with MgCl2 (Sigma) and 2μl of the crude lysate template, using the following primers: MPO1 (5’ TGA-CAC-CTG-CTC-AGC-TGA-AT 3’), MPO2 (5’ TGC-
AGG-CAG-CTG-GTC-TCG-CA- 3’), MPO3 (5’ CTA-CCG-GTG-GAT-GTG-GAA-TGT- 3’). PCR products were analysed by gel electrophoresis on a 2% 
agarose gel with 1μl ethidium bromide (10mg/ml) per 50ml volume. Gels were run at 100V for 30 minutes and visualised using a UV light source. 
 166 
 
Bibliography 
 
ABDULAHAD, W. H., KALLENBERG, C. G., LIMBURG, P. C. & 
STEGEMAN, C. A. 2009. Urinary CD4+ effector memory T cells 
reflect renal disease activity in antineutrophil cytoplasmic 
antibody-associated vasculitis. Arthritis Rheum, 60, 2830-8. 
ABDULAHAD, W. H., STEGEMAN, C. A., LIMBURG, P. C. & 
KALLENBERG, C. G. 2008. Skewed distribution of Th17 
lymphocytes in patients with Wegener's granulomatosis in 
remission. Arthritis Rheum, 58, 2196-205. 
ABDULAHAD, W. H., STEGEMAN, C. A., VAN DER GELD, Y. M., 
DOORNBOS-VAN DER MEER, B., LIMBURG, P. C. & 
KALLENBERG, C. G. 2007. Functional defect of circulating 
regulatory CD4+ T cells in patients with Wegener's 
granulomatosis in remission. Arthritis Rheum, 56, 2080-91. 
ABDULAHAD, W. H., VAN DER GELD, Y. M., STEGEMAN, C. A. 
& KALLENBERG, C. G. 2006. Persistent expansion of CD4+ 
effector memory T cells in Wegener's granulomatosis. Kidney Int, 
70, 938-47. 
ABID HUSSEIN, M. N., BOING, A. N., STURK, A., HAU, C. M. & 
NIEUWLAND, R. 2007. Inhibition of microparticle release 
triggers endothelial cell apoptosis and detachment. Thromb 
Haemost, 98, 1096-107. 
ANDERSON, H. A., MAYLOCK, C. A., WILLIAMS, J. A., 
PAWELETZ, C. P., SHU, H. & SHACTER, E. 2003. Serum-
derived protein S binds to phosphatidylserine and stimulates the 
phagocytosis of apoptotic cells. Nat Immunol, 4, 87-91. 
ARUR, S., UCHE, U. E., REZAUL, K., FONG, M., SCRANTON, V., 
COWAN, A. E., MOHLER, W. & HAN, D. K. 2003. Annexin I is 
an endogenous ligand that mediates apoptotic cell engulfment. 
Dev Cell, 4, 587-98. 
ASARE, Y., SCHMITT, M. & BERNHAGEN, J. 2013. The vascular 
biology of macrophage migration inhibitory factor (MIF). 
Expression and effects in inflammation, atherogenesis and 
angiogenesis. Thromb Haemost, 109, 391-8. 
BALLIEUX, B. E., HIEMSTRA, P. S., KLAR-MOHAMAD, N., 
HAGEN, E. C., VAN ES, L. A., VAN DER WOUDE, F. J. & 
DAHA, M. R. 1994. Detachment and cytolysis of human 
endothelial cells by proteinase 3. Eur J Immunol, 24, 3211-5. 
BANSAL, P. J. & TOBIN, M. C. 2004. Neonatal microscopic 
polyangiitis secondary to transfer of maternal myeloperoxidase-
 167 
 
antineutrophil cytoplasmic antibody resulting in neonatal 
pulmonary hemorrhage and renal involvement. Ann Allergy 
Asthma Immunol, 93, 398-401. 
BAUDEAU, C., DELARUE, F., HE, C. J., NGUYEN, G., ADIDA, C., 
PERALDI, M. N., SRAER, J. D. & RONDEAU, E. 1994. 
Induction of MHC class II molecules HLA-DR, -DP and -DQ and 
ICAM 1 in human podocytes by gamma-interferon. Exp Nephrol, 
2, 306-12. 
BAYLEY, R., KITE, K. A., MCGETTRICK, H. M., SMITH, J. P., 
KITAS, G. D., BUCKLEY, C. D. & YOUNG, S. P. 2015. The 
autoimmune-associated genetic variant PTPN22 R620W enhances 
neutrophil activation and function in patients with rheumatoid 
arthritis and healthy individuals. Ann Rheum Dis, 74, 1588-95. 
BECKER, H., MAASER, C., MICKHOLZ, E., DYONG, A., 
DOMSCHKE, W. & GAUBITZ, M. 2006. Relationship between 
serum levels of macrophage migration inhibitory factor and the 
activity of antineutrophil cytoplasmic antibody-associated 
vasculitides. Clin Rheumatol, 25, 368-72. 
BLUME, K. E., SOEROES, S., KEPPELER, H., STEVANOVIC, S., 
KRETSCHMER, D., RAUTENBERG, M., WESSELBORG, S. & 
LAUBER, K. 2012. Cleavage of annexin A1 by ADAM10 during 
secondary necrosis generates a monocytic "find-me" signal. J 
Immunol, 188, 135-45. 
BLUME, K. E., SOEROES, S., WAIBEL, M., KEPPELER, H., 
WESSELBORG, S., HERRMANN, M., SCHULZE-OSTHOFF, 
K. & LAUBER, K. 2009. Cell surface externalization of annexin 
A1 as a failsafe mechanism preventing inflammatory responses 
during secondary necrosis. J Immunol, 183, 8138-47. 
BOOMSMA, M. M., STEGEMAN, C. A., VAN DER LEIJ, M. J., 
OOST, W., HERMANS, J., KALLENBERG, C. G., LIMBURG, 
P. C. & TERVAERT, J. W. 2000. Prediction of relapses in 
Wegener's granulomatosis by measurement of antineutrophil 
cytoplasmic antibody levels: a prospective study. Arthritis Rheum, 
43, 2025-33. 
BOOTH, A. D., ALMOND, M. K., BURNS, A., ELLIS, P., GASKIN, 
G., NEILD, G. H., PLAISANCE, M., PUSEY, C. D., JAYNE, D. 
R. & PAN-THAMES RENAL RESEARCH, G. 2003. Outcome of 
ANCA-associated renal vasculitis: a 5-year retrospective study. 
Am J Kidney Dis, 41, 776-84. 
BOUAZIZ, J. D., CALBO, S., MAHO-VAILLANT, M., SAUSSINE, 
A., BAGOT, M., BENSUSSAN, A. & MUSETTE, P. 2010. IL-10 
produced by activated human B cells regulates CD4(+) T-cell 
activation in vitro. Eur J Immunol, 40, 2686-91. 
 168 
 
BRINKMANN, V., REICHARD, U., GOOSMANN, C., FAULER, B., 
UHLEMANN, Y., WEISS, D. S., WEINRAUCH, Y. & 
ZYCHLINSKY, A. 2004. Neutrophil extracellular traps kill 
bacteria. Science, 303, 1532-5. 
BROGAN, P. A., SHAH, V., BRACHET, C., HARNDEN, A., MANT, 
D., KLEIN, N. & DILLON, M. J. 2004a. Endothelial and platelet 
microparticles in vasculitis of the young. Arthritis Rheum, 50, 
927-36. 
BROGAN, P. A., SHAH, V., KLEIN, N. & DILLON, M. J. 2004b. 
Vbeta-restricted T cell adherence to endothelial cells: a 
mechanism for superantigen-dependent vascular injury. Arthritis 
Rheum, 50, 589-97. 
BROUWER, E., STEGEMAN, C. A., HUITEMA, M. G., LIMBURG, P. 
C. & KALLENBERG, C. G. 1994. T cell reactivity to proteinase 3 
and myeloperoxidase in patients with Wegener's granulomatosis 
(WG). Clin Exp Immunol, 98, 448-53. 
BURTON, J. L., KEHRLI, M. E., JR., KAPIL, S. & HORST, R. L. 
1995. Regulation of L-selectin and CD18 on bovine neutrophils by 
glucocorticoids: effects of cortisol and dexamethasone. J Leukoc 
Biol, 57, 317-25. 
BYSTROM, J., EVANS, I., NEWSON, J., STABLES, M., TOOR, I., 
VAN ROOIJEN, N., CRAWFORD, M., COLVILLE-NASH, P., 
FARROW, S. & GILROY, D. W. 2008. Resolution-phase 
macrophages possess a unique inflammatory phenotype that is 
controlled by cAMP. Blood, 112, 4117-27. 
CALICH, A. L., PUECHAL, X., PUGNET, G., LONDON, J., 
TERRIER, B., CHARLES, P., MOUTHON, L., GUILLEVIN, L. 
& FRENCH VASCULITIS STUDY, G. 2014. Rituximab for 
induction and maintenance therapy in granulomatosis with 
polyangiitis (Wegener's). Results of a single-center cohort study 
on 66 patients. J Autoimmun, 50, 135-41. 
CARTER, N. A., VASCONCELLOS, R., ROSSER, E. C., TULONE, 
C., MUNOZ-SUANO, A., KAMANAKA, M., EHRENSTEIN, M. 
R., FLAVELL, R. A. & MAURI, C. 2011. Mice lacking 
endogenous IL-10-producing regulatory B cells develop 
exacerbated disease and present with an increased frequency of 
Th1/Th17 but a decrease in regulatory T cells. J Immunol, 186, 
5569-79. 
CARTIN-CEBA, R., GOLBIN, J. M., KEOGH, K. A., PEIKERT, T., 
SANCHEZ-MENENDEZ, M., YTTERBERG, S. R., 
FERVENZA, F. C. & SPECKS, U. 2012. Rituximab for remission 
induction and maintenance in refractory granulomatosis with 
 169 
 
polyangiitis (Wegener's): ten-year experience at a single center. 
Arthritis Rheum, 64, 3770-8. 
CHARLES, L. A., CALDAS, M. L., FALK, R. J., TERRELL, R. S. & 
JENNETTE, J. C. 1991. Antibodies against granule proteins 
activate neutrophils in vitro. J Leukoc Biol, 50, 539-46. 
CHARLES, L. A., FALK, R. J. & JENNETTE, J. C. 1992. Reactivity of 
antineutrophil cytoplasmic autoantibodies with mononuclear 
phagocytes. J Leukoc Biol, 51, 65-8. 
CHATTERJEE, B. E., YONA, S., ROSIGNOLI, G., YOUNG, R. E., 
NOURSHARGH, S., FLOWER, R. J. & PERRETTI, M. 2005. 
Annexin 1-deficient neutrophils exhibit enhanced transmigration 
in vivo and increased responsiveness in vitro. J Leukoc Biol, 78, 
639-46. 
CHAVELE, K. M., MARTINEZ-POMARES, L., DOMIN, J., 
PEMBERTON, S., HASLAM, S. M., DELL, A., COOK, H. T., 
PUSEY, C. D., GORDON, S. & SALAMA, A. D. 2010. Mannose 
receptor interacts with Fc receptors and is critical for the 
development of crescentic glomerulonephritis in mice. J Clin 
Invest, 120, 1469-78. 
CHEADLE, C., BERGER, A. E., ANDRADE, F., JAMES, R., 
JOHNSON, K., WATKINS, T., PARK, J. K., CHEN, Y. C., 
EHRLICH, E., MULLINS, M., CHREST, F., BARNES, K. C. & 
LEVINE, S. M. 2010. Transcription of proteinase 3 and related 
myelopoiesis genes in peripheral blood mononuclear cells of 
patients with active Wegener's granulomatosis. Arthritis Rheum, 
62, 1744-54. 
CHEN, Y., YAO, Y., SUMI, Y., LI, A., TO, U. K., ELKHAL, A., 
INOUE, Y., WOEHRLE, T., ZHANG, Q., HAUSER, C. & 
JUNGER, W. G. 2010. Purinergic signaling: a fundamental 
mechanism in neutrophil activation. Sci Signal, 3, ra45. 
CHOU, J., MACKMAN, N., MERRILL-SKOLOFF, G., PEDERSEN, 
B., FURIE, B. C. & FURIE, B. 2004. Hematopoietic cell-derived 
microparticle tissue factor contributes to fibrin formation during 
thrombus propagation. Blood, 104, 3190-7. 
CHUNG, Y., CHANG, S. H., MARTINEZ, G. J., YANG, X. O., 
NURIEVA, R., KANG, H. S., MA, L., WATOWICH, S. S., 
JETTEN, A. M., TIAN, Q. & DONG, C. 2009. Critical regulation 
of early Th17 cell differentiation by interleukin-1 signaling. 
Immunity, 30, 576-87. 
CIRINO, G., PEERS, S. H., FLOWER, R. J., BROWNING, J. L. & 
PEPINSKY, R. B. 1989. Human recombinant lipocortin 1 has 
acute local anti-inflammatory properties in the rat paw edema test. 
Proc Natl Acad Sci U S A, 86, 3428-32. 
 170 
 
COCKWELL, P., BROOKS, C. J., ADU, D. & SAVAGE, C. O. 1999. 
Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic 
autoantibody-associated glomerulonephritis. Kidney Int, 55, 852-
63. 
COMFURIUS, P., SENDEN, J. M., TILLY, R. H., SCHROIT, A. J., 
BEVERS, E. M. & ZWAAL, R. F. 1990. Loss of membrane 
phospholipid asymmetry in platelets and red cells may be 
associated with calcium-induced shedding of plasma membrane 
and inhibition of aminophospholipid translocase. Biochim Biophys 
Acta, 1026, 153-60. 
COORAY, S. N., GOBBETTI, T., MONTERO-MELENDEZ, T., 
MCARTHUR, S., THOMPSON, D., CLARK, A. J., FLOWER, R. 
J. & PERRETTI, M. 2013. Ligand-specific conformational change 
of the G-protein-coupled receptor ALX/FPR2 determines 
proresolving functional responses. Proc Natl Acad Sci U S A, 110, 
18232-7. 
CSERNOK, E., ERNST, M., SCHMITT, W., BAINTON, D. F. & 
GROSS, W. L. 1994. Activated neutrophils express proteinase 3 
on their plasma membrane in vitro and in vivo. Clin Exp Immunol, 
95, 244-50. 
D'ACQUISTO, F., MERGHANI, A., LECONA, E., ROSIGNOLI, G., 
RAZA, K., BUCKLEY, C. D., FLOWER, R. J. & PERRETTI, M. 
2007a. Annexin-1 modulates T-cell activation and differentiation. 
Blood, 109, 1095-102. 
D'ACQUISTO, F., PASCHALIDIS, N., RAZA, K., BUCKLEY, C. D., 
FLOWER, R. J. & PERRETTI, M. 2008. Glucocorticoid treatment 
inhibits annexin-1 expression in rheumatoid arthritis CD4+ T 
cells. Rheumatology (Oxford), 47, 636-9. 
D'ACQUISTO, F., PASCHALIDIS, N., SAMPAIO, A. L., 
MERGHANI, A., FLOWER, R. J. & PERRETTI, M. 2007b. 
Impaired T cell activation and increased Th2 lineage commitment 
in Annexin-1-deficient T cells. Eur J Immunol, 37, 3131-42. 
DALLI, J., CONSALVO, A. P., RAY, V., DI FILIPPO, C., D'AMICO, 
M., MEHTA, N. & PERRETTI, M. 2013. Proresolving and tissue-
protective actions of annexin A1-based cleavage-resistant peptides 
are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J 
Immunol, 190, 6478-87. 
DALLI, J., JONES, C. P., CAVALCANTI, D. M., FARSKY, S. H., 
PERRETTI, M. & RANKIN, S. M. 2012. Annexin A1 regulates 
neutrophil clearance by macrophages in the mouse bone marrow. 
FASEB J, 26, 387-96. 
DALLI, J., NORLING, L. V., RENSHAW, D., COOPER, D., LEUNG, 
K. Y. & PERRETTI, M. 2008. Annexin 1 mediates the rapid anti-
 171 
 
inflammatory effects of neutrophil-derived microparticles. Blood, 
112, 2512-9. 
DAMAZO, A. S., SAMPAIO, A. L., NAKATA, C. M., FLOWER, R. J., 
PERRETTI, M. & OLIANI, S. M. 2011. Endogenous annexin A1 
counter-regulates bleomycin-induced lung fibrosis. BMC 
Immunol, 12, 59. 
DAMAZO, A. S., YONA, S., D'ACQUISTO, F., FLOWER, R. J., 
OLIANI, S. M. & PERRETTI, M. 2005. Critical protective role 
for annexin 1 gene expression in the endotoxemic murine 
microcirculation. Am J Pathol, 166, 1607-17. 
DAMAZO, A. S., YONA, S., FLOWER, R. J., PERRETTI, M. & 
OLIANI, S. M. 2006. Spatial and temporal profiles for anti-
inflammatory gene expression in leukocytes during a resolving 
model of peritonitis. J Immunol, 176, 4410-8. 
DANIEL, L., FAKHOURI, F., JOLY, D., MOUTHON, L., NUSBAUM, 
P., GRUNFELD, J. P., SCHIFFERLI, J., GUILLEVIN, L., 
LESAVRE, P. & HALBWACHS-MECARELLI, L. 2006. 
Increase of circulating neutrophil and platelet microparticles 
during acute vasculitis and hemodialysis. Kidney Int, 69, 1416-23. 
DAS, A. M., LIM, L. H., FLOWER, R. J. & PERRETTI, M. 1997. 
Dexamethasone reduces cell surface levels of CD11b on human 
eosinophils. Mediators Inflamm, 6, 363-7. 
DE COUPADE, C., SOLITO, E. & LEVINE, J. D. 2003. 
Dexamethasone enhances interaction of endogenous annexin 1 
with L-selectin and triggers shedding of L-selectin in the 
monocytic cell line U-937. Br J Pharmacol, 140, 133-45. 
DEBRET, R., EL BTAOURI, H., DUCA, L., RAHMAN, I., RADKE, 
S., HAYE, B., SALLENAVE, J. M. & ANTONICELLI, F. 2003. 
Annexin A1 processing is associated with caspase-dependent 
apoptosis in BZR cells. FEBS Lett, 546, 195-202. 
DEGUCHI, Y., SHIBATA, N. & KISHIMOTO, S. 1990. Enhanced 
expression of the tumour necrosis factor/cachectin gene in 
peripheral blood mononuclear cells from patients with systemic 
vasculitis. Clin Exp Immunol, 81, 311-4. 
DREIER, R., SCHMID, K. W., GERKE, V. & RIEHEMANN, K. 1998. 
Differential expression of annexins I, II and IV in human tissues: 
an immunohistochemical study. Histochem Cell Biol, 110, 137-48. 
DUFTON, N., HANNON, R., BRANCALEONE, V., DALLI, J., 
PATEL, H. B., GRAY, M., D'ACQUISTO, F., BUCKINGHAM, 
J. C., PERRETTI, M. & FLOWER, R. J. 2010. Anti-inflammatory 
role of the murine formyl-peptide receptor 2: ligand-specific 
effects on leukocyte responses and experimental inflammation. J 
Immunol, 184, 2611-9. 
 172 
 
EHRCHEN, J., STEINMULLER, L., BARCZYK, K., TENBROCK, K., 
NACKEN, W., EISENACHER, M., NORDHUES, U., SORG, C., 
SUNDERKOTTER, C. & ROTH, J. 2007. Glucocorticoids induce 
differentiation of a specifically activated, anti-inflammatory 
subtype of human monocytes. Blood, 109, 1265-74. 
EL KEBIR, D., JOZSEF, L., KHREISS, T., PAN, W., PETASIS, N. A., 
SERHAN, C. N. & FILEP, J. G. 2007. Aspirin-triggered lipoxins 
override the apoptosis-delaying action of serum amyloid A in 
human neutrophils: a novel mechanism for resolution of 
inflammation. J Immunol, 179, 616-22. 
ENARSSON, K., LUNDIN, B. S., JOHNSSON, E., BREZICKA, T. & 
QUIDING-JARBRINK, M. 2007. CD4+ CD25high regulatory T 
cells reduce T cell transendothelial migration in cancer patients. 
Eur J Immunol, 37, 282-91. 
ERRASFA, M. & RUSSO-MARIE, F. 1989. A purified lipocortin shares 
the anti-inflammatory effect of glucocorticosteroids in vivo in 
mice. Br J Pharmacol, 97, 1051-8. 
EUZGER, H. S., FLOWER, R. J., GOULDING, N. J. & PERRETTI, M. 
1999. Differential modulation of annexin I binding sites on 
monocytes and neutrophils. Mediators Inflamm, 8, 53-62. 
FADOK, V. A., BRATTON, D. L., KONOWAL, A., FREED, P. W., 
WESTCOTT, J. Y. & HENSON, P. M. 1998. Macrophages that 
have ingested apoptotic cells in vitro inhibit proinflammatory 
cytokine production through autocrine/paracrine mechanisms 
involving TGF-beta, PGE2, and PAF. J Clin Invest, 101, 890-8. 
FADOK, V. A., VOELKER, D. R., CAMPBELL, P. A., COHEN, J. J., 
BRATTON, D. L. & HENSON, P. M. 1992. Exposure of 
phosphatidylserine on the surface of apoptotic lymphocytes 
triggers specific recognition and removal by macrophages. J 
Immunol, 148, 2207-16. 
FALK, R. J., TERRELL, R. S., CHARLES, L. A. & JENNETTE, J. C. 
1990. Anti-neutrophil cytoplasmic autoantibodies induce 
neutrophils to degranulate and produce oxygen radicals in vitro. 
Proc Natl Acad Sci U S A, 87, 4115-9. 
FAN, X., KRAHLING, S., SMITH, D., WILLIAMSON, P. & 
SCHLEGEL, R. A. 2004. Macrophage surface expression of 
annexins I and II in the phagocytosis of apoptotic lymphocytes. 
Mol Biol Cell, 15, 2863-72. 
FERRARO, A. J., DRAYSON, M. T., SAVAGE, C. O. & 
MACLENNAN, I. C. 2008. Levels of autoantibodies, unlike 
antibodies to all extrinsic antigen groups, fall following B cell 
depletion with Rituximab. Eur J Immunol, 38, 292-8. 
 173 
 
FINKIELMAN, J. D., LEE, A. S., HUMMEL, A. M., VISS, M. A., 
JACOB, G. L., HOMBURGER, H. A., PEIKERT, T., 
HOFFMAN, G. S., MERKEL, P. A., SPIERA, R., ST CLAIR, E. 
W., DAVIS, J. C., JR., MCCUNE, W. J., TIBBS, A. K., 
YTTERBERG, S. R., STONE, J. H., SPECKS, U. & GROUP, W. 
R. 2007. ANCA are detectable in nearly all patients with active 
severe Wegener's granulomatosis. Am J Med, 120, 643 e9-14. 
FLETCHER, J. M., LONERGAN, R., COSTELLOE, L., KINSELLA, 
K., MORAN, B., O'FARRELLY, C., TUBRIDY, N. & MILLS, K. 
H. 2009. CD39+Foxp3+ regulatory T Cells suppress pathogenic 
Th17 cells and are impaired in multiple sclerosis. J Immunol, 183, 
7602-10. 
FRANCIS, J. W., BALAZOVICH, K. J., SMOLEN, J. E., MARGOLIS, 
D. I. & BOXER, L. A. 1992. Human neutrophil annexin I 
promotes granule aggregation and modulates Ca(2+)-dependent 
membrane fusion. J Clin Invest, 90, 537-44. 
FREDMAN, G., KAMALY, N., SPOLITU, S., MILTON, J., 
GHORPADE, D., CHIASSON, R., KURIAKOSE, G., 
PERRETTI, M., FAROKHZAD, O. & TABAS, I. 2015. Targeted 
nanoparticles containing the proresolving peptide Ac2-26 protect 
against advanced atherosclerosis in hypercholesterolemic mice. 
Sci Transl Med, 7, 275ra20. 
FREE, M. E., BUNCH, D. O., MCGREGOR, J. A., JONES, B. E., 
BERG, E. A., HOGAN, S. L., HU, Y., PRESTON, G. A., 
JENNETTE, J. C., FALK, R. J. & SU, M. A. 2013. Patients with 
antineutrophil cytoplasmic antibody-associated vasculitis have 
defective Treg cell function exacerbated by the presence of a 
suppression-resistant effector cell population. Arthritis Rheum, 65, 
1922-33. 
FREELEY, S. J., COUGHLAN, A. M., POPAT, R. J., DUNN-
WALTERS, D. K. & ROBSON, M. G. 2013. Granulocyte colony 
stimulating factor exacerbates antineutrophil cytoplasmic antibody 
vasculitis. Ann Rheum Dis, 72, 1053-8. 
FREYSSINETT, J. M. 2005. ISTH Working Group on Vascular Biology 
2005. Meeting of The International Society on Thrombosis and 
Haemostasis: 51st Annual Scientific and Standardization 
Committee Meeting. Sydney, Australia. 
GABILLET, J., MILLET, A., PEDERZOLI-RIBEIL, M., TACNET-
DELORME, P., GUILLEVIN, L., MOUTHON, L., FRACHET, P. 
& WITKO-SARSAT, V. 2012. Proteinase 3, the autoantigen in 
granulomatosis with polyangiitis, associates with calreticulin on 
apoptotic neutrophils, impairs macrophage phagocytosis, and 
promotes inflammation. J Immunol, 189, 2574-83. 
 174 
 
GAN, P. Y., STEINMETZ, O. M., TAN, D. S., O'SULLIVAN, K. M., 
OOI, J. D., IWAKURA, Y., KITCHING, A. R. & 
HOLDSWORTH, S. R. 2010. Th17 cells promote autoimmune 
anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol, 21, 
925-31. 
GASSER, O. & SCHIFFERLI, J. A. 2004. Activated polymorphonuclear 
neutrophils disseminate anti-inflammatory microparticles by 
ectocytosis. Blood, 104, 2543-8. 
GASTARDELO, T. S., DAMAZO, A. S., DALLI, J., FLOWER, R. J., 
PERRETTI, M. & OLIANI, S. M. 2009. Functional and 
ultrastructural analysis of annexin A1 and its receptor in 
extravasating neutrophils during acute inflammation. Am J Pathol, 
174, 177-83. 
GATENBY, P. A., LUCAS, R. M., ENGELSEN, O., PONSONBY, A. 
L. & CLEMENTS, M. 2009. Antineutrophil cytoplasmic 
antibody-associated vasculitides: could geographic patterns be 
explained by ambient ultraviolet radiation? Arthritis Rheum, 61, 
1417-24. 
GAVINS, F. N., KAMAL, A. M., D'AMICO, M., OLIANI, S. M. & 
PERRETTI, M. 2005. Formyl-peptide receptor is not involved in 
the protection afforded by annexin 1 in murine acute myocardial 
infarct. FASEB J, 19, 100-2. 
GETTING, S. J., FLOWER, R. J. & PERRETTI, M. 1997. Inhibition of 
neutrophil and monocyte recruitment by endogenous and 
exogenous lipocortin 1. Br J Pharmacol, 120, 1075-82. 
GOLD, R., PEPINSKY, R. B., ZETTL, U. K., TOYKA, K. V. & 
HARTUNG, H. P. 1996. Lipocortin-1 (annexin-1) suppresses 
activation of autoimmune T cell lines in the Lewis rat. J 
Neuroimmunol, 69, 157-64. 
GOU, S. J., YUAN, J., CHEN, M., YU, F. & ZHAO, M. H. 2013. 
Circulating complement activation in patients with anti-neutrophil 
cytoplasmic antibody-associated vasculitis. Kidney Int, 83, 129-
37. 
GOULDING, N. J., EUZGER, H. S., BUTT, S. K. & PERRETTI, M. 
1998. Novel pathways for glucocorticoid effects on neutrophils in 
chronic inflammation. Inflamm Res, 47 Suppl 3, S158-65. 
GOULDING, N. J., GODOLPHIN, J. L., SHARLAND, P. R., PEERS, 
S. H., SAMPSON, M., MADDISON, P. J. & FLOWER, R. J. 
1990. Anti-inflammatory lipocortin 1 production by peripheral 
blood leucocytes in response to hydrocortisone. Lancet, 335, 
1416-8. 
GOULDING, N. J. & GUYRE, P. M. 1993. Lipocortin-1 Binding to 
Human-Leukocytes Correlates with Its Ability to Inhibit Igg 
 175 
 
Interactions with Fc-Gamma Receptors. Biochemical and 
Biophysical Research Communications, 192, 351-358. 
GOULDING, N. J., JEFFERISS, C. M., PAN, L., RIGBY, W. F. & 
GUYRE, P. M. 1992. Specific binding of lipocortin-1 (annexin I) 
to monocytes and neutrophils is decreased in rheumatoid arthritis. 
Arthritis Rheum, 35, 1395-7. 
GRATTENDICK, K., STUART, R., ROBERTS, E., LINCOLN, J., 
LEFKOWITZ, S. S., BOLLEN, A., MOGUILEVSKY, N., 
FRIEDMAN, H. & LEFKOWITZ, D. L. 2002. Alveolar 
macrophage activation by myeloperoxidase: a model for 
exacerbation of lung inflammation. Am J Respir Cell Mol Biol, 26, 
716-22. 
GRAYSON, P. C., CARMONA-RIVERA, C., XU, L., LIM, N., GAO, 
Z., ASARE, A. L., SPECKS, U., STONE, J. H., SEO, P., 
SPIERA, R. F., LANGFORD, C. A., HOFFMAN, G. S., 
KALLENBERG, C. G., ST CLAIR, E. W., TCHAO, N. K., 
YTTERBERG, S. R., PHIPPARD, D. J., MERKEL, P. A., 
KAPLAN, M. J., MONACH, P. A. & RITUXIMAB IN, A.-A. V.-
I. T. N. R. G. 2015. Neutrophil-Related Gene Expression and 
Low-Density Granulocytes Associated With Disease Activity and 
Response to Treatment in Antineutrophil Cytoplasmic Antibody-
Associated Vasculitis. Arthritis Rheumatol, 67, 1922-32. 
GRIFFITH, M. E., COULTHART, A. & PUSEY, C. D. 1996. T cell 
responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in 
patients with systemic vasculitis. Clin Exp Immunol, 103, 253-8. 
GRYGLEWSKI, R. J., PANCZENKO, B., KORBUT, R., 
GRODZINSKA, L. & OCETKIEWICZ, A. 1975. Corticosteroids 
inhibit prostaglandin release from perfused mesenteric blood 
vessels of rabbit and from perfused lungs of sensitized guinea pig. 
Prostaglandins, 10, 343-55. 
GUIDO, B. C., ZANATELLI, M., TAVARES-DE-LIMA, W., OLIANI, 
S. M. & DAMAZO, A. S. 2013. Annexin-A1 peptide down-
regulates the leukocyte recruitment and up-regulates interleukin-
10 release into lung after intestinal ischemia-reperfusion in mice. J 
Inflamm (Lond), 10, 10. 
HAFEZI-MOGHADAM, A. & LEY, K. 1999. Relevance of L-selectin 
shedding for leukocyte rolling in vivo. J Exp Med, 189, 939-48. 
HAKKIM, A., FURNROHR, B. G., AMANN, K., LAUBE, B., ABED, 
U. A., BRINKMANN, V., HERRMANN, M., VOLL, R. E. & 
ZYCHLINSKY, A. 2010. Impairment of neutrophil extracellular 
trap degradation is associated with lupus nephritis. Proc Natl Acad 
Sci U S A, 107, 9813-8. 
 176 
 
HALBWACHS-MECARELLI, L., BESSOU, G., LESAVRE, P., 
LOPEZ, S. & WITKO-SARSAT, V. 1995. Bimodal distribution 
of proteinase 3 (PR3) surface expression reflects a constitutive 
heterogeneity in the polymorphonuclear neutrophil pool. FEBS 
Lett, 374, 29-33. 
HANAYAMA, R., TANAKA, M., MIWA, K., SHINOHARA, A., 
IWAMATSU, A. & NAGATA, S. 2002. Identification of a factor 
that links apoptotic cells to phagocytes. Nature, 417, 182-7. 
HANNON, R., CROXTALL, J. D., GETTING, S. J., ROVIEZZO, F., 
YONA, S., PAUL-CLARK, M. J., GAVINS, F. N., PERRETTI, 
M., MORRIS, J. F., BUCKINGHAM, J. C. & FLOWER, R. J. 
2003. Aberrant inflammation and resistance to glucocorticoids in 
annexin 1-/- mouse. FASEB J, 17, 253-5. 
HARPER, L., REN, Y., SAVILL, J., ADU, D. & SAVAGE, C. O. 2000. 
Antineutrophil cytoplasmic antibodies induce reactive oxygen-
dependent dysregulation of primed neutrophil apoptosis and 
clearance by macrophages. Am J Pathol, 157, 211-20. 
HARTT, J. K., BARISH, G., MURPHY, P. M. & GAO, J. L. 1999. N-
formylpeptides induce two distinct concentration optima for 
mouse neutrophil chemotaxis by differential interaction with two 
N-formylpeptide receptor (FPR) subtypes. Molecular 
characterization of FPR2, a second mouse neutrophil FPR. J Exp 
Med, 190, 741-7. 
HASHIMOTO, A., MURAKAMI, Y., KITASATO, H., HAYASHI, I. & 
ENDO, H. 2007. Glucocorticoids co-interact with lipoxin A4 via 
lipoxin A4 receptor (ALX) up-regulation. Biomed Pharmacother, 
61, 81-5. 
HEADLAND, S. E., JONES, H. R., NORLING, L. V., KIM, A., 
SOUZA, P. R., CORSIERO, E., GIL, C. D., NERVIANI, A., 
DELL'ACCIO, F., PITZALIS, C., OLIANI, S. M., JAN, L. Y. & 
PERRETTI, M. 2015. Neutrophil-derived microvesicles enter 
cartilage and protect the joint in inflammatory arthritis. Sci Transl 
Med, 7, 315ra190. 
HICKEY, M. J., FORSTER, M., MITCHELL, D., KAUR, J., DE 
CAIGNY, C. & KUBES, P. 2000. L-selectin facilitates emigration 
and extravascular locomotion of leukocytes during acute 
inflammatory responses in vivo. J Immunol, 165, 7164-70. 
HONG, Y., ELEFTHERIOU, D., HUSSAIN, A. A., PRICE-KUEHNE, 
F. E., SAVAGE, C. O., JAYNE, D., LITTLE, M. A., SALAMA, 
A. D., KLEIN, N. J. & BROGAN, P. A. 2012. Anti-neutrophil 
cytoplasmic antibodies stimulate release of neutrophil 
microparticles. J Am Soc Nephrol, 23, 49-62. 
 177 
 
HOSHINO, A., NAGAO, T., ITO-IHARA, T., ISHIDA-OKAWARA, 
A., UNO, K., MUSO, E., NAGI-MIURA, N., OHNO, N., 
TOKUNAKA, K., NAOE, S., HASHIMOTO, H., YASUHARA, 
M., YAMAMOTO, K. & SUZUKI, K. 2007. Trafficking of QD-
conjugated MPO-ANCA in murine systemic vasculitis and 
glomerulonephritis model mice. Microbiol Immunol, 51, 551-66. 
HOSHINO, A., NAGAO, T., NAGI-MIURA, N., OHNO, N., 
YASUHARA, M., YAMAMOTO, K., NAKAYAMA, T. & 
SUZUKI, K. 2008. MPO-ANCA induces IL-17 production by 
activated neutrophils in vitro via classical complement pathway-
dependent manner. J Autoimmun, 31, 79-89. 
HRUSKOVA, Z., RIHOVA, Z., MARECKOVA, H., JANCOVA, E., 
RYSAVA, R., ZAVADA, J., MERTA, M., LOSTER, T. & 
TESAR, V. 2009. Intracellular cytokine production in ANCA-
associated vasculitis: low levels of interleukin-10 in remission are 
associated with a higher relapse rate in the long-term follow-up. 
Arch Med Res, 40, 276-84. 
HUANG, K. S., MCGRAY, P., MATTALIANO, R. J., BURNE, C., 
CHOW, E. P., SINCLAIR, L. K. & PEPINSKY, R. B. 1987. 
Purification and Characterization of Proteolytic Fragments of 
Lipocortin-I That Inhibit Phospholipase-A2. Journal of Biological 
Chemistry, 262, 7639-7645. 
HUANG, X. R., TIPPING, P. G., SHUO, L. & HOLDSWORTH, S. R. 
1997. Th1 responsiveness to nephritogenic antigens determines 
susceptibility to crescentic glomerulonephritis in mice. Kidney Int, 
51, 94-103. 
HUUGEN, D., XIAO, H., VAN ESCH, A., FALK, R. J., PEUTZ-
KOOTSTRA, C. J., BUURMAN, W. A., TERVAERT, J. W., 
JENNETTE, J. C. & HEERINGA, P. 2005. Aggravation of anti-
myeloperoxidase antibody-induced glomerulonephritis by 
bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. 
Am J Pathol, 167, 47-58. 
IWATA, Y., MATSUSHITA, T., HORIKAWA, M., DILILLO, D. J., 
YANABA, K., VENTURI, G. M., SZABOLCS, P. M., 
BERNSTEIN, S. H., MAGRO, C. M., WILLIAMS, A. D., HALL, 
R. P., ST CLAIR, E. W. & TEDDER, T. F. 2011. Characterization 
of a rare IL-10-competent B-cell subset in humans that parallels 
mouse regulatory B10 cells. Blood, 117, 530-41. 
JAGIELLO, P., ARIES, P., ARNING, L., WAGENLEITER, S. E., 
CSERNOK, E., HELLMICH, B., GROSS, W. L. & EPPLEN, J. 
T. 2005. The PTPN22 620W allele is a risk factor for Wegener's 
granulomatosis. Arthritis Rheum, 52, 4039-43. 
 178 
 
JANSEN, F., YANG, X., HOYER, F. F., PAUL, K., HEIERMANN, N., 
BECHER, M. U., ABU HUSSEIN, N., KEBSCHULL, M., 
BEDORF, J., FRANKLIN, B. S., LATZ, E., NICKENIG, G. & 
WERNER, N. 2012. Endothelial microparticle uptake in target 
cells is annexin I/phosphatidylserine receptor dependent and 
prevents apoptosis. Arterioscler Thromb Vasc Biol, 32, 1925-35. 
JENNETTE, J. C., FALK, R. J., BACON, P. A., BASU, N., CID, M. C., 
FERRARIO, F., FLORES-SUAREZ, L. F., GROSS, W. L., 
GUILLEVIN, L., HAGEN, E. C., HOFFMAN, G. S., JAYNE, D. 
R., KALLENBERG, C. G., LAMPRECHT, P., LANGFORD, C. 
A., LUQMANI, R. A., MAHR, A. D., MATTESON, E. L., 
MERKEL, P. A., OZEN, S., PUSEY, C. D., RASMUSSEN, N., 
REES, A. J., SCOTT, D. G., SPECKS, U., STONE, J. H., 
TAKAHASHI, K. & WATTS, R. A. 2013. 2012 revised 
International Chapel Hill Consensus Conference Nomenclature of 
Vasculitides. Arthritis Rheum, 65, 1-11. 
JOHN, C. D., CHRISTIAN, H. C., MORRIS, J. F., FLOWER, R. J., 
SOLITO, E. & BUCKINGHAM, J. C. 2003. Kinase-dependent 
regulation of the secretion of thyrotrophin and luteinizing 
hormone by glucocorticoids and annexin 1 peptides. J 
Neuroendocrinol, 15, 946-57. 
JONES, R. B., TERVAERT, J. W., HAUSER, T., LUQMANI, R., 
MORGAN, M. D., PEH, C. A., SAVAGE, C. O., SEGELMARK, 
M., TESAR, V., VAN PAASSEN, P., WALSH, D., WALSH, M., 
WESTMAN, K., JAYNE, D. R. & EUROPEAN VASCULITIS 
STUDY, G. 2010. Rituximab versus cyclophosphamide in ANCA-
associated renal vasculitis. N Engl J Med, 363, 211-20. 
JOVANOVIC, D. V., DI BATTISTA, J. A., MARTEL-PELLETIER, J., 
JOLICOEUR, F. C., HE, Y., ZHANG, M., MINEAU, F. & 
PELLETIER, J. P. 1998. IL-17 stimulates the production and 
expression of proinflammatory cytokines, IL-beta and TNF-alpha, 
by human macrophages. J Immunol, 160, 3513-21. 
JY, W., MAO, W. W., HORSTMAN, L., TAO, J. & AHN, Y. S. 1995. 
Platelet microparticles bind, activate and aggregate neutrophils in 
vitro. Blood Cells Mol Dis, 21, 217-31; discussion 231a. 
KAIN, R., EXNER, M., BRANDES, R., ZIEBERMAYR, R., 
CUNNINGHAM, D., ALDERSON, C. A., DAVIDOVITS, A., 
RAAB, I., JAHN, R., ASHOUR, O., SPITZAUER, S., SUNDER-
PLASSMANN, G., FUKUDA, M., KLEMM, P., REES, A. J. & 
KERJASCHKI, D. 2008. Molecular mimicry in pauci-immune 
focal necrotizing glomerulonephritis. Nat Med, 14, 1088-96. 
KAMAL, A. M., SMITH, S. F., DE SILVA WIJAYASINGHE, M., 
SOLITO, E. & CORRIGAN, C. J. 2001. An annexin 1 (ANXA1)-
 179 
 
derived peptide inhibits prototype antigen-driven human T cell 
Th1 and Th2 responses in vitro. Clin Exp Allergy, 31, 1116-25. 
KAMESH, L., HEWARD, J. M., WILLIAMS, J. M., GOUGH, S. C., 
CHAVELE, K. M., SALAMA, A., PUSEY, C., SAVAGE, C. O. 
& HARPER, L. 2009. CT60 and +49 polymorphisms of CTLA 4 
are associated with ANCA-positive small vessel vasculitis. 
Rheumatology (Oxford), 48, 1502-5. 
KANTARI, C., PEDERZOLI-RIBEIL, M., AMIR-MOAZAMI, O., 
GAUSSON-DOREY, V., MOURA, I. C., LECOMTE, M. C., 
BENHAMOU, M. & WITKO-SARSAT, V. 2007. Proteinase 3, 
the Wegener autoantigen, is externalized during neutrophil 
apoptosis: evidence for a functional association with phospholipid 
scramblase 1 and interference with macrophage phagocytosis. 
Blood, 110, 4086-95. 
KAO, W., GU, R., JIA, Y., WEI, X., FAN, H., HARRIS, J., ZHANG, 
Z., QUINN, J., MORAND, E. F. & YANG, Y. H. 2014. A formyl 
peptide receptor agonist suppresses inflammation and bone 
damage in arthritis. Br J Pharmacol. 
KESSENBROCK, K., KRUMBHOLZ, M., SCHONERMARCK, U., 
BACK, W., GROSS, W. L., WERB, Z., GRONE, H. J., 
BRINKMANN, V. & JENNE, D. E. 2009. Netting neutrophils in 
autoimmune small-vessel vasculitis. Nat Med, 15, 623-5. 
KETTRITZ, R., JENNETTE, J. C. & FALK, R. J. 1997. Crosslinking of 
ANCA-antigens stimulates superoxide release by human 
neutrophils. J Am Soc Nephrol, 8, 386-94. 
KHANDPUR, R., CARMONA-RIVERA, C., VIVEKANANDAN-
GIRI, A., GIZINSKI, A., YALAVARTHI, S., KNIGHT, J. S., 
FRIDAY, S., LI, S., PATEL, R. M., SUBRAMANIAN, V., 
THOMPSON, P., CHEN, P., FOX, D. A., PENNATHUR, S. & 
KAPLAN, M. J. 2013. NETs are a source of citrullinated 
autoantigens and stimulate inflammatory responses in rheumatoid 
arthritis. Sci Transl Med, 5, 178ra40. 
KIM, Y. S., KO, J., KIM, I. S., JANG, S. W., SUNG, H. J., LEE, H. J., 
LEE, S. Y., KIM, Y. & NA, D. S. 2003. PKCdelta-dependent 
cleavage and nuclear translocation of annexin A1 by phorbol 12-
myristate 13-acetate. Eur J Biochem, 270, 4089-94. 
KITCHING, A. R., HOLDSWORTH, S. R. & TIPPING, P. G. 1999a. 
IFN-gamma mediates crescent formation and cell-mediated 
immune injury in murine glomerulonephritis. J Am Soc Nephrol, 
10, 752-9. 
KITCHING, A. R., TIPPING, P. G. & HOLDSWORTH, S. R. 1999b. 
IL-12 directs severe renal injury, crescent formation and Th1 
responses in murine glomerulonephritis. Eur J Immunol, 29, 1-10. 
 180 
 
KITCHING, A. R., TIPPING, P. G., TIMOSHANKO, J. R. & 
HOLDSWORTH, S. R. 2000. Endogenous interleukin-10 
regulates Th1 responses that induce crescentic glomerulonephritis. 
Kidney Int, 57, 518-25. 
KNIGHT, A., SANDIN, S. & ASKLING, J. 2008. Risks and relative 
risks of Wegener's granulomatosis among close relatives of 
patients with the disease. Arthritis Rheum, 58, 302-7. 
KNIGHT, J. S., LUO, W., O'DELL, A. A., YALAVARTHI, S., ZHAO, 
W., SUBRAMANIAN, V., GUO, C., GRENN, R. C., 
THOMPSON, P. R., EITZMAN, D. T. & KAPLAN, M. J. 2014. 
Peptidylarginine deiminase inhibition reduces vascular damage 
and modulates innate immune responses in murine models of 
atherosclerosis. Circ Res, 114, 947-56. 
LAAN, M., CUI, Z. H., HOSHINO, H., LOTVALL, J., SJOSTRAND, 
M., GRUENERT, D. C., SKOOGH, B. E. & LINDEN, A. 1999. 
Neutrophil recruitment by human IL-17 via C-X-C chemokine 
release in the airways. J Immunol, 162, 2347-52. 
LANDE, R., GANGULY, D., FACCHINETTI, V., FRASCA, L., 
CONRAD, C., GREGORIO, J., MELLER, S., CHAMILOS, G., 
SEBASIGARI, R., RICCIERI, V., BASSETT, R., AMURO, H., 
FUKUHARA, S., ITO, T., LIU, Y. J. & GILLIET, M. 2011. 
Neutrophils activate plasmacytoid dendritic cells by releasing self-
DNA-peptide complexes in systemic lupus erythematosus. Sci 
Transl Med, 3, 73ra19. 
LANGFORD, C. A., MONACH, P. A., SPECKS, U., SEO, P., 
CUTHBERTSON, D., MCALEAR, C. A., YTTERBERG, S. R., 
HOFFMAN, G. S., KRISCHER, J. P., MERKEL, P. A. & 
VASCULITIS CLINICAL RESEARCH, C. 2014. An open-label 
trial of abatacept (CTLA4-IG) in non-severe relapsing 
granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis, 73, 
1376-9. 
LAURINO, S., CHAUDHRY, A., BOOTH, A., CONTE, G. & JAYNE, 
D. 2010. Prospective study of TNFalpha blockade with 
adalimumab in ANCA-associated systemic vasculitis with renal 
involvement. Nephrol Dial Transplant, 25, 3307-14. 
LE HIR, M., HAAS, C., MARINO, M. & RYFFEL, B. 1998. Prevention 
of crescentic glomerulonephritis induced by anti-glomerular 
membrane antibody in tumor necrosis factor-deficient mice. Lab 
Invest, 78, 1625-31. 
LE, Y., GONG, W., LI, B., DUNLOP, N. M., SHEN, W., SU, S. B., YE, 
R. D. & WANG, J. M. 1999. Utilization of two seven-
transmembrane, G protein-coupled receptors, formyl peptide 
receptor-like 1 and formyl peptide receptor, by the synthetic 
 181 
 
hexapeptide WKYMVm for human phagocyte activation. J 
Immunol, 163, 6777-84. 
LEONI, G., NEUMANN, P. A., KAMALY, N., QUIROS, M., NISHIO, 
H., JONES, H. R., SUMAGIN, R., HILGARTH, R. S., ALAM, 
A., FREDMAN, G., ARGYRIS, I., RIJCKEN, E., KUSTERS, D., 
REUTELINGSPERGER, C., PERRETTI, M., PARKOS, C. A., 
FAROKHZAD, O. C., NEISH, A. S. & NUSRAT, A. 2015. 
Annexin A1-containing extracellular vesicles and polymeric 
nanoparticles promote epithelial wound repair. J Clin Invest, 125, 
1215-27. 
LI, S., HOLDSWORTH, S. R. & TIPPING, P. G. 1997. Antibody 
independent crescentic glomerulonephritis in mu chain deficient 
mice. Kidney Int, 51, 672-8. 
LI, S., KURTS, C., KONTGEN, F., HOLDSWORTH, S. R. & 
TIPPING, P. G. 1998. Major histocompatibility complex class II 
expression by intrinsic renal cells is required for crescentic 
glomerulonephritis. J Exp Med, 188, 597-602. 
LIM, L. H., FLOWER, R. J., PERRETTI, M. & DAS, A. M. 2000. 
Glucocorticoid receptor activation reduces CD11b and CD49d 
levels on murine eosinophils: characterization and functional 
relevance. Am J Respir Cell Mol Biol, 22, 693-701. 
LIM, L. H., SOLITO, E., RUSSO-MARIE, F., FLOWER, R. J. & 
PERRETTI, M. 1998. Promoting detachment of neutrophils 
adherent to murine postcapillary venules to control inflammation: 
effect of lipocortin 1. Proc Natl Acad Sci U S A, 95, 14535-9. 
LITTLE, M. A., AL-ANI, B., REN, S., AL-NUAIMI, H., LEITE, M., 
JR., ALPERS, C. E., SAVAGE, C. O. & DUFFIELD, J. S. 2012. 
Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies 
recapitulate systemic vasculitis in mice with a humanized immune 
system. PLoS One, 7, e28626. 
LITTLE, M. A., NAZAR, L. & FARRINGTON, K. 2004. Outcome in 
glomerulonephritis due to systemic small vessel vasculitis: effect 
of functional status and non-vasculitic co-morbidity. Nephrol Dial 
Transplant, 19, 356-64. 
LITTLE, M. A., NIGHTINGALE, P., VERBURGH, C. A., HAUSER, 
T., DE GROOT, K., SAVAGE, C., JAYNE, D., HARPER, L. & 
EUROPEAN VASCULITIS STUDY, G. 2010. Early mortality in 
systemic vasculitis: relative contribution of adverse events and 
active vasculitis. Ann Rheum Dis, 69, 1036-43. 
LITTLE, M. A., SMYTH, C. L., YADAV, R., AMBROSE, L., COOK, 
H. T., NOURSHARGH, S. & PUSEY, C. D. 2005. Antineutrophil 
cytoplasm antibodies directed against myeloperoxidase augment 
leukocyte-microvascular interactions in vivo. Blood, 106, 2050-8. 
 182 
 
LITTLE, M. A., SMYTH, L., SALAMA, A. D., MUKHERJEE, S., 
SMITH, J., HASKARD, D., NOURSHARGH, S., COOK, H. T. & 
PUSEY, C. D. 2009. Experimental autoimmune vasculitis: an 
animal model of anti-neutrophil cytoplasmic autoantibody-
associated systemic vasculitis. Am J Pathol, 174, 1212-20. 
LIU, J. H., FENG, D., ZHANG, Y. F., SHANG, Y., WU, Y., LI, X. F. & 
PEI, L. 2015. Chloral Hydrate Preconditioning Protects Against 
Ischemic Stroke via Upregulating Annexin A1. CNS Neurosci 
Ther, 21, 718-26. 
LOCATELLI, I., SUTTI, S., JINDAL, A., VACCHIANO, M., 
BOZZOLA, C., REUTELINGSPERGER, C., KUSTERS, D., 
BENA, S., PAROLA, M., PATERNOSTRO, C., BUGIANESI, E., 
MCARTHUR, S., ALBANO, E. & PERRETTI, M. 2014. 
Endogenous annexin A1 is a novel protective determinant in 
nonalcoholic steatohepatitis in mice. Hepatology, 60, 531-44. 
LUDVIKSSON, B. R., SNELLER, M. C., CHUA, K. S., TALAR-
WILLIAMS, C., LANGFORD, C. A., EHRHARDT, R. O., 
FAUCI, A. S. & STROBER, W. 1998. Active Wegener's 
granulomatosis is associated with HLA-DR+ CD4+ T cells 
exhibiting an unbalanced Th1-type T cell cytokine pattern: 
reversal with IL-10. J Immunol, 160, 3602-9. 
LYONS, P. A., RAYNER, T. F., TRIVEDI, S., HOLLE, J. U., WATTS, 
R. A., JAYNE, D. R., BASLUND, B., BRENCHLEY, P., 
BRUCHFELD, A., CHAUDHRY, A. N., COHEN TERVAERT, 
J. W., DELOUKAS, P., FEIGHERY, C., GROSS, W. L., 
GUILLEVIN, L., GUNNARSSON, I., HARPER, L., 
HRUSKOVA, Z., LITTLE, M. A., MARTORANA, D., 
NEUMANN, T., OHLSSON, S., PADMANABHAN, S., PUSEY, 
C. D., SALAMA, A. D., SANDERS, J. S., SAVAGE, C. O., 
SEGELMARK, M., STEGEMAN, C. A., TESAR, V., VAGLIO, 
A., WIECZOREK, S., WILDE, B., ZWERINA, J., REES, A. J., 
CLAYTON, D. G. & SMITH, K. G. 2012. Genetically distinct 
subsets within ANCA-associated vasculitis. N Engl J Med, 367, 
214-23. 
MADERNA, P., YONA, S., PERRETTI, M. & GODSON, C. 2005. 
Modulation of phagocytosis of apoptotic neutrophils by 
supernatant from dexamethasone-treated macrophages and 
annexin-derived peptide Ac(2-26). J Immunol, 174, 3727-33. 
MAHR, A., GUILLEVIN, L., POISSONNET, M. & AYME, S. 2004. 
Prevalences of polyarteritis nodosa, microscopic polyangiitis, 
Wegener's granulomatosis, and Churg-Strauss syndrome in a 
French urban multiethnic population in 2000: a capture-recapture 
estimate. Arthritis Rheum, 51, 92-9. 
 183 
 
MAINE, C. J., HAMILTON-WILLIAMS, E. E., CHEUNG, J., 
STANFORD, S. M., BOTTINI, N., WICKER, L. S. & 
SHERMAN, L. A. 2012. PTPN22 alters the development of 
regulatory T cells in the thymus. J Immunol, 188, 5267-75. 
MANCUSO, F., FLOWER, R. J. & PERRETTI, M. 1995. Leukocyte 
transmigration, but not rolling or adhesion, is selectively inhibited 
by dexamethasone in the hamster post-capillary venule. 
Involvement of endogenous lipocortin 1. J Immunol, 155, 377-86. 
MARINAKI, S., KALSCH, A. I., GRIMMINGER, P., BREEDIJK, A., 
BIRCK, R., SCHMITT, W. H., WEISS, C., VAN DER WOUDE, 
F. J. & YARD, B. A. 2006. Persistent T-cell activation and 
clinical correlations in patients with ANCA-associated systemic 
vasculitis. Nephrol Dial Transplant, 21, 1825-32. 
MESRI, M. & ALTIERI, D. C. 1998. Endothelial cell activation by 
leukocyte microparticles. J Immunol, 161, 4382-7. 
MESRI, M. & ALTIERI, D. C. 1999. Leukocyte microparticles 
stimulate endothelial cell cytokine release and tissue factor 
induction in a JNK1 signaling pathway. J Biol Chem, 274, 23111-
8. 
MIGEOTTE, I., COMMUNI, D. & PARMENTIER, M. 2006. Formyl 
peptide receptors: a promiscuous subfamily of G protein-coupled 
receptors controlling immune responses. Cytokine Growth Factor 
Rev, 17, 501-19. 
MIGEOTTE, I., RIBOLDI, E., FRANSSEN, J. D., GREGOIRE, F., 
LOISON, C., WITTAMER, V., DETHEUX, M., ROBBERECHT, 
P., COSTAGLIOLA, S., VASSART, G., SOZZANI, S., 
PARMENTIER, M. & COMMUNI, D. 2005. Identification and 
characterization of an endogenous chemotactic ligand specific for 
FPRL2. J Exp Med, 201, 83-93. 
MILLET, A., MARTIN, K. R., BONNEFOY, F., SAAS, P., MOCEK, J., 
ALKAN, M., TERRIER, B., KERSTEIN, A., TAMASSIA, N., 
SATYANARAYANAN, S. K., ARIEL, A., RIBEIL, J. A., 
GUILLEVIN, L., CASSATELLA, M. A., MUELLER, A., 
THIEBLEMONT, N., LAMPRECHT, P., MOUTHON, L., 
PERRUCHE, S. & WITKO-SARSAT, V. 2015. Proteinase 3 on 
apoptotic cells disrupts immune silencing in autoimmune 
vasculitis. J Clin Invest, 125, 4107-21. 
MOFFATT, O. D., DEVITT, A., BELL, E. D., SIMMONS, D. L. & 
GREGORY, C. D. 1999. Macrophage recognition of ICAM-3 on 
apoptotic leukocytes. J Immunol, 162, 6800-10. 
MORAND, E. F., HUTCHINSON, P., HARGREAVES, A., 
GOULDING, N. J., BOYCE, N. W. & HOLDSWORTH, S. R. 
 184 
 
1995. Detection of intracellular lipocortin 1 in human leukocyte 
subsets. Clin Immunol Immunopathol, 76, 195-202. 
MOREL, O., TOTI, F., HUGEL, B., BAKOUBOULA, B., CAMOIN-
JAU, L., DIGNAT-GEORGE, F. & FREYSSINET, J. M. 2006. 
Procoagulant microparticles: disrupting the vascular homeostasis 
equation? Arterioscler Thromb Vasc Biol, 26, 2594-604. 
MORGAN, M. D., DAY, C. J., PIPER, K. P., KHAN, N., HARPER, L., 
MOSS, P. A. & SAVAGE, C. O. 2010. Patients with Wegener's 
granulomatosis demonstrate a relative deficiency and functional 
impairment of T-regulatory cells. Immunology, 130, 64-73. 
MORGAN, M. D., DRAYSON, M. T., SAVAGE, C. O. & HARPER, L. 
2011. Addition of infliximab to standard therapy for ANCA-
associated vasculitis. Nephron Clin Pract, 117, c89-97. 
MULDER, A. H., HEERINGA, P., BROUWER, E., LIMBURG, P. C. & 
KALLENBERG, C. G. 1994. Activation of granulocytes by anti-
neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-
dependent process. Clin Exp Immunol, 98, 270-8. 
MULLER KOBOLD, A. C., KALLENBERG, C. G. & TERVAERT, J. 
W. 1998. Leucocyte membrane expression of proteinase 3 
correlates with disease activity in patients with Wegener's 
granulomatosis. Br J Rheumatol, 37, 901-7. 
MYERS, C. L., WERTHEIMER, S. J., SCHEMBRI-KING, J., PARKS, 
T. & WALLACE, R. W. 1992. Induction of ICAM-1 by TNF-
alpha, IL-1 beta, and LPS in human endothelial cells after 
downregulation of PKC. Am J Physiol, 263, C767-72. 
NAGAI, H., TAKIZAWA, T., NISHIYORI, T. & KODA, A. 1982. 
Experimental glomerulonephritis in mice as a model for 
immunopharmacological studies. Jpn J Pharmacol, 32, 1117-24. 
NAKAZAWA, D., SHIDA, H., TOMARU, U., YOSHIDA, M., 
NISHIO, S., ATSUMI, T. & ISHIZU, A. 2014. Enhanced 
formation and disordered regulation of NETs in myeloperoxidase-
ANCA-associated microscopic polyangiitis. J Am Soc Nephrol, 
25, 990-7. 
NAKAZAWA, D., TOMARU, U., SUZUKI, A., MASUDA, S., 
HASEGAWA, R., KOBAYASHI, T., NISHIO, S., KASAHARA, 
M. & ISHIZU, A. 2012. Abnormal conformation and impaired 
degradation of propylthiouracil-induced neutrophil extracellular 
traps: implications of disordered neutrophil extracellular traps in a 
rat model of myeloperoxidase antineutrophil cytoplasmic 
antibody-associated vasculitis. Arthritis Rheum, 64, 3779-87. 
NG, F. S., WONG, K. Y., GUAN, S. P., MUSTAFA, F. B., KAJIJI, T. 
S., BIST, P., BISWAS, S. K., WONG, W. S. & LIM, L. H. 2011. 
Annexin-1-deficient mice exhibit spontaneous airway 
 185 
 
hyperresponsiveness and exacerbated allergen-specific antibody 
responses in a mouse model of asthma. Clin Exp Allergy, 41, 
1793-803. 
NOGUEIRA, E., HAMOUR, S., SAWANT, D., HENDERSON, S., 
MANSFIELD, N., CHAVELE, K. M., PUSEY, C. D. & 
SALAMA, A. D. 2010. Serum IL-17 and IL-23 levels and 
autoantigen-specific Th17 cells are elevated in patients with 
ANCA-associated vasculitis. Nephrol Dial Transplant, 25, 2209-
17. 
NOLAN, S. L., KALIA, N., NASH, G. B., KAMEL, D., HEERINGA, P. 
& SAVAGE, C. O. 2008. Mechanisms of ANCA-mediated 
leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol, 
19, 973-84. 
NORONHA, I. L., KRUGER, C., ANDRASSY, K., RITZ, E. & 
WALDHERR, R. 1993. In situ production of TNF-alpha, IL-1 
beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int, 
43, 682-92. 
O'BRIEN, E. C., ABDULAHAD, W. H., RUTGERS, A., HUITEMA, 
M. G., O'REILLY, V. P., COUGHLAN, A. M., HARRINGTON, 
M., HEERINGA, P., LITTLE, M. A. & HICKEY, F. B. 2015. 
Intermediate monocytes in ANCA vasculitis: increased surface 
expression of ANCA autoantigens and IL-1beta secretion in 
response to anti-MPO antibodies. Sci Rep, 5, 11888. 
O'SULLIVAN, K. M., LO, C. Y., SUMMERS, S. A., ELGASS, K. D., 
MCMILLAN, P. J., LONGANO, A., FORD, S. L., GAN, P. Y., 
KERR, P. G., KITCHING, A. R. & HOLDSWORTH, S. R. 2015. 
Renal participation of myeloperoxidase in antineutrophil 
cytoplasmic antibody (ANCA)-associated glomerulonephritis. 
Kidney Int, 88, 1030-46. 
ODOBASIC, D., GAN, P. Y., SUMMERS, S. A., SEMPLE, T. J., 
MULJADI, R. C., IWAKURA, Y., KITCHING, A. R. & 
HOLDSWORTH, S. R. 2011. Interleukin-17A promotes early but 
attenuates established disease in crescentic glomerulonephritis in 
mice. Am J Pathol, 179, 1188-98. 
OHLSSON, S. M., OHLSSON, S., SODERBERG, D., GUNNARSSON, 
L., PETTERSSON, A., SEGELMARK, M. & HELLMARK, T. 
2014. Neutrophils from vasculitis patients exhibit an increased 
propensity for activation by anti-neutrophil cytoplasmic 
antibodies. Clin Exp Immunol, 176, 363-72. 
OHLSSON, S. M., PETTERSSON, A., OHLSSON, S., SELGA, D., 
BENGTSSON, A. A., SEGELMARK, M. & HELLMARK, T. 
2012. Phagocytosis of apoptotic cells by macrophages in anti-
 186 
 
neutrophil cytoplasmic antibody-associated systemic vasculitis. 
Clin Exp Immunol, 170, 47-56. 
OHWATARI, R., FUKUDA, S., IWABUCHI, K., INUYAMA, Y., 
ONOE, K. & NISHIHIRA, J. 2001. Serum level of macrophage 
migration inhibitory factor as a useful parameter of clinical course 
in patients with Wegener's granulomatosis and relapsing 
polychondritis. Ann Otol Rhinol Laryngol, 110, 1035-40. 
OLIANI, S. M., PAUL-CLARK, M. J., CHRISTIAN, H. C., FLOWER, 
R. J. & PERRETTI, M. 2001. Neutrophil interaction with 
inflamed postcapillary venule endothelium alters annexin 1 
expression. Am J Pathol, 158, 603-15. 
OOI, J. D., CHANG, J., HICKEY, M. J., BORZA, D. B., FUGGER, L., 
HOLDSWORTH, S. R. & KITCHING, A. R. 2012. The 
immunodominant myeloperoxidase T-cell epitope induces local 
cell-mediated injury in antimyeloperoxidase glomerulonephritis. 
Proc Natl Acad Sci U S A, 109, E2615-24. 
PALMER, M. B., VICHOT, A. A., CANTLEY, L. G. & MOECKEL, G. 
W. 2014. Quantification and localization of M2 macrophages in 
human kidneys with acute tubular injury. Int J Nephrol Renovasc 
Dis, 7, 415-9. 
PASCHALIDIS, N., HUGGINS, A., ROWBOTHAM, N. J., 
FURMANSKI, A. L., CROMPTON, T., FLOWER, R. J., 
PERRETTI, M. & D'ACQUISTO, F. 2010. Role of endogenous 
annexin-A1 in the regulation of thymocyte positive and negative 
selection. Cell Cycle, 9, 784-93. 
PASCHALIDIS, N., IQBAL, A. J., MAIONE, F., WOOD, E. G., 
PERRETTI, M., FLOWER, R. J. & D'ACQUISTO, F. 2009. 
Modulation of experimental autoimmune encephalomyelitis by 
endogenous annexin A1. J Neuroinflammation, 6, 33. 
PATEL, H. B., KORNERUP, K. N., SAMPAIO, A. L., D'ACQUISTO, 
F., SEED, M. P., GIROL, A. P., GRAY, M., PITZALIS, C., 
OLIANI, S. M. & PERRETTI, M. 2012. The impact of 
endogenous annexin A1 on glucocorticoid control of 
inflammatory arthritis. Ann Rheum Dis, 71, 1872-80. 
PAUST, H. J., TURNER, J. E., STEINMETZ, O. M., PETERS, A., 
HEYMANN, F., HOLSCHER, C., WOLF, G., KURTS, C., 
MITTRUCKER, H. W., STAHL, R. A. & PANZER, U. 2009. The 
IL-23/Th17 axis contributes to renal injury in experimental 
glomerulonephritis. J Am Soc Nephrol, 20, 969-79. 
PEDERZOLI-RIBEIL, M., MAIONE, F., COOPER, D., AL-KASHI, A., 
DALLI, J., PERRETTI, M. & D'ACQUISTO, F. 2010. Design and 
characterization of a cleavage-resistant Annexin A1 mutant to 
 187 
 
control inflammation in the microvasculature. Blood, 116, 4288-
96. 
PENDERGRAFT, W. F., 3RD, HERLITZ, L. C., THORNLEY-
BROWN, D., ROSNER, M. & NILES, J. L. 2014. Nephrotoxic 
effects of common and emerging drugs of abuse. Clin J Am Soc 
Nephrol, 9, 1996-2005. 
PERRETTI, M. 1997. Endogenous mediators that inhibit the leukocyte-
endothelium interaction. Trends Pharmacol Sci, 18, 418-25. 
PERRETTI, M., AHLUWALIA, A., HARRIS, J. G., GOULDING, N. J. 
& FLOWER, R. J. 1993. Lipocortin-1 fragments inhibit neutrophil 
accumulation and neutrophil-dependent edema in the mouse. A 
qualitative comparison with an anti-CD11b monoclonal antibody. 
J Immunol, 151, 4306-14. 
PERRETTI, M., CHIANG, N., LA, M., FIERRO, I. M., MARULLO, S., 
GETTING, S. J., SOLITO, E. & SERHAN, C. N. 2002. 
Endogenous lipid- and peptide-derived anti-inflammatory 
pathways generated with glucocorticoid and aspirin treatment 
activate the lipoxin A4 receptor. Nat Med, 8, 1296-302. 
PERRETTI, M., CHRISTIAN, H., WHELLER, S. K., AIELLO, I., 
MUGRIDGE, K. G., MORRIS, J. F., FLOWER, R. J. & 
GOULDING, N. J. 2000. Annexin I is stored within gelatinase 
granules of human neutrophil and mobilized on the cell surface 
upon adhesion but not phagocytosis. Cell Biol Int, 24, 163-74. 
PERRETTI, M., CROXTALL, J. D., WHELLER, S. K., GOULDING, 
N. J., HANNON, R. & FLOWER, R. J. 1996. Mobilizing 
lipocortin 1 in adherent human leukocytes downregulates their 
transmigration. Nat Med, 2, 1259-62. 
PERRETTI, M. & D'ACQUISTO, F. 2009. Annexin A1 and 
glucocorticoids as effectors of the resolution of inflammation. Nat 
Rev Immunol, 9, 62-70. 
PERRETTI, M. & DALLI, J. 2009. Exploiting the Annexin A1 pathway 
for the development of novel anti-inflammatory therapeutics. Br J 
Pharmacol, 158, 936-46. 
PERRETTI, M. & FLOWER, R. J. 1993. Modulation of IL-1-induced 
neutrophil migration by dexamethasone and lipocortin 1. J 
Immunol, 150, 992-9. 
PERRETTI, M. & FLOWER, R. J. 1996. Measurement of lipocortin 1 
levels in murine peripheral blood leukocytes by flow cytometry: 
modulation by glucocorticoids and inflammation. Br J Pharmacol, 
118, 605-10. 
PERRETTI, M., GETTING, S. J., SOLITO, E., MURPHY, P. M. & 
GAO, J. L. 2001. Involvement of the receptor for formylated 
 188 
 
peptides in the in vivo anti-migratory actions of annexin 1 and its 
mimetics. Am J Pathol, 158, 1969-73. 
PERRETTI, M., LEROY, X., BLAND, E. J. & MONTERO-
MELENDEZ, T. 2015. Resolution Pharmacology: Opportunities 
for Therapeutic Innovation in Inflammation. Trends Pharmacol 
Sci, 36, 737-55. 
PERRETTI, M., WHELLER, S. K., FLOWER, R. J., WAHID, S. & 
PITZALIS, C. 1999. Modulation of cellular annexin I in human 
leukocytes infiltrating DTH skin reactions. J Leukoc Biol, 65, 583-
9. 
PIETRANI, N. T., FERREIRA, C. N., RODRIGUES, K. F., BOSCO, A. 
A., OLIVEIRA, M. C., TEIXEIRA, A. L., FERREIRA, A. V., 
SOUSA, L. P. & GOMES, K. B. 2014. Annexin A1 
concentrations is decreased in patients with diabetes type 2 and 
nephropathy. Clin Chim Acta, 436, 181-2. 
PLUSKOTA, E., WOODY, N. M., SZPAK, D., BALLANTYNE, C. M., 
SOLOVIEV, D. A., SIMON, D. I. & PLOW, E. F. 2008. 
Expression, activation, and function of integrin alphaMbeta2 
(Mac-1) on neutrophil-derived microparticles. Blood, 112, 2327-
35. 
PORGES, A. J., REDECHA, P. B., KIMBERLY, W. T., CSERNOK, E., 
GROSS, W. L. & KIMBERLY, R. P. 1994. Anti-neutrophil 
cytoplasmic antibodies engage and activate human neutrophils via 
Fc gamma RIIa. J Immunol, 153, 1271-80. 
RAJAKARIAR, R., LAWRENCE, T., BYSTROM, J., HILLIARD, M., 
COLVILLE-NASH, P., BELLINGAN, G., FITZGERALD, D., 
YAQOOB, M. M. & GILROY, D. W. 2008. Novel biphasic role 
for lymphocytes revealed during resolving inflammation. Blood, 
111, 4184-92. 
RALSTON, D. R., MARSH, C. B., LOWE, M. P. & WEWERS, M. D. 
1997. Antineutrophil cytoplasmic antibodies induce monocyte IL-
8 release. Role of surface proteinase-3, alpha1-antitrypsin, and 
Fcgamma receptors. J Clin Invest, 100, 1416-24. 
RAROK, A. A., STEGEMAN, C. A., LIMBURG, P. C. & 
KALLENBERG, C. G. 2002. Neutrophil membrane expression of 
proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated 
vasculitis. J Am Soc Nephrol, 13, 2232-8. 
RESCHER, U., GOEBELER, V., WILBERS, A. & GERKE, V. 2006. 
Proteolytic cleavage of annexin 1 by human leukocyte elastase. 
Biochimica Et Biophysica Acta-Molecular Cell Research, 1763, 
1320-1324. 
ROGER, T., CHANSON, A. L., KNAUP-REYMOND, M. & 
CALANDRA, T. 2005. Macrophage migration inhibitory factor 
 189 
 
promotes innate immune responses by suppressing glucocorticoid-
induced expression of mitogen-activated protein kinase 
phosphatase-1. Eur J Immunol, 35, 3405-13. 
ROMANI, L., MENCACCI, A., CENCI, E., SPACCAPELO, R., DEL 
SERO, G., NICOLETTI, I., TRINCHIERI, G., BISTONI, F. & 
PUCCETTI, P. 1997. Neutrophil production of IL-12 and IL-10 in 
candidiasis and efficacy of IL-12 therapy in neutropenic mice. J 
Immunol, 158, 5349-56. 
RONCO, P., VERROUST, P., MIGNON, F., KOURILSKY, O., 
VANHILLE, P., MEYRIER, A., MERY, J. P. & MOREL-
MAROGER, L. 1983. Immunopathological studies of polyarteritis 
nodosa and Wegener's granulomatosis: a report of 43 patients with 
51 renal biopsies. Q J Med, 52, 212-23. 
ROSALES, J. L. & ERNST, J. D. 1997. Calcium-dependent neutrophil 
secretion: characterization and regulation by annexins. J Immunol, 
159, 6195-202. 
ROSENGARTH, A. & LUECKE, H. 2003. A calcium-driven 
conformational switch of the N-terminal and core domains of 
annexin A1. J Mol Biol, 326, 1317-25. 
ROTH, A. J., OOI, J. D., HESS, J. J., VAN TIMMEREN, M. M., 
BERG, E. A., POULTON, C. E., MCGREGOR, J., BURKART, 
M., HOGAN, S. L., HU, Y., WINNIK, W., NACHMAN, P. H., 
STEGEMAN, C. A., NILES, J., HEERINGA, P., KITCHING, A. 
R., HOLDSWORTH, S., JENNETTE, J. C., PRESTON, G. A. & 
FALK, R. J. 2013. Epitope specificity determines pathogenicity 
and detectability in ANCA-associated vasculitis. J Clin Invest, 
123, 1773-83. 
RUTH, A. J., KITCHING, A. R., KWAN, R. Y., ODOBASIC, D., OOI, 
J. D., TIMOSHANKO, J. R., HICKEY, M. J. & HOLDSWORTH, 
S. R. 2006. Anti-neutrophil cytoplasmic antibodies and effector 
CD4+ cells play nonredundant roles in anti-myeloperoxidase 
crescentic glomerulonephritis. J Am Soc Nephrol, 17, 1940-9. 
RUTH, A. J., KITCHING, A. R., SEMPLE, T. J., TIPPING, P. G. & 
HOLDSWORTH, S. R. 2003. Intrinsic renal cell expression of 
CD40 directs Th1 effectors inducing experimental crescentic 
glomerulonephritis. J Am Soc Nephrol, 14, 2813-22. 
SAKAGUCHI, S. 2004. Naturally arising CD4+ regulatory t cells for 
immunologic self-tolerance and negative control of immune 
responses. Annu Rev Immunol, 22, 531-62. 
SAKAMOTO, T., REPASKY, W. T., UCHIDA, K., HIRATA, A. & 
HIRATA, F. 1996. Modulation of cell death pathways to apoptosis 
and necrosis of H2O2-treated rat thymocytes by lipocortin I. 
Biochem Biophys Res Commun, 220, 643-7. 
 190 
 
SALLAI, K., NAGY, E., DERFALVY, B., MUZES, G. & GERGELY, 
P. 2005. Antinucleosome antibodies and decreased 
deoxyribonuclease activity in sera of patients with systemic lupus 
erythematosus. Clin Diagn Lab Immunol, 12, 56-9. 
SANDERS, J. S., HUITMA, M. G., KALLENBERG, C. G. & 
STEGEMAN, C. A. 2006. Prediction of relapses in PR3-ANCA-
associated vasculitis by assessing responses of ANCA titres to 
treatment. Rheumatology (Oxford), 45, 724-9. 
SANGALETTI, S., TRIPODO, C., CHIODONI, C., GUARNOTTA, C., 
CAPPETTI, B., CASALINI, P., PICONESE, S., PARENZA, M., 
GUIDUCCI, C., VITALI, C. & COLOMBO, M. P. 2012. 
Neutrophil extracellular traps mediate transfer of cytoplasmic 
neutrophil antigens to myeloid dendritic cells toward ANCA 
induction and associated autoimmunity. Blood, 120, 3007-18. 
SAWMYNADEN, P. & PERRETTI, M. 2006. Glucocorticoid 
upregulation of the annexin-A1 receptor in leukocytes. Biochem 
Biophys Res Commun, 349, 1351-5. 
SCANNELL, M., FLANAGAN, M. B., DESTEFANI, A., WYNNE, K. 
J., CAGNEY, G., GODSON, C. & MADERNA, P. 2007. 
Annexin-1 and peptide derivatives are released by apoptotic cells 
and stimulate phagocytosis of apoptotic neutrophils by 
macrophages. J Immunol, 178, 4595-605. 
SCHLAEPFER, D. D. & HAIGLER, H. T. 1987. Characterization of 
Ca2+-dependent phospholipid binding and phosphorylation of 
lipocortin I. J Biol Chem, 262, 6931-7. 
SCHREIBER, A., BUSJAHN, A., LUFT, F. C. & KETTRITZ, R. 2003. 
Membrane expression of proteinase 3 is genetically determined. J 
Am Soc Nephrol, 14, 68-75. 
SCHREIBER, A., LUFT, F. C. & KETTRITZ, R. 2004. Membrane 
proteinase 3 expression and ANCA-induced neutrophil activation. 
Kidney Int, 65, 2172-83. 
SCHREIBER, A., PHAM, C. T., HU, Y., SCHNEIDER, W., LUFT, F. 
C. & KETTRITZ, R. 2012. Neutrophil serine proteases promote 
IL-1beta generation and injury in necrotizing crescentic 
glomerulonephritis. J Am Soc Nephrol, 23, 470-82. 
SCHREIBER, A., ROLLE, S., PERIPELITTCHENKO, L., 
RADEMANN, J., SCHNEIDER, W., LUFT, F. C. & KETTRITZ, 
R. 2010. Phosphoinositol 3-kinase-gamma mediates antineutrophil 
cytoplasmic autoantibody-induced glomerulonephritis. Kidney Int, 
77, 118-28. 
SCHREIBER, A., XIAO, H., FALK, R. J. & JENNETTE, J. C. 2006. 
Bone marrow-derived cells are sufficient and necessary targets to 
 191 
 
mediate glomerulonephritis and vasculitis induced by anti-
myeloperoxidase antibodies. J Am Soc Nephrol, 17, 3355-64. 
SCHREIBER, A., XIAO, H., JENNETTE, J. C., SCHNEIDER, W., 
LUFT, F. C. & KETTRITZ, R. 2009. C5a receptor mediates 
neutrophil activation and ANCA-induced glomerulonephritis. J 
Am Soc Nephrol, 20, 289-98. 
SERHAN, C. N. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins 
are the first lipid mediators of endogenous anti-inflammation and 
resolution. Prostaglandins Leukot Essent Fatty Acids, 73, 141-62. 
SHAHRARA, S., PICKENS, S. R., DORFLEUTNER, A. & POPE, R. 
M. 2009. IL-17 induces monocyte migration in rheumatoid 
arthritis. J Immunol, 182, 3884-91. 
SHAW, S. K., MA, S., KIM, M. B., RAO, R. M., HARTMAN, C. U., 
FROIO, R. M., YANG, L., JONES, T., LIU, Y., NUSRAT, A., 
PARKOS, C. A. & LUSCINSKAS, F. W. 2004. Coordinated 
redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 
accompany neutrophil transmigration. J Exp Med, 200, 1571-80. 
SMITH, S. F., TETLEY, T. D., GUZ, A. & FLOWER, R. J. 1990. 
Detection of Lipocortin 1 in Human Lung Lavage Fluid - 
Lipocortin Degradation as a Possible Proteolytic Mechanism in 
the Control of Inflammatory Mediators and Inflammation. 
Environmental Health Perspectives, 85, 135-144. 
SOLITO, E., DE COUPADE, C., CANAIDER, S., GOULDING, N. J. & 
PERRETTI, M. 2001. Transfection of annexin 1 in monocytic 
cells produces a high degree of spontaneous and stimulated 
apoptosis associated with caspase-3 activation. Br J Pharmacol, 
133, 217-28. 
SOLITO, E., KAMAL, A., RUSSO-MARIE, F., BUCKINGHAM, J. C., 
MARULLO, S. & PERRETTI, M. 2003a. A novel calcium-
dependent proapoptotic effect of annexin 1 on human neutrophils. 
FASEB J, 17, 1544-6. 
SOLITO, E., MULLA, A., MORRIS, J. F., CHRISTIAN, H. C., 
FLOWER, R. J. & BUCKINGHAM, J. C. 2003b. Dexamethasone 
induces rapid serine-phosphorylation and membrane translocation 
of annexin 1 in a human folliculostellate cell line via a novel 
nongenomic mechanism involving the glucocorticoid receptor, 
protein kinase C, phosphatidylinositol 3-kinase, and mitogen-
activated protein kinase. Endocrinology, 144, 1164-74. 
SOLITO, E., ROMERO, I. A., MARULLO, S., RUSSO-MARIE, F. & 
WEKSLER, B. B. 2000. Annexin 1 binds to U937 monocytic cells 
and inhibits their adhesion to microvascular endothelium: 
involvement of the alpha 4 beta 1 integrin. J Immunol, 165, 1573-
81. 
 192 
 
SPECKS, U., MERKEL, P. A., SEO, P., SPIERA, R., LANGFORD, C. 
A., HOFFMAN, G. S., KALLENBERG, C. G., ST CLAIR, E. W., 
FESSLER, B. J., DING, L., VIVIANO, L., TCHAO, N. K., 
PHIPPARD, D. J., ASARE, A. L., LIM, N., IKLE, D., JEPSON, 
B., BRUNETTA, P., ALLEN, N. B., FERVENZA, F. C., 
GEETHA, D., KEOGH, K., KISSIN, E. Y., MONACH, P. A., 
PEIKERT, T., STEGEMAN, C., YTTERBERG, S. R., 
MUELLER, M., SEJISMUNDO, L. P., MIERAS, K., STONE, J. 
H. & GROUP, R.-I. R. 2013. Efficacy of remission-induction 
regimens for ANCA-associated vasculitis. N Engl J Med, 369, 
417-27. 
SPURR, L., NADKARNI, S., PEDERZOLI-RIBEIL, M., GOULDING, 
N. J., PERRETTI, M. & D'ACQUISTO, F. 2011. Comparative 
analysis of Annexin A1-formyl peptide receptor 2/ALX 
expression in human leukocyte subsets. Int Immunopharmacol, 11, 
55-66. 
SRIKRISHNA, G., PANNEERSELVAM, K., WESTPHAL, V., 
ABRAHAM, V., VARKI, A. & FREEZE, H. H. 2001a. Two 
proteins modulating transendothelial migration of leukocytes 
recognize novel carboxylated glycans on endothelial cells. J 
Immunol, 166, 4678-88. 
SRIKRISHNA, G., TOOMRE, D. K., MANZI, A., 
PANNEERSELVAM, K., FREEZE, H. H., VARKI, A. & 
VARKI, N. M. 2001b. A novel anionic modification of N-glycans 
on mammalian endothelial cells is recognized by activated 
neutrophils and modulates acute inflammatory responses. J 
Immunol, 166, 624-32. 
STABLES, M. J., SHAH, S., CAMON, E. B., LOVERING, R. C., 
NEWSON, J., BYSTROM, J., FARROW, S. & GILROY, D. W. 
2011. Transcriptomic analyses of murine resolution-phase 
macrophages. Blood, 118, e192-208. 
STASSEN, P. M., DERKS, R. P., KALLENBERG, C. G. & 
STEGEMAN, C. A. 2008. Venous thromboembolism in ANCA-
associated vasculitis--incidence and risk factors. Rheumatology 
(Oxford), 47, 530-4. 
STEGEMAN, C. A., TERVAERT, J. W. & KALLENBERG, C. G. 
1994. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis 
and follow-up in systemic vasculitis. Ann Med Interne (Paris), 
145, 523-32. 
STONE, J. H., MERKEL, P. A., SPIERA, R., SEO, P., LANGFORD, C. 
A., HOFFMAN, G. S., KALLENBERG, C. G., ST CLAIR, E. W., 
TURKIEWICZ, A., TCHAO, N. K., WEBBER, L., DING, L., 
SEJISMUNDO, L. P., MIERAS, K., WEITZENKAMP, D., IKLE, 
 193 
 
D., SEYFERT-MARGOLIS, V., MUELLER, M., BRUNETTA, 
P., ALLEN, N. B., FERVENZA, F. C., GEETHA, D., KEOGH, 
K. A., KISSIN, E. Y., MONACH, P. A., PEIKERT, T., 
STEGEMAN, C., YTTERBERG, S. R., SPECKS, U. & GROUP, 
R.-I. R. 2010. Rituximab versus cyclophosphamide for ANCA-
associated vasculitis. N Engl J Med, 363, 221-32. 
STRAUSBAUGH, H. J. & ROSEN, S. D. 2001. A potential role for 
annexin 1 as a physiologic mediator of glucocorticoid-induced L-
selectin shedding from myeloid cells. J Immunol, 166, 6294-300. 
SUMIDA, K., UBARA, Y., SUWABE, T., HAYAMI, N., 
HIRAMATSU, R., HASEGAWA, E., YAMANOUCHI, M., 
HOSHINO, J., SAWA, N., TAKEMOTO, F., TAKAICHI, K. & 
OHASHI, K. 2011. Complete remission of myeloperoxidase-anti-
neutrophil cytoplasmic antibody-associated crescentic 
glomerulonephritis complicated with rheumatoid arthritis using a 
humanized anti-interleukin 6 receptor antibody. Rheumatology, 
50, 1928-1930. 
SUMMERS, S. A., PHOON, R. K., OOI, J. D., HOLDSWORTH, S. R. 
& KITCHING, A. R. 2011. The IL-27 receptor has biphasic 
effects in crescentic glomerulonephritis mediated through Th1 
responses. Am J Pathol, 178, 580-90. 
SUN, Y., WANG, Y., LI, J. H., ZHU, S. H., TANG, H. T. & XIA, Z. F. 
2013. Macrophage migration inhibitory factor counter-regulates 
dexamethasone-induced annexin 1 expression and influences the 
release of eicosanoids in murine macrophages. Immunology, 140, 
250-8. 
SUZUKI, Y., SHIRATO, I., OKUMURA, K., RAVETCH, J. V., 
TAKAI, T., TOMINO, Y. & RA, C. 1998. Distinct contribution of 
Fc receptors and angiotensin II-dependent pathways in anti-GBM 
glomerulonephritis. Kidney Int, 54, 1166-74. 
TAEKEMA-ROELVINK, M. E., VAN KOOTEN, C., HEEMSKERK, 
E., SCHROEIJERS, W. & DAHA, M. R. 2000. Proteinase 3 
interacts with a 111-kD membrane molecule of human umbilical 
vein endothelial cells. J Am Soc Nephrol, 11, 640-8. 
TAN, D. S., GAN, P. Y., O'SULLIVAN, K. M., HAMMETT, M. V., 
SUMMERS, S. A., OOI, J. D., LUNDGREN, B. A., BOYD, R. 
L., SCOTT, H. S., KITCHING, A. R., CHIDGEY, A. P. & 
HOLDSWORTH, S. R. 2013. Thymic deletion and regulatory T 
cells prevent antimyeloperoxidase GN. J Am Soc Nephrol, 24, 
573-85. 
TANNA, A., SALAMA, A. D., BROOKES, P. & PUSEY, C. D. 2012. 
Familial granulomatosis with polyangiitis: three cases of this rare 
 194 
 
disorder in one Indoasian family carrying an identical HLA DPB1 
allele. BMJ Case Rep, 2012. 
TANRIVER, Y., MARTIN-FONTECHA, A., RATNASOTHY, K., 
LOMBARDI, G. & LECHLER, R. 2009. Superantigen-activated 
regulatory T cells inhibit the migration of innate immune cells and 
the differentiation of naive T cells. J Immunol, 183, 2946-56. 
TARZI, R. M., DAVIES, K. A., CLAASSENS, J. W., VERBEEK, J. S., 
WALPORT, M. J. & COOK, H. T. 2003. Both Fcgamma receptor 
I and Fcgamma receptor III mediate disease in accelerated 
nephrotoxic nephritis. Am J Pathol, 162, 1677-83. 
TARZI, R. M., DAVIES, K. A., ROBSON, M. G., FOSSATI-JIMACK, 
L., SAITO, T., WALPORT, M. J. & COOK, H. T. 2002. 
Nephrotoxic nephritis is mediated by Fcgamma receptors on 
circulating leukocytes and not intrinsic renal cells. Kidney Int, 62, 
2087-96. 
TIMOSHANKO, J. R., HOLDSWORTH, S. R., KITCHING, A. R. & 
TIPPING, P. G. 2002. IFN-gamma production by intrinsic renal 
cells and bone marrow-derived cells is required for full expression 
of crescentic glomerulonephritis in mice. J Immunol, 168, 4135-
41. 
TIMOSHANKO, J. R., KITCHING, A. R., HOLDSWORTH, S. R. & 
TIPPING, P. G. 2001. Interleukin-12 from intrinsic cells is an 
effector of renal injury in crescentic glomerulonephritis. J Am Soc 
Nephrol, 12, 464-71. 
TIPPING, P. G., HUANG, X. R., QI, M., VAN, G. Y. & TANG, W. W. 
1998. Crescentic glomerulonephritis in CD4- and CD8-deficient 
mice. Requirement for CD4 but not CD8 cells. Am J Pathol, 152, 
1541-8. 
TIPPING, P. G., KITCHING, A. R., HUANG, X. R., MUTCH, D. A. & 
HOLDSWORTH, S. R. 1997. Immune modulation with 
interleukin-4 and interleukin-10 prevents crescent formation and 
glomerular injury in experimental glomerulonephritis. Eur J 
Immunol, 27, 530-7. 
TODD, S. K., PEPPER, R. J., DRAIBE, J., TANNA, A., PUSEY, C. D., 
MAURI, C. & SALAMA, A. D. 2014. Regulatory B cells are 
numerically but not functionally deficient in anti-neutrophil 
cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 
TSAO, F. H., MEYER, K. C., CHEN, X., ROSENTHAL, N. S. & HU, J. 
1998. Degradation of annexin I in bronchoalveolar lavage fluid 
from patients with cystic fibrosis. Am J Respir Cell Mol Biol, 18, 
120-8. 
TURNER, J. E., KREBS, C., TITTEL, A. P., PAUST, H. J., MEYER-
SCHWESINGER, C., BENNSTEIN, S. B., STEINMETZ, O. M., 
 195 
 
PRINZ, I., MAGNUS, T., KORN, T., STAHL, R. A., KURTS, C. 
& PANZER, U. 2012. IL-17A production by renal gammadelta T 
cells promotes kidney injury in crescentic GN. J Am Soc Nephrol, 
23, 1486-95. 
VAGO, J. P., NOGUEIRA, C. R., TAVARES, L. P., SORIANI, F. M., 
LOPES, F., RUSSO, R. C., PINHO, V., TEIXEIRA, M. M. & 
SOUSA, L. P. 2012. Annexin A1 modulates natural and 
glucocorticoid-induced resolution of inflammation by enhancing 
neutrophil apoptosis. J Leukoc Biol, 92, 249-58. 
VAN DER VEEN, B. S., CHEN, M., MULLER, R., VAN TIMMEREN, 
M. M., PETERSEN, A. H., LEE, P. A., SATCHELL, S. C., 
MATHIESON, P. W., SALEEM, M. A., STEGEMAN, C. A., 
ZWERINA, J., MOLEMA, G. & HEERINGA, P. 2011. Effects of 
p38 mitogen-activated protein kinase inhibition on anti-neutrophil 
cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann 
Rheum Dis, 70, 356-65. 
VAN DER WOUDE, F. J., RASMUSSEN, N., LOBATTO, S., WIIK, 
A., PERMIN, H., VAN ES, L. A., VAN DER GIESSEN, M., 
VAN DER HEM, G. K. & THE, T. H. 1985. Autoantibodies 
against neutrophils and monocytes: tool for diagnosis and marker 
of disease activity in Wegener's granulomatosis. Lancet, 1, 425-9. 
VARGUNAM, M., ADU, D., TAYLOR, C. M., MICHAEL, J., 
RICHARDS, N., NEUBERGER, J. & THOMPSON, R. A. 1992. 
Endothelium myeloperoxidase-antimyeloperoxidase interaction in 
vasculitis. Nephrol Dial Transplant, 7, 1077-81. 
VERGNOLLE, N., COMERA, C. & BUENO, L. 1995. Annexin-1 Is 
Overexpressed and Specifically Secreted during Experimentally-
Induced Colitis in Rats. European Journal of Biochemistry, 232, 
603-610. 
VERGNOLLE, N., COMERA, C., MORE, J., ALVINERIE, M. & 
BUENO, L. 1997. Expression and secretion of lipocortin 1 in gut 
inflammation are not regulated by pituitary-adrenal axis. Am J 
Physiol, 273, R623-9. 
VOLL, R. E., HERRMANN, M., ROTH, E. A., STACH, C., KALDEN, 
J. R. & GIRKONTAITE, I. 1997. Immunosuppressive effects of 
apoptotic cells. Nature, 390, 350-1. 
VONG, L., D'ACQUISTO, F., PEDERZOLI-RIBEIL, M., LAVAGNO, 
L., FLOWER, R. J., WITKO-SARSAT, V. & PERRETTI, M. 
2007. Annexin 1 cleavage in activated neutrophils: a pivotal role 
for proteinase 3. J Biol Chem, 282, 29998-30004. 
VOSWINKEL, J., ASSMANN, G., HELD, G., PITANN, S., GROSS, 
W. L., HOLL-ULRICH, K., HERLYN, K. & MUELLER, A. 
2008. Single cell analysis of B lymphocytes from Wegener's 
 196 
 
granulomatosis: B cell receptors display affinity maturation within 
the granulomatous lesions. Clin Exp Immunol, 154, 339-45. 
WAECHTER, V., SCHMID, M., HEROVA, M., WEBER, A., 
GUNTHER, V., MARTI-JAUN, J., WUST, S., ROSINGER, M., 
GEMPERLE, C. & HERSBERGER, M. 2012. Characterization of 
the promoter and the transcriptional regulation of the lipoxin A4 
receptor (FPR2/ALX) gene in human monocytes and 
macrophages. J Immunol, 188, 1856-67. 
WALLNER, B. P., MATTALIANO, R. J., HESSION, C., CATE, R. L., 
TIZARD, R., SINCLAIR, L. K., FOELLER, C., CHOW, E. P., 
BROWNING, J. L., RAMACHANDRAN, K. L. & PEPINSKY, 
R. B. 1986. Cloning and Expression of Human Lipocortin, a 
Phospholipase-A2 Inhibitor with Potential Antiinflammatory 
Activity. Nature, 320, 77-81. 
WATTS, R. A., MAHR, A., MOHAMMAD, A. J., GATENBY, P., 
BASU, N. & FLORES-SUAREZ, L. F. 2015. Classification, 
epidemiology and clinical subgrouping of antineutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial 
Transplant, 30 Suppl 1, i14-22. 
WEIDNER, S., CARL, M., RIESS, R. & RUPPRECHT, H. D. 2004. 
Histologic analysis of renal leukocyte infiltration in antineutrophil 
cytoplasmic antibody-associated vasculitis: importance of 
monocyte and neutrophil infiltration in tissue damage. Arthritis 
Rheum, 50, 3651-7. 
WEIDNER, S., NEUPERT, W., GOPPELT-STRUEBE, M. & 
RUPPRECHT, H. D. 2001. Antineutrophil cytoplasmic antibodies 
induce human monocytes to produce oxygen radicals in vitro. 
Arthritis Rheum, 44, 1698-706. 
WEYD, H., ABELER-DORNER, L., LINKE, B., MAHR, A., 
JAHNDEL, V., PFRANG, S., SCHNOLZER, M., FALK, C. S. & 
KRAMMER, P. H. 2013. Annexin A1 on the surface of early 
apoptotic cells suppresses CD8+ T cell immunity. PLoS One, 8, 
e62449. 
WILDE, B., THEWISSEN, M., DAMOISEAUX, J., KNIPPENBERG, 
S., HILHORST, M., VAN PAASSEN, P., WITZKE, O. & 
COHEN TERVAERT, J. W. 2013. Regulatory B cells in ANCA-
associated vasculitis. Ann Rheum Dis, 72, 1416-9. 
WILLIAMS, S. L., MILNE, I. R., BAGLEY, C. J., GAMBLE, J. R., 
VADAS, M. A., PITSON, S. M. & KHEW-GOODALL, Y. 2010. 
A proinflammatory role for proteolytically cleaved annexin A1 in 
neutrophil transendothelial migration. J Immunol, 185, 3057-63. 
WITKO-SARSAT, V., LESAVRE, P., LOPEZ, S., BESSOU, G., 
HIEBLOT, C., PRUM, B., NOEL, L. H., GUILLEVIN, L., 
 197 
 
RAVAUD, P., SERMET-GAUDELUS, I., TIMSIT, J., 
GRUNFELD, J. P. & HALBWACHS-MECARELLI, L. 1999. A 
large subset of neutrophils expressing membrane proteinase 3 is a 
risk factor for vasculitis and rheumatoid arthritis. J Am Soc 
Nephrol, 10, 1224-33. 
XIAO, H., DAIRAGHI, D. J., POWERS, J. P., ERTL, L. S., 
BAUMGART, T., WANG, Y., SEITZ, L. C., PENFOLD, M. E., 
GAN, L., HU, P., LU, B., GERARD, N. P., GERARD, C., 
SCHALL, T. J., JAEN, J. C., FALK, R. J. & JENNETTE, J. C. 
2014. C5a receptor (CD88) blockade protects against MPO-
ANCA GN. J Am Soc Nephrol, 25, 225-31. 
XIAO, H., HEERINGA, P., HU, P., LIU, Z., ZHAO, M., ARATANI, Y., 
MAEDA, N., FALK, R. J. & JENNETTE, J. C. 2002. 
Antineutrophil cytoplasmic autoantibodies specific for 
myeloperoxidase cause glomerulonephritis and vasculitis in mice. 
J Clin Invest, 110, 955-63. 
XIAO, H., HEERINGA, P., LIU, Z., HUUGEN, D., HU, P., MAEDA, 
N., FALK, R. J. & JENNETTE, J. C. 2005. The role of 
neutrophils in the induction of glomerulonephritis by anti-
myeloperoxidase antibodies. Am J Pathol, 167, 39-45. 
XIAO, H., SCHREIBER, A., HEERINGA, P., FALK, R. J. & 
JENNETTE, J. C. 2007. Alternative complement pathway in the 
pathogenesis of disease mediated by anti-neutrophil cytoplasmic 
autoantibodies. Am J Pathol, 170, 52-64. 
XIE, G., ROSHANDEL, D., SHERVA, R., MONACH, P. A., LU, E. Y., 
KUNG, T., CARRINGTON, K., ZHANG, S. S., PULIT, S. L., 
RIPKE, S., CARETTE, S., DELLARIPA, P. F., EDBERG, J. C., 
HOFFMAN, G. S., KHALIDI, N., LANGFORD, C. A., MAHR, 
A. D., ST CLAIR, E. W., SEO, P., SPECKS, U., SPIERA, R. F., 
STONE, J. H., YTTERBERG, S. R., RAYCHAUDHURI, S., DE 
BAKKER, P. I., FARRER, L. A., AMOS, C. I., MERKEL, P. A. 
& SIMINOVITCH, K. A. 2013. Association of granulomatosis 
with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A 
gene variants: evidence from genome-wide analysis. Arthritis 
Rheum, 65, 2457-68. 
XING, G. Q., CHEN, M., LIU, G., ZHENG, X., E, J. & ZHAO, M. H. 
2010. Differential deposition of C4d and MBL in glomeruli of 
patients with ANCA-negative pauci-immune crescentic 
glomerulonephritis. J Clin Immunol, 30, 144-56. 
YANG, D., CHEN, Q., GERTZ, B., HE, R., PHULSUKSOMBATI, M., 
YE, R. D. & OPPENHEIM, J. J. 2002. Human dendritic cells 
express functional formyl peptide receptor-like-2 (FPRL2) 
throughout maturation. J Leukoc Biol, 72, 598-607. 
 198 
 
YANG, J. J., KETTRITZ, R., FALK, R. J., JENNETTE, J. C. & 
GAIDO, M. L. 1996. Apoptosis of endothelial cells induced by the 
neutrophil serine proteases proteinase 3 and elastase. Am J Pathol, 
149, 1617-26. 
YANG, Y., LEECH, M., HUTCHINSON, P., HOLDSWORTH, S. R. & 
MORAND, E. F. 1997. Antiinflammatory effect of lipocortin 1 in 
experimental arthritis. Inflammation, 21, 583-96. 
YANG, Y. H., MORAND, E. F., GETTING, S. J., PAUL-CLARK, M., 
LIU, D. L., YONA, S., HANNON, R., BUCKINGHAM, J. C., 
PERRETTI, M. & FLOWER, R. J. 2004. Modulation of 
inflammation and response to dexamethasone by Annexin 1 in 
antigen-induced arthritis. Arthritis Rheum, 50, 976-84. 
YANG, Y. H., SONG, W., DEANE, J. A., KAO, W., OOI, J. D., NGO, 
D., KITCHING, A. R., MORAND, E. F. & HICKEY, M. J. 2013. 
Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-
dependent inflammation. J Immunol, 190, 997-1007. 
YANG, Y. H., TOH, M. L., CLYNE, C. D., LEECH, M., AEBERLI, D., 
XUE, J., DACUMOS, A., SHARMA, L. & MORAND, E. F. 
2006. Annexin 1 negatively regulates IL-6 expression via effects 
on p38 MAPK and MAPK phosphatase-1. J Immunol, 177, 8148-
53. 
YASHIRO, M., MUSO, E., ITOH-IHARA, T., OYAMA, A., 
HASHIMOTO, K., KAWAMURA, T., ONO, T. & SASAYAMA, 
S. 2000. Significantly high regional morbidity of MPO-ANCA-
related angitis and/or nephritis with respiratory tract involvement 
after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis, 
35, 889-95. 
YAZID, S., GARDNER, P. J., CARVALHO, L., CHU, C. J., FLOWER, 
R. J., SOLITO, E., LEE, R. W., ALI, R. R. & DICK, A. D. 2015. 
Annexin-A1 restricts Th17 cells and attenuates the severity of 
autoimmune disease. J Autoimmun, 58, 1-11. 
YE, R. D., BOULAY, F., WANG, J. M., DAHLGREN, C., GERARD, 
C., PARMENTIER, M., SERHAN, C. N. & MURPHY, P. M. 
2009. International Union of Basic and Clinical Pharmacology. 
LXXIII. Nomenclature for the formyl peptide receptor (FPR) 
family. Pharmacol Rev, 61, 119-61. 
YONA, S., BUCKINGHAM, J. C., PERRETTI, M. & FLOWER, R. J. 
2004. Stimulus-specific defect in the phagocytic pathways of 
annexin 1 null macrophages. Br J Pharmacol, 142, 890-8. 
YONA, S., HEINSBROEK, S. E., PEISER, L., GORDON, S., 
PERRETTI, M. & FLOWER, R. J. 2006. Impaired phagocytic 
mechanism in annexin 1 null macrophages. Br J Pharmacol, 148, 
469-77. 
 199 
 
YOSHIDA, M., IWAHORI, T., NAKABAYASHI, I., AKASHI, M., 
WATANABE, T. & YOSHIKAWA, N. 2005. In vitro production 
of myeloperoxidase anti-neutrophil cytoplasmic antibody and 
establishment of Th1-type T cell lines from peripheral blood 
lymphocytes of patients. Clin Exp Rheumatol, 23, 227-30. 
ZHAO, L., DAVID, M. Z., HYJEK, E., CHANG, A. & MEEHAN, S. 
M. 2015. M2 macrophage infiltrates in the early stages of ANCA-
associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol, 
10, 54-62. 
ZWAAL, R. F. & SCHROIT, A. J. 1997. Pathophysiologic implications 
of membrane phospholipid asymmetry in blood cells. Blood, 89, 
1121-32. 
 
